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Abstract
The treatment of mobile tumors with a scanned ion beam requires dedicated beam delivery
and treatment planning techniques. Interference effects (interplay) between beam and tumor
motion can lead to clinically unacceptable dose distributions. Motion mitigation techniques,
such as beam gating or irradiation under abdominal compression, can effectively reduce tumor
motion but typically do not fully compensate motion-induced dose inhomogeneities. Further
mitigation therefore is desirable.
In this work, the dosimetric impact of optimized treatment plan parameters on dose hetero-
geneities caused by residual tumor motion was investigated. For this purpose, a 4D treatment
planning system (4DTPS) for the treatment of moving tumors with a scanned ion beam was
developed based on previous efforts at GSI Helmholtz Center for Heavy Ion Research (GSI).
The system was validated in dedicated experiments, reaching an accuracy of (−1± 4)% for the
typical beam configuration. The new software enabled extensive experiments, simulations, and
treatment planning studies for liver cancer patients. The results show that an enlarged beam
spot size can considerably mitigate motion-induced dose inhomogeneities for treatments with
respiratory gating and under abdominal compression. Moreover, the 4DTPS allowed 4D dose
reconstructions of the first treatments of liver tumors with a scanned ion beam at the Heidelberg
Ion-Beam Therapy Center (HIT), revealing a considerable degradation of the dose coverage in
an exemplary case (V95 = 92.8%).
The 4DTPS is currently used as a basis for further research at GSI and by international col-
laborators. Results of this work have contributed to the world’s first treatments of moving liver
tumors with a scanned carbon ion beam at HIT.
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Zusammenfassung
Die Bestrahlung bewegter Tumoren mit gescannten Ionenstrahlen stellt hohe Anforderungen an
Strahlapplikation und Bestrahlungsplanung. Interferenzen zwischen Tumor- und Strahlbewe-
gung (sogenanntes Interplay) können bei dieser Therapieform zu einer klinisch inakzeptablen
Beeinträchtigung der applizierten Dosis führen. Spezielle Techniken, wie die unterbrochene Be-
strahlung (Gating) oder die Bestrahlung unter abdominaler Kompression, ermöglichen eine ef-
fektive Einschränkung der Tumorbewegung, jedoch in der Regel keine vollständige Kompensa-
tion der Dosisbeeinträchtigungen.
Ziel dieser Arbeit war die Durchführung von Studien zur Kompensation von Dosisinhomogeni-
täten mit Hilfe optimierter Bestrahlungsparameter. Hierfür war zunächst die Weiterentwicklung
eines 4D-Bestrahlungsplanungsprogramms für die Bestrahlung bewegter Tumoren mit einem
gescannten Ionenstrahl notwendig. Bei der experimentellen Validierung des Systems konnte für
die typische Strahlkonfiguration eine Übereinstimmung der gerechneten und gemessenen Dosis
von im Mittel (−1± 4)% erreicht werden. In auf dieser Basis durchgeführten Experimenten,
Simulationen und Bestrahlungsplanungsstudien für Lebertumorbehandlungen konnte gezeigt
werden, dass insbesondere die Verwendung eines vergrößerten Strahlfokus in Verbindung mit
Gating und abdominaler Kompression eine deutliche Verringerung der bewegungsbedingten
Dosisbeeinträchtigungen erzielt. Weiterhin wurden mit Hilfe des Systems Dosisrekonstruktio-
nen der ersten Bestrahlungen von Lebertumoren am Heidelberger Ionenstrahl-Therapiezentrum
(HIT) durchgeführt und ergaben beispielhaft bewegungsinduzierte Abweichungen von rund 7 %
in Bezug auf die geplante Dosisabdeckung (V95 = 92.8%).
Das 4D-Bestrahlungsplanungsprogramm wird derzeit als Grundlage weiterer Forschungsar-
beiten am GSI Helmholtz Center for Heavy Ion Research (GSI) und von internationalen Kolla-
borationspartnern genutzt. Ergebnisse aus dieser Arbeit flossen in die Vorbereitung der weltweit
ersten Bestrahlungen von atembewegten Lebertumoren mit einem gescannten Kohlenstoffstrahl
am HIT ein.
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1 Introduction
1.1 Motivation
According to the German Federal Statistical Office (Destatis), in 2010, every fourth case of death
in Germany—that is over 218.000—was due to cancer (2012). Today, the available treatment
options for cancer include surgery, chemotherapy, radiotherapy and combinations of these. The
goal of radiotherapy is the sterilization of all tumor cells, while protecting normal tissue at the
highest possible level. As a promising alternative to modern x-ray therapy, ion beam therapy
has been developed at several research facilities over the last twenty years. Clinical studies have
shown that the physical and biological advantages of ion beams enable superior dose conformity
and tumor control rates for some indications (Durante and Loeffler, 2010; Schulz-Ertner et al.,
2007; Tsujii et al., 2004). At most facilities, broad beams and patient-specific absorbers are used
to conform the dose to the tumor (passive beam delivery). As a promising alternative, a beam
scanning technique has demonstrated potential for treatments with even higher precision. The
technique employs a narrow beam (pencil beam) to sequentially irradiate the tumor. However,
the full benefit of this technique currently can only be realized for stationary tumors. Tumors
in the chest or abdomen, such as lung and liver tumors, usually are subject to respiratory-
induced motion. The interaction of tumor and pencil beam motion (interplay) results in strongly
inhomogeneous dose distributions, compromising the precision of the beam scanning technique.
Hence, only few patients with moving tumors have so far been treated with scanned ion beams.
Most of these treatments were delivered in apnea under general anesthesia which poses further
clinical workload (RPTC, 2011). Several other strategies have been proposed to facilitate the
safe treatment of moving tumors. One of these techniques is synchronization of the irradiation
with the tumor motion, such that the tumor is only irradiated in a defined motion window,
so-called gating (Minohara et al., 2000). An alternative approach is constriction of the tumor
motion using abdominal compression (Hof et al., 2003). Both techniques have been used for the
treatment of liver cancer at Heidelberg Ion-Beam Therapy Center (HIT) since 2011.
Patients with liver cancer have an especially poor prognosis. The five year survival rate is
only ten percent (Robert Koch Institute, 2012). Historically, the application of radiotherapy
for inoperable liver cancer was limited by the dose tolerance level of the normal liver tissue
(Skinner et al., 2011). Although modern x-ray therapy can safely deliver these treatments,
there is evidence that a further dose increase can improve the survival rate for these patients
(Dawson et al., 2000; Seong et al., 2003). Clinical studies at National Institute of Radiological
Sciences (NIRS) in Chiba (Japan) indicate that the treatment of liver tumors with passively
delivered carbon ions is safe and effective (Kato et al., 2004). The application of scanned
carbon ion beam therapy at HIT for these tumors, therefore, seems promising.
This dissertation addresses the topic of treatment planning for moving tumors in scanned ion
beam therapy. In the context of the liver treatments at HIT, particular focus is given to the
compensation of dose degradation caused by residual tumor motion.
1
1.2 Scope of this work
The scope of this dissertation can be grouped into two main objectives:
(I) A research treatment planning system for scanned carbon ion therapy is to be developed,
which is suited for treatment planning of moving tumors. The developments should be
based on previous work in this particular field by other authors (Krämer et al., 2000; Bert
and Rietzel, 2007; Gemmel et al., 2011) and consider the current state of research in
radiotherapy of moving tumors. The extension of existing functionality is to be focused
on the application to a clinical environment.
(II) The safe treatment of moving liver tumors requires precautions like gating or abdominal
compression. However, residual tumor motion can still cause unacceptable dose degrada-
tion. To address this issue, Bert et al. (2009) have proposed a concept of robust super-
position of pencil beams. Experiments and simulation studies are to be conducted which
extend this concept to complex geometries. Furthermore, treatment planning studies with
patient data are required, in order to assess the clinical applicability of the concept.
The structure of this dissertation is as follows. Chapter 2 will give an overview of the physical
and biological fundamentals of ion beam therapy. Furthermore, the impact of organ motion on
beam delivery and the treatment planning process will be introduced. Chapter 3 will deal with
the implementation and verification of a treatment planning system geared to the treatment of
moving tumors with scanned ion beams. In chapter 4, the impact of a robust superposition of
pencil beams on the delivered dose to moving targets is studied in experiments and simulations.
In the subsequent chapter, the concept is transferred to treatment planning for carbon ion ther-
apy of liver cancer using patient data. A discussion of the results and future directions will be
given in chapter 6. Finally, the thesis will be concluded in chapter 7.
2 1. Introduction
2 Research background and fundamentals
In this chapter the field of research will be introduced in which this work is embedded and
the conceptions required for the understanding of the subsequent chapters will be clarified.
The chapter consists of four parts. The first section will introduce the physical, biological and
technical fundamentals of ion beam radiotherapy. Subsequently, the problem of organ motion
in radiotherapy will be addressed. In particular, the implications for scanned ion beam therapy
will be emphasized. The necessary precautions for the deployment of scanned ion beams in
the presence of organ motion include a dedicated treatment planning work flow which will be
introduced in the third section. Finally, a brief summary will be given.
2.1 Ion beam therapy
In the past decades ion beam therapy has developed alongside conventional x-ray therapy into
a promising branch of radiation therapy that offers superior dose distributions while sparing
normal tissue to a large extent (figure 2.1 on the following page). In 1946 Robert R. Wilson first
recognized the potential benefits of the favorable depth-dose profile of ion beams for precision
cancer therapy (Wilson, 1946). Initial research on the physical and biological properties of
protons was followed by the first patient treatments with proton beams at Lawrence Berkeley
Laboratory (LBL), Berkeley (USA) in the early 1950s (Tobias et al., 1958). The first proton
therapy facility embedded in a clinical environment started operation in 1990 at Loma Linda
University Medical Center (LLUMC) (USA), soon followed by other facilities in the United States,
like the Francis H. Burr Proton Therapy Center at Massachusetts General Hospital (MGH).
In the mid-1970s for the first time also heavier ions, mainly He2+ and 20Ne, were employed
for therapy at LBL, to exploit their increased biological effectiveness. Shortly after the end of
the Berkeley ion therapy project in the early 1990s the heavy ion therapy project at NIRS in
Chiba (Japan) started to employ similar concepts for carbon ions like those pioneered at LBL
(Hirao et al., 1992). Up to that time only passive beam delivery systems had been used for ion
beam therapy (section 2.1.3.1). In parallel, more elaborate active beam delivery solutions (sec-
tion 2.1.3.2) were developed at Paul Scherrer Institut (PSI), Villigen (Switzerland) for protons
(Pedroni et al., 1995) and at GSI, Darmstadt (Germany) for 12C ions (Haberer et al., 1993).
From 1997–2008 the first patient treatments with a scanned heavy ion beam were performed
in a clinical trial at GSI in close collaboration with the German Cancer Research Center (DKFZ),
the University Clinic Heidelberg (UCHD) and the Research Center Rossendorf (FZD). Most
of the over 400 patients had tumors in the brain or at the base of the skull. A dedicated
treatment planning system was used for treatment plan optimization, including full biologi-
cal modeling of the enhanced biological effectiveness of the 12C ions (Krämer et al., 2000;
Krämer and Scholz, 2000). Despite the technical complexity of the system, the raster-scan tech-
nique has proven capable of sub-millimeter accuracy and stable operation. Clinical follow-up
studies have shown high control rates for the treated tumor entities combined with very low
side effects (Schulz-Ertner et al., 2007). These promising clinical results have encouraged the
3
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Figure 4. Comparison of treatment plans with 2 fields of carbon ion (IMPT—left panel) and with
9 fields of x-rays (IMRT—right panel) [23]. In both cases the conformity to the target volume is
good but for carbon ions the dose to the normal tissues is much smaller.
can be determined from the intrinsic repair capacity as given by the parameters α and β of the
dose response curve of the same tissue to the photons. The very successful experience of more
than two hundred patients treated till now at GSI with this treatment planning fully confirms
the basic rationale of these calculations.
The IMPT plan of figure 2 has been obtained by making use of the properties mentioned
under points (1), (2) and (3). In this case, and in most others, the advantage of an inverse dose
profile, with the high dose and high LET at the end of the range (figure 1), allows reducing the
dose to the normal tissues outside the target volume by a factor of 2–3. This applies also to
protons, yet carbon ions are more effective for radio-resistant tumours. These types of tumours
are thus the elective targets in a carbon ion facility, while protontherapy is well adapted to other
cases in which a tumour is close to the organs at risk that cannot be irradiated. These arguments
are important since a protontherapy facility is about 30% cheaper than a carbon ion centre,
which requires a total investment cost of about 100 Me.
How is IMPT implemented in practice? The inverse dose distribution of particles having
a well defined range allows division of the target volume into slices of equal particle energy
and treatment of each slice separately by moving the beam in a raster-like pattern over the
area where the raster pattern is sub-divided into small volumes called voxels. The necessary
particle fluence for each voxel is calculated before the treatment and the beam in it moved
from one position to the next when this number of particles is reached. When one slice is
treated, the energy of the beam is reduced for the next slice. In practice, the complete target
volume consists of 10 000–30 000 voxels (i.e. three-dimensional pixels), which are treated
in 2–6 min. Intensity control raster (or voxel) scanning was introduced by GSI for carbon
ions (in three dimensions) and by PSI for protons (in a two-dimensional version, in which
the third dimension is scanned by moving the patient’s bed), as described in [6, 7]. All the
newly built hadrontherapy facilities will have the possibility of treating patients with active
three-dimensional scanning systems.
Scanning allows treating any irregular shaped tumour with a precision given by half the
width of the beam. In figure 5 the iso-energy slices of a tumour are shown together with one iso-
energy slice in an enlarged scale where the calculated beam positions are given as circles and
the measured ones as points. In order to reach a good homogeneity, the pencil beam has a half
width that covers approximately three beam positions in the vertical and horizontal directions.
A last advantage—point (4)—of particle beams, and especially of ions like carbon, is
the ‘in situ’ production of positron emitters like carbons 10 and 11 and oxygen 15. Because
Figure 2.1.: Comparison f treatment plans for scanned carbon ions (i tensity-modulated par-
ticle therapy) with 2 fields (left) and x-rays (intensity-modulated radiation therapy)
with 9 fields (right). At a comparable level of dose conformity the dose to normal
tissue is drastically reduced for the IMPT plan. Figure from (Amaldi and Kraft, 2005).
skin. In contrast to photons, the dose profiles of protons
and heavier ions are characterized by a distinct narrow
peak !“Bragg peak”" at the end of their path. The posi-
tion of this peak can be precisely adjusted to the desired
depth in tissue by changing the kinetic energy of the
incident ions. Protons and heavier ions differ in two fea-
tures essentially: First, protons have a similar biological
effect as photons !at the same absorbed dose", while
heavy ions show higher effectiveness, ranging from low
RBE values in the plateau region to a significant en-
hancement in the Bragg peak !Kraft, 2000". Second,
heavy ions !unlike protons" exhibit a characteristic dose
tail behind the Bragg peak, which is caused by second-
ary fragments produced in nuclear reactions along the
stopping path of the ions, resulting in a complex radia-
tion field !Schardt et al., 1996".
The dose deposited in tissue is the most important
physical quantity in radiotherapy. It is defined !ICRU,
1993" by the term absorbed dose !unit Gray #Gy$" as the
mean energy d! deposited by ionizing radiation in a
mass element dm,
D =
d!
dm
#1 Gy = 1 J/kg$ . !1"
In radiation therapy !RT" water is used as tissue ref-
erence medium. Dose measurements are normally per-
formed with air-filled ionization chambers and have to
be converted to the absorbed dose in water by correc-
tion factors. For a parallel beam with particle fluence F
the dose deposited in a thin slice of an absorber material
with mass density " can be calculated as follows:
D#Gy$ = 1.6# 10−9#
dE
dx %keV$m &# F#cm−2$
#
1
"
% cm3g & , !2"
where dE /dx is the energy loss of the particles per unit
path length !specific energy loss or “stopping power”". A
similar related quantity is the linear energy transfer
!LET", nit keV/$m, which refers to the energy depos-
ited in he stopping medium by the slowing-down par-
ticle.
For particle therapy the photon-equivalent dose,
sometimes referred to as biological dose or Gray-
equivalent dose, defined as the product of absorbed dose
and RBE, is most significant because it includes the
larger efficacy of ions. The units are named Cobalt-
Gray-Equivalent !CGE" or Gray-Equivalent !GyE". Ac-
cording to recent recommendations !ICRU, 2007" for
proton beam therapy, now the term ‘‘RBE-weighted’’
dose and the unit Gy !RBE" should be used. Similar
recommendations for heavy-ion therapy are in progress,
but presently still the unit GyE is commonly used within
the clinical community.
1. Stopping of high-energy ions
In this section the basic formulas describing the stop-
ping of ions in a thick absorber are recalled. The theory
of stopping and range of ions in matter has been treated
in extended reviews !Fano, 1963; Ahlen, 1980; Sigmund,
2004; Ziegler et al., 2008". Radiotherapy of deep-seated
tumors r quires ion beam ranges in tissue of up to 30 cm
corresponding to specific energies up to 220 MeV/u for
protons and helium ions, 430 MeV/u for carbon ions,
and 600 MeV/u for neon ions with particle velocities %
'v /c(0.7. At these velocities the energy-loss rate
dE /dx in the slowing-down process is dominated by in-
elastic collisions with the target electrons !electronic
stopping" and can be well described by the Bethe-Bloch
formula !Bethe, 1930; Bloch, 1933a, 1933b", here given
in the relativistic version described by Fano !1963", in-
cluding the shell correction term C/Zt and the density
effect correction term & /2,
dE
dx
=
4'e4ZtZp
2
mev2
%ln2mev2)I* − ln!1 − %2"
− %2 −
C
Zt
−
&
2& . !3"
Zp and Zt denote the nuclear charges of the projectile
and target, me and e are the mass and charge of the
electron, and )I* is the mean ionization energy of the
target atom or molecule. For liquid water the value )I*
=79.7 eV was obtained from energy-loss measurements
with 70 MeV protons !Bichsel and Hiraoka, 1992; Bich-
sel et al., 2000". From recent precision Bragg curve mea-
surements for protons and various heavier ions values of
75–78 eV were deduced !Kumazaki et al., 2007; Paul,
2007; Schardt et al., 2008". Stopping-power curves for
FIG. 1. !Color online" Depth-dose profiles of 60Co ( radiation,
megavolt photons, and 12C ions in water.
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Figure 2.2.: Depth-dose profiles in water for ph ton and 12C ion radi tion at different energies.
The relative dose for 12C ions features a sharp maximum at the end of the finite
range. The photon curve drops exponentially after reaching a maximum in the
ntrance channel (build-up effect). The decrease of the Bragg maximum and the
increased width is caused by a larg r energy loss straggling. The tail after the Bragg
maximum is caused by lighter fragments due to nuclear reactions. From Schardt
et al. (2010).
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design and construction of several dedicated heavy ion facilities based on the scanning tech-
nique. As the first clinical center employing beam scanning, the HIT started clinical operation in
2009 (Haberer et al., 2004; Combs et al., 2010). A similar scanning system for carbon therapy
was implemented at NIRS Furukawa et al. (2010b). The first centers using commercial beam
scanning systems for protons were the MD Anderson Cancer Center (MDACC), Houston (USA)
in 2006 and the Rinecker Proton Therapy Center (RPTC), Munich (Germany) in 2009. Several
other facilities are presently under construction or in the planning phase. To date worldwide
about 40 ion-beam therapy facilities are in operation, most of them using proton beams with
passive beam delivery systems. About 20 facilities are in the design or construction phase, four
of them are designed to use carbon ion beams (PTCOG, 2011).
The following sections will introduce the physical, biological and technical concepts of ion
beam therapy. After a brief discussion of the underlying physics of ion beams the implications
for radiobiology will be discussed. Since large parts of this work require a basic understanding
of the technical framework of ion beam delivery, especially of the fully active scanner systems
as they are used at GSI and HIT, a separate section will be dedicated to their introduction.
2.1.1 Physical properties
The main rationale for using ion beams for localized tumor therapy is their favorable depth-dose
profile compared to photons. A comparison of the depth-dose curves for photons and ions with
different energies is shown in figure 2.2 on the preceding page (Schardt et al., 2010). After a
shallow maximum in the entrance region, caused by the dose build-up due to forward scattered
Compton electrons (Alpen, 1998), the photon depth dose profile drops exponentially with the
penetration depth. In contrast, the ion depth dose-curve features a distinct narrow peak with a
sharp dose fall-off at the end of the particle range. This curve is called Bragg curve or Bragg peak,
named after its discoverer, Sir William Henri Bragg (Bragg, 1905). The position of the Bragg
peak in depth can be precisely controlled by varying the kinetic energy of the incident ions. This
’inverse’ depth-dose profile, the small lateral scattering and the finite particle range evidently are
particularly appealing for the treatment of deep-seated tumors, sparing normal tissue, especially
behind the Bragg peak. The underlying physics will be discussed in the following sections.
2.1.1.1 Dose deposition and electronic stopping
The dose, D, deposited in the tissue is of central importance in radiotherapy and is defined by
the ratio of the absorbed energy dE per mass element dm (ICRU, 1993b):
D =
dE
dm
[
1Gy= 1J/kg
]
. (2.1)
For a parallel beam traversing a thin layer of material the absorbed dose is determined by the
specific energy loss per unit length or stopping power of the particles, dE/dx , the fluence, F , and
the material mass density, ρ:
D[Gy] = 1.6 · 10−9× dE
dx
[
keV
µm
]
× F [cm−2]× 1
ρ
[
cm3
g
]
. (2.2)
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protons and 12C ions in water are shown in Fig. 2.
Due to the 1/!2 dependence the energy loss increases
with decreasing particle energy. At high velocities the
atomic electrons are completely stripped off and the
projectile charge is equal to the atomic charge number
Zp. At lower velocities !for light ions below about
10 MeV/u", the mean charge state decreases due to the
interplay of ionization and recombination processes and
Zp in Eq. !3" has to be replaced by the effective charge
Zeff, which can be described by the empirical formula
!Barkas, 1963"
Zeff = Zp#1 − exp!− 125!Zp
−2/3"$ . !4"
The maximum energy-loss rate, corresponding to the
Bragg peak, is reached at a projectile velocity of
vp % Zp
2/3v0, !5"
where v0=e2 /" is the Bohr velocity and the correspond-
ing ! value is e2 /"c=1/137. For 12C ions this maximum
occurs at a specific energy of %350 keV/u. At still lower
projectile energies !Ep#10 keV/u" elastic collisions
with target nuclei begin to contribute significantly to the
energy loss and dominate the stopping process at the
very end of the particle path !the last few $m". The
corresponding dose contribution is, however, very small
and can be neglected in radiotherapy applications
!Elsässer et al., 2009".
The total path length of the particle’s trajectory in the
absorber is given by
R!E" = &
0
E 'dE!
dx
(−1dE!, !6"
which for heavy charged projectiles is nearly the same as
the mean range R, i.e., the average traversed absorber
thickness, because heavy ions are very little scattered
and travel almost on a straight line. Ranges of various
ion beams in water are shown in Fig. 3. The range of
ions with the same specific energy scales with a factor of
A /Z2.
2. Energy-loss and range straggling
According to Eq. !3" the energy loss of a single carbon
ion plotted as a function of absorber depth would result
in a very sharp peak near the stopping point. For ex-
ample, for an incident 300 MeV/u carbon ion the dE /dx
peak-to-entrance value is about 80 !see Fig. 2". However,
statistical fluctuations of the energy loss in the large
number of collisions of the slowing-down process result
in a broadening of the Bragg peak for an ion beam con-
sisting of many particles. These fluctuations are de-
scribed by the !asymmetric" Vavilov distribution
!Vavilov, 1957" for charged particles passing through a
thin layer of matter !energy-loss straggling". In the limit
of many collisions the Vavilov distribution becomes a
Gaussian !Bohr, 1940; Ahlen, 1980",
f!%E" =
1
)2&' exp
!%E − %E"2
2'2
!7"
with
' = 4&ZeffZte4N%x*1 − !2/21 − !2 + . !8"
The variance 'R
2 of the range straggling is related to
the variance 'E
2 of the energy-loss straggling by
'R
2 = &
0
Ei 'd'E
dx
('dE
dx
(−3dE . !9"
The ratio of the straggling width 'R and mean range R
is nearly constant and can be described by
'R
R
=
1
)Mf' EMc2( , !10"
where f is a slowly varying function depending on the
absorber !Rossi, 1952" and E and M are the particle
energy and mass. For light ions stopped in water the
relative straggling 'R /R is of the order of 10−3. Because
FIG. 2. !Color online" Specific energy loss dE /dx of 12C ions
and protons in water. The range of 12C ions in water corre-
sponding to their specific energy is indicated at the top.
FIG. 3. !Color online" Mean range of heavy ions in water.
386 Schardt, Elsässer, and Schulz-Ertner: Heavy-ion tumor therapy: Physical and …
Rev. Mod. Phys., Vol. 82, No. 1, January–March 2010
Figure 2.3.: Specific energy loss of 12C and protons in water (Schardt et al., 2010).
Different energy loss processes contribute to the total stopping power, dE/dx . The required
maximum penetration depth of about 30 cm in the human body corresponds to kinetic energies
of protons and carbon ions of 200 and 430 MeV/u, respectively. In this medium relativistic
regime the total stopping power is dominated by inelastic scattering of the ions with the target
electrons. The collisions result in ionization and excitation of the target atoms. Elastic collisions
with the target nuclei (nuclear stopping) only contribute significantly to the total energy loss
at very small particle energies, i.e. near the end of their range. Radiative energy losses play a
role in the highly relativistic regime only and therefore can be neglected as well (Nakamura and
Particle Data Group, 2010). Thus, the considerations will be limited to the electronic stopping
power here.
In the energy range of interest the electronic stopping power is well described by th Bethe
formula (Bethe, 1930; Bloch, 1933b,a; Fano, 1963)
−
〈
dE
dx
〉
=
4pie4Zz2
mec2β2
[
ln
(
2mec
2β2
I(1− β2)
)
− β2− C
Z
]
(2.3)
Here β = v/c is given by the velocity v of the incident particle normalized to the speed of light
c. Z and z are the nuclear charges of the target and the projectile, respectively. me denotes
the mass and e the elementary charge of the electron. The mean ionization potential, I , of
the target atoms or molecules is usually obtained empirically and is around 75–78 eV for liquid
water (Schardt et al., 2008; Paul, 2007; Kumazaki et al., 2007). Values for other materials are
summarized in ICRU (1993, 1984). Equation (2.3) also includes the shell correction term, C/Z ,
which takes into account the orbital velocities of the target electrons at low particle energies.
Detailed reviews on the shell correction term and other low energy corrections of the electronic
stopping power are given in (ICRU, 1993; Ziegler, 1999).
Figure 2.3 shows the mean electronic stopping power for carbon ions and protons in the rel-
evant energy regime for ion beam therapy (Schardt et al., 2010). The energy loss increases
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sharply with decreasing particle velocity, due to the 1/β2 dependence in (2.3). At lower ve-
locities recombination processes with the target electrons gradually lower the effective charge
of the projectile and result into a decreasing energy loss rate after reaching a maximum at a
specific energy of ≈350keV/u in the case of 12C ions. This effect can be incorporated into (2.3)
by replacing z with the effective charge zeff. Empirically zeff can be parametrized using Barkas’
formula (Barkas and Berger, 1964):
zeff = z
[
1− exp(−125βz−2/3)
]
. (2.4)
Figure 2.3 also shows the minor contribution of the elastic scattering with the target nuclei at
the very end of the particle range (dashed line).
2.1.1.2 Range straggling and lateral scattering
The Bethe formula describes the mean electronic stopping power only. However, energy loss by
inelastic Coulomb scattering is governed by large statistical fluctuations. For a beam of many
slowing down particles this results in a significant broadening and a reduced peak-to-entrance
dose ratio of the Bragg peak (figure 2.2). In the limit of a large number of collisions or thick
layers the energy loss obeys a Gaussian probability distribution. The energy loss fluctuations
directly translate into range straggling (Bohr, 1940; Ahlen, 1980). The ratio σR/R of the strag-
gling width σR and the mean range R is proportional to 1/
p
M with M , the ion mass. Thus, the
broadening of the Bragg peak is less pronounced for heavier ions. For example the ratio σR/R
is about a factor 3.5 smaller for 12C ions than for protons (Schardt et al., 2010).
On their way through the material the particles undergo small lateral deflections, due to
elastic scattering off the target nuclei. This has been described analytically by Molière (1948)
and is in very good agreement with measurements (Gottschalk et al., 1993). Heavier target
nuclei cause a larger angular spread for the same thickness of a material layer. The angular
spread also depends significantly on the particle’s energy and increases towards the lower end
of the particle range. Compared to a proton beam with the same range in water of about 16 cm
the angular spread of a 12C beam is more than three times smaller (Schardt et al., 2010). In
clinical practice ion beams therefore offer significantly sharper dose gradients and better sparing
of normal tissue (Weber and Kraft, 2009).
2.1.1.3 Nuclear fragmentation
The cross section for nuclear interactions is orders of magnitude smaller than for Coulomb inter-
action. Nuclear fragmentation reactions nevertheless play a significant role at large penetration
depths. For ions heavier than protons projectile fragments contribute significantly to the ab-
sorbed dose and lead to dose tails at the distal end of the depth dose profile (figure 2.2). To
a lesser extent fragments of the target nuclei also contribute. However, these have very low
ranges and do not travel with the beam. For all ions except protons projectile fragmentation is
the dominant process. In collisions of the projectile with a target nucleus a partial disintegra-
tion of the projectile results into excited states of the remaining projectile fragments, followed
by de-excitation through the emission of nucleons, nucleon clusters and photons. Detailed re-
views of the underlying fundamental processes have been published elsewhere (Goldhaber and
Heckman, 1978; Hüfner, 1985; Lynch, 1987).
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Nuclear fragmentation leads to a loss of primary particles and a build-up of mostly lower-Z
fragments increasing with depth. For kinematical reasons these lighter fragments move with
approximately the same velocity and into the same direction as the primary particles. While
the rare heavier fragments are stopped rather quickly, the lighter hydrogen and helium frag-
ments have larger ranges and produce significant dose tails behind the Bragg peak. Due to the
exponential loss of primary particles, the depth dose profiles feature a gradually diminishing
peak-to-entrance dose ratio (figure 2.2). Additionally the profiles are increasingly broadened
by straggling (Schardt et al., 2010). These effects are more pronounced for heavier ions and
become intolerable for therapy for ions heavier than 20Ne (Kraft, 2000). Taking into account
the dose contributions of nuclear fragments based on measured data is essential for treatment
planning. This is particularly important for the inclusion of the biological efficacy of the differ-
ent constituents of a mixed particle beam (section 2.1.2). For this reason, measurements have
been performed at many centers to assess the magnitude of fragmentation, the relative com-
position of isotopes and their contribution to the absorbed dose (Maccabee and Ritter, 1974;
Schimmerling et al., 1983; Llacer et al., 1984; Schall et al., 1996; Hättner et al., 2006).
2.1.1.4 Track structure and radial dose distribution
Ions lose their energy by ionization and excitation of the target electrons via inelastic Coulomb
scattering. The liberated electrons undergo frequent elastic and inelastic scattering and may
cause secondary ionization of the target atoms if their kinetic energy is sufficiently high. For
electron energies larger than ≈50eV ionization is the dominant process leading to large num-
bers of additional electrons (Kraft, 2000; Schardt et al., 2010). The energy spectrum of the
electrons defines both, the radial dose profile around the track and the track diameter. Since
most of the electrons only receive small energy transfers or are scattered in forward direc-
tion, the radial dose is concentrated at the track core and quickly falls off with larger radial
distances r. The existing models (Chatterjee and Schaefer, 1976; Katz and Cucinotta, 1999)
and Monte Carlo codes (Paretzke, 1986; Krämer, 1995) all predict an approximate 1/r2 de-
pendence for the radial dose fall-off. This has been confirmed by dosimetry experiments (Varma
et al., 1977). For the dose contribution at smaller radii than 10nm a flat profile is often assumed
(Scholz and Kraft, 1996). The maximum track extension, rmax, is determined by the energy of
the most energetic electrons and empirically can be related to the energy, E, of the primary
particle: rmax ∝ E1.7 (Kiefer and Straaten, 1986). Due to the z2 and the 1/β2 dependence of
equation (2.3), the track structure of ions is considerably dependent on the ion species and
energy. Figure 2.4 on the facing page demonstrates the much more dense ionization patterns
of carbon ions compared to protons at different energies obtained by a Monte Carlo simulation
(Krämer and Durante, 2010). Most of the electrons have very low energies, resulting into ranges
on the nanometer scale and a very localized energy deposition. For decreasing energy the in-
creasing stopping power of the ions translates into significantly larger numbers of secondary
electrons. The energy deposition of the electrons in the material is often described using the
linear energy transfer (LET) or restricted energy loss. The LET is closely related to dE/dx and
defines the locally transferred energy to the medium, excluding contributions of electrons with
energies above a certain threshold (ICRU, 1984; Nakamura and Particle Data Group, 2010).
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Fig. 1. (Color online) Depth dose distributions (left hand side) and lateral spread (right hand side) of various beam modalities.
2 Physical beam model
The complexity of interactions of ion beams with living
matter makes it difficult to provide purely experimental
base data sets for treatment planning. Hence one has to
rely on sufficiently accurate – and fast – calculations to
obtain base data like depth dose distributions and parti-
cle spectra. The requirements of a physical model can be
summarized as follows:
– handle all ions of therapeutical interest, i.e. Z <= 8;
– work on a three-dimensional grid, i.e. the millions of
voxels of a computed tomography (CT);
– the accuracy of the dose distribution should be ≈5%
(average), ≈7% (max);
– the position of single Bragg peaks should be repro-
duced within 0.5 mm (1/2 CT voxel);
– the calculation of complete treatment plans based on
a physical model should be reasonably fast, a few sec-
onds or minutes per patient plan for a single CPU.
2.1 Microscopic calculations
Given the stochastic nature of the basic interactions of
the charged projectiles with the atoms and molecules of
the traversed matter, one might be tempted to apply ab
initio methods such as Monte Carlo simulations. Various
such attempts exist, for example the code PARTRAC [3]
which is dedicated to describe the damage to DNA or
the GSI grown TRAX [4,5], used to calculate ion track
structure and related quantities. Such codes use a set of
cross sections for elementary interactions, typically elas-
tic scattering, ionization, excitation, rather than relying
on condensed random walk. Their design is usually aimed
towards “track segment conditions”, i.e. short slabs (mi-
cro/nanometer) of matter with almost negligible energy
loss, and negligible probability of nuclear reactions. These
are difficult to include anyway, because electromagnetic
cross sections are of the order of σem ≈ 10−16 cm2,
whereas nuclear interaction cross sections are of the order
σnucl ≈ 10−24 cm2, i.e. eight orders of magnitudes lower.
Figure 2 shows TRAX simulations of δ-electrons from ions
Fig. 2. (Color online) Simulated paths of δ-electrons created
by ions of various energies in water.
of various energies. The dense emission pattern of ions at
low energies can be seen. Most electrons have very low
energies, below 100 eV. The inserted DNA schematics
emphasizes the scale of the simulation, i.e. nanometers.
Although such visual simulations do not readily provide
quantitative measures, they nevertheless have been veri-
fied experimentally, by means of the so called OPAC (op-
tical avalanche chambers) which is able to visualize ion
tracks in gas at low pressure [6,7].
Figure 2.4.: Simulated paths of s condary elec rons with different energies created by protons
and carbon ions at different specific energies. The DNA molecule illustrates the geo-
metrical dimension of the track structure. Figure courtesy of M. Krämer.
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Figure 2.5.: (a) Direct and indirect radiation damage to the DNA. Direct damage is caused by
energy deposition in direct hits from electrons liberated in ionization processes. Free
hydroxyl radicals (OH), formed by ionization in the hydrolysis of water, can cause
indirect damage to the DNA in chemical reactions. (b) Schematic illustration of
selected types of radiation damage to the DNA. The effectiveness of the repair
mechanisms of cells depends on the complexity of the damage.
2.1.2 Radiobiology
The goal of radiotherapy is to inactivate all tumor cells and thus prevent further cell growth
and cell division. Radiation damage can be induced everywhere in the cell. However, it is
commonly acknowledged that the most critical structure of a cell with respect to radiation
damage is the deoxyribonucleic acid (DNA) which is located inside the cell nucleus (Munro,
1970). Although cells have a number of sophisticated repair mechanisms, the repair capacities
are limited, depending on the type of damage (Sancar et al., 2004). Commonly, direct and
indirect radiation-provoked effects are distinguished, as shown schematically in figure 2.5a. Di-
rect effects are caused by the ionization of a DNA constituent itself. Consequently, molecular
bonds can be destroyed and result in break-up of a single or both DNA strands (figure 2.5b).
Furthermore, randomly created new bonds may be formed and alter the DNA structure. While
single-strand breaks can be repaired rather efficiently, double-strand breaks often result in even-
tual cell death. In general, they are considered the critical events for lethal lesions. Direct effects
are of increased importance for ion radiation. For more sparsely ionizing radiation like photons,
however, the majority of the radiation-induced effects are indirect effects. Most notably, free
and highly reactive hydroxyl-radicals (OH) are created in the radiation-induced hydrolysis of
water molecules surrounding the cell nucleus. Although they have a short lifetime, they can
migrate over several nanometers and are capable of damaging the DNA structure. Due to larger
recombination of radicals these effects are of less importance for ion radiation. Direct and in-
direct radiation damage occur in parallel and can accumulate to an extent so that the repair of
the DNA is no longer possible.
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A key advantage of heavy ion beams in radiotherapy applications is their increased biological
efficiency in the target region, compared to photon irradiation. The large ionization densities
along the ion tracks at the Bragg peak can cause clustered lesions of the DNA molecule, i.e.
multiple double-strand breaks, which have a small probability of being repaired, resulting into
subsequent cell death. Figure 2.4 illustrates the spatial distribution of the secondary electron
halo around the track of protons and 12C ions in relation to the size of a DNA molecule. Most
of the insight into the response of cells to radiation has been acquired for photon radiation.
Hence, the biological effect of ion radiation is commonly described relative to a reference photon
response, using the concept of the relative biological effectiveness (RBE). The RBE is defined as
the ratio of the reference photon dose to the dose level needed for a specific ion radiation in
order to achieve the same biological effect (isoeffect)
RBE=
Drefγ
Dion
∣∣∣∣
isoeffect
. (2.5)
Comparisons of RBE values are valid only for the same effect and effect level (biological end-
point) and the same reference radiation. In ion beam tumor therapy the most relevant biological
endpoints are cell survival and certain normal tissue side effects. In the following the term RBE
is used synonymously with the RBE for cell survival. Figure 2.6 on the next page illustrates
the calculation of RBE at the 10% and 1 % survival level. The survival curve for ion irradia-
tion shows a steeper fall-off in survival while the x-ray curve exhibits a characteristic shoulder.
Consequently, the RBE values are dependent on the dose level. In addition to the physically
absorbed dose, as defined in equation (2.1), the term of a photon-equivalent or biological dose
incorporating the RBE is often convenient. The difference to the physical dose is marked by ex-
pressing the biological dose in units of GyE or Gy (RBE). The latter notation is recommended by
the International Commission on Radiation Units and Measurements (ICRU) and will be used
in the following (ICRU, 2007). The shouldered curve describing the cell survival, S, in depen-
dence of the dose level, D, is commonly described by an exponential linear-quadratic model
(LQ-model) (Fowler, 1989):
S(D) = exp
(−αD− βD2) . (2.6)
The ratio α/β is characteristic of the tissue type and radiation quality and is related to the repair
capacities of the cells. A large α/β ratio indicates a small repair capacity or, equivalently, a large
radiation sensitivity.
The systematics of the RBE are complex. Apart from the biological endpoint the RBE depends
on other physical and biological parameters, the most important ones being the dose level, the
LET, the particle species and the tissue type. The reader is referred to the reviews by Kraft
(2000), Scholz (2003), Fokas et al. (2009) and Schardt et al. (2010) for detailed discussion of
the various RBE systematics. It should be noted that the increased biological effectiveness of
ions can only be exploited to the maximum extent if it is more pronounced in the tumor than in
the normal tissue. Due to the LET dependence the RBE is elevated also in the entrance channel
for relatively heavy ions, like argon. In contrast, carbon ions feature a sharp RBE maximum
which coincides with the Bragg peak (Kraft, 2000). In proton therapy the assumption of a
constant RBE of 1.1 over the treatment field is feasible (Paganetti et al., 2002). For carbon ions
the RBE varies over a factor of ten from values close to 1.0 in the entrance channel to typical
values around 5.0 in the target region. Even higher values of around 10.0 can result in the
normal tissue beyond the field edges (Kraft and Kraft, 2009).
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ing factor considers the radiosensitivity of different or-
gans. In order to determine the equivalent dose !in
Sievert", both weighting factors must be taken into ac-
count. These are maximum values chosen to assess the
radiation risk in the most conservative way. However,
they should not be confused with the RBE, which is a
much more powerful and versatile concept taking into
account the radiation quality and tissue-specific re-
sponse as well as the biological end point and the dose
level of the radiation.
The RBE is defined as the ratio of the dose of a ref-
erence radiation !typically x rays or ! rays" to the dose
of the radiation in question !e.g., ions" to produce an
identical biological effect !isoeffect",
RBEiso =
Dref
Dion
. !15"
It is important to note that the statement of a RBE
value requires both the specification of the reference ra-
diation and the level of the biological effect. In Fig. 25
we show the determination of the RBE by typical cell
survival curves for x rays and heavy ions. The RBE val-
ues for cell inactivation are indicated for two effect lev-
els, namely 10% and 1% cell survival.
The RBE is the most important quantity in biological
treatment planning of heavy-ion therapy, since it deter-
mines the photon-equivalent dose by multiplication with
the absorbed !physical" dose. The photon-equivalent
dose, sometimes abbreviated as biological dose, quanti-
fies the dose of conventional radiation that would yield
the same biological effect as the applied radiation. It is
conveniently used to compare the results of conven-
tional radiation with other radiation qualities such as
neutrons, protons, or carbon ions. The RBE can be used
for many biological end points such as DNA strand
breaks, mutations, or transformations. In the scope of
heavy-ion therapy, however, the RBE for cell killing and
normal-tissue complications are most relevant.
3. Dependencies of RBE
In contrast to proton therapy, where the low LET of
protons is believed to allow the application of a single
factor !RBE=1.1" throughout the entire radiation field
!Paganetti et al., 2002", the situation in heavy-ion
therapy is much more complex because of the large
variations of LET. From the previous section, we know
that the mixed radiation field of a carbon-ion SOBP is
comprised not only of carbon ions with a large energy
spread but also of lighter fragments. Additionally, the
levels of absorbed dose can vary largely within single
fractions and between different tumor sites. Therefore,
we need to understand how the biological effect of
heavy ions depends on the parameters relevant for ra-
diotherapy.
First, the RBE depends on the dose level as already
shown in Fig. 25. In general, it is higher for lower dose
levels and lower for larger doses owing to the shoulder
shape of the photon response curve !Weyrather et al.,
1999; Furusawa et al., 2000". For application in ion
therapy that means that the biological differences be-
tween conventional radiation and particle beams dimin-
ish if the dose is escalated.
Second, the response of cellular systems depends on
the energy or LET of the penetrating particle. Figure 26
presenting a compilation of different cell survival experi-
ments with V79 hamster cells !a frequently used cell line
in radiobiology laboratories" reveals that the RBE in-
creases with LET up to an ion-dependent maximum
value and decreases for higher LET values !Belli et al.,
1998; Furusawa et al., 2000". According to the higher
ionization density in the track center of particles with a
larger LET, the radiation damage is more severe, thus
increasing the RBE. However, at a certain LET value
the dose deposition is so large that a single-particle tra-
versal sufficiently reduces the cell survival probability. In
that case, the additional dose deposited by ions with a
larger LET is wasted and we would not expect a larger
FIG. 25. !Color online" Determination of RBE for cell inacti-
vation for 10% and 1% survival level for a typical heavy ion
irradiation. FIG. 26. Dependence of RBE"="ion/" on LET and particle
type, where " and "ion are the linear part of the survival curve
for photons and ions, respectively. Data are redrawn from Belli
et al. !1998" and Furusawa et al. !2000". From Scholz, 2003.
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Figure 2.6.: Sketch of typical cell survival curves for photon and heavy ion irradiation. The ion
curve shows a steeper decrease with dose and lacks the characteristic shouldered
form of the photon curve. The RBE value depends on the survival level, or equiva-
lently, on the dose level (Schardt et al., 2010).
The large variations in RBE facilitate the need for a biological model which is able to predict
the RBE in a mixed radiation field over a wide range of atomic numbers and energies. At GSI this
is done using the local effect model (LEM) developed by Scholz et al. (Scholz and Kraft, 1994,
1996). The model predicts the biological efficacy starting from the dose dependence of the
cell inactivation by x-rays which was measured in cell experiments, the radial dose distribution
around the particle track and the size of the cell nucleus. The general underlying assumption
is that there is no fundamental difference in the physical dose deposited by photons or ions via
secondary electrons. The different biological response solely originates from the characteristics
of the dose deposition patt rn. While for photons a homogeneous dose dist ibution over the
cell nucleus can be assumed, particle irradiation leads to highly localized dose distributions at
the same total dose. Assuming the x-ray response is valid also for these high local doses, the
dose response for ions can then be determined according to the x-ray response at the same dose
level. Improved versions of the LEM have been published over the years (Elsaesser and Scholz,
2006, 2007; Elsaesser et al., 2009) and the model has been successfully tested in numerous
cell experiments (Mitaroff et al., 1998; Krämer and Scholz, 2000; Krämer et al., 2003) and is
incorporated into the GSI treatment planning system which has been used in the past in clinical
routine in the GSI pilot project from 1995–2008 (Krämer et al., 2000; Krämer and Scholz, 2000)
as well as at HIT since 2009.
2.1.3 Beam delivery
Ion beam therapy requires complex beam delivery systems capable of accelerating ion to ther-
apeutic energies of several hundred MeV/u, transporting the ion beams to the treatment area
and guiding them onto the target with the necessary accuracy. Particle acceleration is typically
realized using either cyclotron or synchrotron accelerators. Cyclotrons nowadays can be built
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Figure 2.7.: Schematic of a passive beam delivery system. The narrow, mono-energetic beam is
scattered to match the required lateral dimensions. Lateral and longitudinal adap-
tion to the tumor is performed by different passive modulator devices. The distal
edge of the tumor is conformed by an individually machined compensator. The
hatched area indicates the resulting inevitable irradiation of normal tissue. Figure
redrawn from (Schardt et al., 2010).
very compact and offer continuous beams with stable beam intensities. However, active energy
variation is not possible with this design, therefore passive degraders have to be used at the cost
of beam intensity and quality. Synchrotrons in contrast provide pulse-to-pulse active energy
variation. The beams have to be injected into the synchrotron ring by a dedicated linear accel-
erator. Ion optics are used to keep the ions on track during further acceleration and storage.
While cyclotrons are used in most proton facilities, to date all heavy ion centers employ the
synchrotron solution.
A single Bragg peak does not adequately cover the target volume with a homogeneous dose,
consequently the beams need to be shaped, once the beam has been guided to the treatment
area. Two different strategies have been developed over the years and are in use today in
different variations. The following section will introduce passive and active beam shaping sys-
tems, concentrating on the fully active beam delivery system at GSI and HIT which are of major
interest in this work.
2.1.3.1 Passive beam shaping
Passive beam shaping systems employ different devices inserted into the beam line to manipu-
late the beam laterally and longitudinally. In the following, the basic concept shall be presented.
More detailed overviews of passive beam shaping techniques and the specific devices can be
found in Chu et al. (1993); Kraft (2000) and Gottschalk and Pedroni (2008). In figure 2.7
the concept of passive beam shaping is shown schematically. First the initial narrow beam is
broadened with a scattering device to generate a broad and flat lateral beam profile. Here,
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e.g., passive double scattering systems or magnetic wobbler devices are frequently used (Kraft,
2000). The mono energetic beam beam is then spread out over the required depth using a
range modulator. In practice, ridge filters or rotating wheels of varying thickness are employed
(Chu et al., 1993). Stacking of Bragg peaks at different depths results into a so-called spread-out
Bragg peak (SOBP). The SOBP is then shifted to the needed depth using a range shifter. Again,
this is a passive absorber that is chosen at the required material thickness. The discussed de-
vices are not patient-specific although, e.g., a whole library of range modulators may be needed
for different longitudinal field extensions. In addition, devices machined individually for each
patient are needed to tailor the beam to the respective target as much as possible. The lateral
extension of the treatment field is defined by a collimator, typically made from brass, in order
to yield sharp lateral field gradients. The collimator is followed by a range compensator usually
made from polymethyl methacrylate (PMMA) and designed such that the SOBP is adjusted to
the distal edge of the tumor in beam’s-eye-view (BEV). A major deficiency of the compensator is
the incapacity to form the proximal edge of the tumor. This results into parts of the SOBP dose
being deposited in surrounding normal tissue, as depicted by the hatched area in figure 2.7.
For historical reasons, the vast majority of ion beam therapy centers worldwide employ pas-
sive beam delivery techniques. Although passive beam delivery techniques have been refined
over the years, they carry intrinsic limitations, e.g., a restricted tumor conformity, the need for
patient-specific hardware and an inflexibility in dose modulation. Many of the limitations can
be overcome using active beam shaping techniques which will be introduced in the next section.
2.1.3.2 Active beam shaping
Active beam shaping systems employ beam scanning techniques to distribute the beam over
the target area. The basic idea is to dissect the tumor into layers of iso-energy in beam’s-eye-
view (BEV). Each of these iso-energy layers or -slices is covered with a grid of target points
which are irradiated sequentially using a thin pencil beam. This approach is suited to irradiate
volumes of arbitrary shape without any need for additional patient-specific hardware. Since the
dose can be modulated on a per-spot basis, the technique is intrinsically intensity-modulated
and allows for very conformal treatments with extensive sparing of normal tissue (see also
figure 2.1 on page 4). Also, variable RBE distributions can be incorporated into the planning at
any point in the treatment field so that homogeneous biologically equivalent dose distributions
can be realized. The amount of material in the beam is drastically reduced, yielding efficient
beam usage and less neutron flux towards the patient.
Beam scanning has been developed in parallel at PSI for protons (spot scanning) and at GSI
(raster scanning) for carbon ions in the 1990s. The strategy at PSI was to use a cyclotron with
passive energy variation in combination with horizontal beam scanning, facilitated by magnetic
deflection, and a mechanical couch displacement in the vertical direction. The reader is referred
to Pedroni et al. (1995) for more details on the implementation.
In the following section the GSI concept of a fully active three-dimensional scanning system
for therapy will be given attention to. For more comprehensive reviews the reader is referred
to the literature (Haberer et al., 1993; Kraft, 2000; Schardt et al., 2010). A schematic of the
GSI raster-scan system, is given in figure 2.8 on the next page. A thin pencil beam of 12C ions is
extracted from a synchrotron providing active energy control. The position of the Bragg peak in
depth is defined by the beam energy. The dose is delivered slice-by-slice with each of the slices
corresponding to a fixed beam energy (IES). The Bragg peaks are stacked in depth over the
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Figure 2.8.: Schematic of the GSI raster-scan system. The treatment is performed slice-by-slice by
moving the beam on a meander-like path. The beam position and the delivered dose
are constantly monitored and fed back into the treatment control system. Figure
from Krämer (2009).
(a) (b)
Figure 2.9.: (a) Lateral pencil beam overlap ensures adequate target dose homogeneity in the
transversal direction. Commonly, the raster spacing, ∆s, is adjusted to 2–3 mm and
the beam’s FWHM amounts to roughly three times the raster spacing. (b) The pris-
tine Bragg peaks are broadened in depth using a ripple-filter (RiFi) and then are
stacked in depth. Sufficient overlap is maintained to yield a homogeneous target
dose in the longitudinal dimension (SOBP). The standard RiFi is optimized for an IES
spacing,∆z, of 3 mm.
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longitudinal extension of the tumor (figure 2.9b). In each IES a raster of target points, so-called
raster points, is adjusted to match the tumor cross section in BEV. The beam is guided over the
raster on a continuous and optimized path by two orthogonal magnetic deflection units. The
dwell time of the beam at a raster point is controlled by an intensity monitoring system, moving
the beam to the next position when the variable pre-defined dose of a raster point has been
delivered. The stability of the beam position is ensured by using a fast feed-back loop between
the magnet power supplies and two multi-wire proportional chambers (MWPCs) measuring the
beam position. After the completion of an energy slice the irradiation is interrupted and the
next beam energy is requested from the accelerator for the next IES of the treatment plan. The
treatment control system (TCS) communicates with the accelerator control system (ACS) and
requests the appropriate beam parameters and the beam intensity for each slice, namely the
size of the beam spot, the beam energy and the beam intensity. For each of the available sets
of beam parameters the ACS holds a data base with optimized settings for the synchrotron and
all magnets in the beam line. In this way, the accelerator is capable of providing reproducible
and stable conditions for each of the parameter sets. The technical design of the HIT beam
delivery system in large parts is based on the GSI prototype and therefore is very similar. A
major technical achievement is the transfer of the raster-scan concept to an iso-centric gantry
system in one of the three treatment rooms (Haberer et al., 2004).
In raster-scanning at GSI the target dose homogeneity is assured by two means. Firstly, the
lateral overlap of the thin pencil beams is chosen sufficiently large in order to compensate
for the expected positioning uncertainties of the beam spots. This is illustrated in figure 2.9a
for the typical configuration in which a beam FWHM of three times the lateral raster spacing
is used. Secondly, the iso-energy slices spacing is chosen such that the individual Bragg peaks
have enough overlap. However, the number of IESs should be kept small to reduce the treatment
time. For this reason, the pristine Bragg peaks are broadened in depth by using a so-called ripple-
filter (RiFi)—the only passive device in the beam line— similar to the ridge filters employed for
passive beam delivery. The standard RiFi is optimized for an IES spacing of 3 mm and guarantees
longitudinal dose homogeneity (Weber and Kraft, 1999). The concept of longitudinal beam
overlap is shown in figure 2.9b. In chapter 4 the approach of achieving target dose homogeneity
by lateral and longitudinal beam overlap in stationary irradiations will be extended to moving
targets and constitutes one of the major research questions addressed in this thesis.
2.2 Treatment of moving tumors
Modern radiotherapy modalities like photon intensity-modulated radiation therapy (IMRT) and
ion beam therapy offer high precision and superior dose conformity. The increased accuracy
allows for treatment of tumors very close to critical structures sparing the normal tissue to a
large extent. As a result of this development, the reduction of safety-margins and the escalation
of the therapeutic dose in the tumor are of frequent clinical interest. However, at many sites
of the human body the advantage of the increased conformity of these techniques is severely
limited or compromised, due to organ motion. Normal tissue toxicity puts constraints on the
therapeutic tumor dose, even though higher dose levels yield better local control and would be
desirable for some entities (Rengan et al., 2004; Rosenzweig et al., 2005; Kong et al., 2005).
Consequently, motion management constitutes a major contemporary research field in radio-
therapy. This section will clarify the different manifestations of organ motion, their implications
for ion beam therapy and the existing techniques proposed to mitigate motion effects.
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2.2.1 Origin and extent of organ motion
The following section will briefly introduce the different types of organ motion or anatomy
changes and their characteristics. Extensive reviews on the topic have been published elsewhere
(Langen and Jones, 2001). Organ motion is commonly divided into patient motion, inter-
fractional and intra-fractional motion.
Patient motion comprises position-related uncertainties during or in-between fractions or
imaging sessions. The application of patient immobilization prior to each fraction is common
clinical practice. Depending on the time-scale of patient motion it can impact inter- or intra-
fractional motion.
Inter-fractional organ motion refers to changes in the anatomy in-between fractions on a typ-
ical time-scale of minutes to days. The sources of inter-fractional motion and anatomy changes
are diverse. Lung tumor shrinkage and lung density changes over a treatment course were, e.g.,
observed by Mori et al. (2009). Changes in the base line of respiratory breathing patterns were
i.a. reported by Sonke et al. (2008). Prostate tumors are frequently subject to position changes
due to varying bladder or gut filling (Fokdal et al., 2004).
Intra-fractional organ motion occurs on a time-scale of seconds, i.e. during treatment, mainly
as a result of respiration or heart beat. In this work, respiration-induced intra-fractional organ
motion will be focused on.1 Intra-fractional tumor motion shows a large variation depending
on the individual conditions. However, respiration-induced tumor motion is consistently found
to be more pronounced in the superior-inferior (SI) direction than in the anterior-posterior (AP)
and left-right (LR) directions (Seppenwoolde et al., 2002; Britton et al., 2007; Liu et al., 2007;
Case et al., 2010). Liu et al. (2007) report lung tumor motion amplitudes in SI direction larger
than 5 mm in approximately 40 % of their patients. They also found correlations with respect to
tumor size and T-staging. Liver tumor motion was assessed, e.g., by Case et al. (2010). They
measured a mean amplitude in SI direction of 8 mm. A detailed overview on intra-fractional
motion in lung and liver was published by Shirato et al. (2004).
2.2.2 Implications of organ motion
Organ motion generally leads to the spatial deformation of the dose distribution and a blurring
of the dose gradients in ion beam therapy similarly to photon therapy, since the tumor centroid
is partially moving in and out of the field (Bortfeld et al., 2004). Typically, this also leads to in-
creased exposure of the surrounding normal tissue. The additional sources of dose deterioration
for ion beams will be briefly discussed in the following.
2.2.2.1 Changes in the radiological path length
The radiological path length is defined as the geometrical depth traversed in a given material
multiplied by its mass density (Alpen, 1998). For x-ray photons the changes in absorbed dose
with the radiological depth are small, except for the small build-up region in the entrance chan-
nel, as shown in figure 2.2 on page 4 for the depth in water. Variations in material density,
therefore, have little effect on the dose. It can also be seen from the figure that ions, in contrast,
1 In the following, the term organ motion will be used synonymously with intra-fractional motion, unless stated
otherwise.
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Figure 2. Intra-fractional motion not only changes the geometrical position of the tumor but also
causes changes in the radiological depth. In this example, respiratory motion moves a lung tumor
in and out of the displayed axial slice. Due to a high difference in density between tumor mass and
surrounding lung tissue, the displayed iso-range lines that also reflect the position of a Bragg peak
are strongly influenced when comparing inhale versus exhale.
Any concept to compensate for the uncertainties due to organ motion thus needs to
incorporate not only the geometrical motion but also the influence on the beam’s range which
has severe dosimetric impact.
2.2. Impact of inter-field motion on IMPT plans
In IMPT treatment plans, conformal dose distributions can be achieved by parallel optimization
of the particle numbers of multiple fields. IMPT has been implemented for protons (Lomax
1999) as well as carbon beam therapy (Gemmel et al 2008) and is delivered with a scanned
beam. Lomax studied the impact of inter-field motion in IMPT with a scanned proton beam
(Lomax 2008). For a 5 mm shift of the dose distribution, he reports considerable under-dosage
(up to 20%) within the clinical target volume (CTV) for the treatment modality distal edge
tracking (DET) and ‘regular’ 3D IMPT plans that are optimized for maximal sparing of organs
at risk (OAR) in the vicinity. Especially strong dose gradients that rely on the nominal match
between the contributing fields are very sensitive to changes of the patient’s/organ’s position
in between the delivery of the contributing fields. This inter-field motion is of course also
contributing to intra-field motion that will be covered in the next section.
2.3. Interference of scanned beams and organ motion
Since the early days of beam scanning assessment, it was known that the application of a
scanned beam in therapy of intra-fractionally moving tumors would be challenging (Phillips
et al 1992). In these initial studies, Phillips et al showed that the dose uniformity is very
dependent on the motion amplitude and the relative direction of beam motion and target
motion. In addition, it was found that multiple irradiations of the volume decrease the
sensitivity to these interference effects, an approach called rescanning that will be discussed in
section 3.3.3. Figure 3 schematically shows the formation of interplay along with a simulation
example for a NSCLC patient (12C, one field, one fraction, absorbed dose).
In the last few years, multiple authors studied this so-called interplay effect in simulations
(for artificial geometries and for patients) as well as in experiments (for artificial geometries
and in animal studies).
Figure 2.10.: Changes in the radiological depth induced by lung tumor motion. The variations
are visualized by iso-range lines for posterior-anterior incidence of the ion beam.
As the tum r (GTV) moves in and ou of the displayed axial slice the radiological
depth is modified, due to the higher density of the tumor with respect to the lung
tissue. The induced range changes also affect the dose to normal tissue, e.g., the
chest wall. Figure from Bert and Durante (2011).
are much m re sensitive to densi y chang s along their path thr ugh the patient. As the densi y
changes translate directly into a modulation of the i n range in the tissue, structures near the
Bragg peak can be subject to large deviations in absorbed dose w.r.t. the planned dose. This
effect is independent from the beam delivery technique. Range changes may result, e.g., from
varying lung density, bony structures moving in and out of the beam, or small patient position-
ing errors. Figure 2.10 visualizes the significant changes in radiological depth induced by a
moving lung tumor, due to its higher density with respect to the lung (Bert and Durante, 2011).
2.2.2.2 Int rference of beam and target motion
In contrast to passive beam delivery techniques beam scanning deliver the dose to the tar-
get volume in a sequential way using thin pencil beams (section 2.1.3.2). Delivery times per
field typically are on the order of minutes, i.e. much longer than typical breathing cycl . In
this case, interference between the dynamic beam delivery and the target motion can compro-
mise the dose uniformity and conformity, leading to significant over- and underdose (Phillips
et al., 1992) as well as unintended exposure of normal tissue. This so-called interplay effect
(figure 2.11) among other parameters strongly depends on the motion amplitude, the relative
direction between target and beam motion and the extraction rate of the accelerator (Lambert
et al., 2005; Groezinger et al., 2006; Bert et al., 2008). The modeling of the interplay effect and
the determining parameters is of great interest for treatment planning and will be discussed in
detail later in chapter 3. The inherent sensitivity of beam scanning to dose distortions in the
presence of organ motion so far severely limits the clinical application of scanned ion beams for
moving tumors.
2.2.3 Motion mitigation techniques
The impact of inter- and intra-fractional organ motion on the target dose distribution and the
dose in the surrounding normal tissue is a general problem in radiotherapy, therefore, many of
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Figure 4. The general phenotype of interplay patterns is determined by the motion direction
and the scan path which was line-by-line scanning. In comparison to the stationary reference
(a) up–down target motion in beam’s eye view (b) leads to diagonal patterns because the detector
moves vertically during horizontal beam motion. The slope of these patterns depends on the scan
speed and the motion period (see figure 5). Left–right target motion (c) results in stripe patterns
on the left and right sides of the irradiated area. The extent of these stripes is comparable to the
motion amplitude.
Table 2. Results of the treatment-planning study (one fraction, single field). Besides motion
characteristics of each patient, the statistics (mean, standard deviation, minimum, maximum) of
the volume covered by 95% of the planned dose is listed for each motion amplitude.
Patient GTV Motion (mm) Period (s) Mean (%) SD (%) Min (%) Max (%)
A 3D 6.6 2-6 78.8 17.9 37.0 99.8
LR 1.6 2 79.3 17.7 50.1 98.9
AP 5.6 4 78.6 19.2 37.0 97.8
SI 3.1 6 78.4 17.2 43.9 99.8
B 3D 9.6 2-6 67.1 6.1 55.5 85.2
LR 0.7 2 63.4 3.2 57.6 69.5
AP 0.9 4 67.8 2.3 63.4 71.9
SI 9.5 6 70.1 8.7 55.5 85.2
C 3D 14.1 2-6 69.8 8.0 51.7 90.1
LR 12.2 2 71.1 8.5 58.7 90.1
AP 6.1 4 68.0 7.8 51.7 79.6
SI 3.5 6 70.2 7.6 55.0 80.2
D 3D 11.4 2-6 71.6 15.6 32.4 95.0
LR 3.7 2 71.9 17.0 36.4 94.2
AP 5.0 4 70.0 19.4 32.4 95.0
SI 9.6 6 72.8 8.8 58.3 90.9
E 3D 6.0 2-6 67.7 16.1 25.7 99.5
LR 3.1 2 63.9 12.1 46.3 80.5
AP 3.2 4 69.6 3.9 62.9 78.2
SI 4.0 6 69.6 24.8 25.7 99.5
All 2-6 71.0 14.2 25.7 99.8
2 69.9 14.0 36.4 98.9
4 70.8 13.3 32.4 97.8
6 72.2 15.2 25.7 99.8
phase but with the treatment plan optimized to the ITVR. The treated volume is remarkably
larger because the full extent of tumor motion was included in treatment plan optimization.
Figure 2.11.: Impact of the interplay effect on the dose response of radiographic films. (a)
static dose distribution, (b)–(c) show the heterogeneous optical density distribu-
tions obtained for films moving in up-down an left-ri ht direction w.r.t. he b am
incidence. Figure from Bert et al. (2008).
the employed concepts are of relevance also in photon therapy. The mitigation of inter-fractional
organ motion on the basis of repeated imaging, re-planning and adapted treatment delivery is a
separate field of research, usually called adaptive radiotherapy (ART), and will not be discussed
in further detail here. Reviews for adaptive treatment of prostate and liver tumors have, e.g.,
been published by Ghilezan et al. (2010) and Brock and Dawson (2010).
Various different strategies have been developed to face the problem of intra-fractional organ
motion. The following section will introduce these strategies with a focus on scanned beam
delivery. A more detailed discussion of motion management has been published by Bert and
Durante (2011). It should be emphasized that most of the discussed strategies require dedi-
cated treatment planning. Treatment planning for moving targets in ion beam therapy will be
introduced separately in section 2.3.
2.2.3.1 Organ motion reduction
A common approach is aimed on the reduction of organ motion. For instance, abdominal com-
pression has successfully been used in liver and lung treatment with photons to reduce the mean
motion below 10 mm (Negoro et al., 2001; Hof et al., 2003). The compression is usually ap-
plied mechanically via an adjustable plate on a frame (Eccles et al., 2011). The technique is also
employed for scanned carbon therapy of hepatocellular cancer at HIT. The partial or complete
suppression of respiration can, e.g., be achieved by using jet-ventilation (Hof et al., 2003) or ap-
neic oxygenation (RPTC, 2011). All these approaches, however, increase the clinical workload
with respect to technical requirements and patient setup time.
2.2.3.2 Treatment margins and plan adaption
The adaption of the treatment plan in practice is often used in conjunction with additional
motion mitigation techniques. Optimization of safety margins is done during treatment planning
which will be introduced later in this chapter. For reasons of clarity, the common definitions of
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Figure 2.12: The clinical target volume (CTV) encom-
passes the gross tumor volume (GTV), in-
cluding possible microscopic tumor spread.
The internal target volume (ITV) is formed
from the union of CTV contours through-
out the full motion cycle. PTV margins take
into account geometrical uncertainties and
avoidance of organs at risk (OARs).
CTV
PTV
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GTV
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treatment margins shall be given here already. The ICRU recommends the definition of a number
of volumes for treatment planning (ICRU, 1993a, 1999):
Gross Tumor volume: ‘The GTV is the gross palpable or visible/demonstrable extent and location
of malignant growth.’
Clinical Target Volume: ‘The CTV is a tissue volume that contains a demonstrable GTV and/or
subclinical microscopic malignant disease, which has to be eliminated. This volume thus has
to be treated adequately in order to achieve the aim of therapy, cure or palliation.’
Planning Target Volume: ‘The PTV is a geometrical concept, and it is defined to select an appro-
priate beam size and beam arrangements, taking into consideration the net effect of all the
possible geometrical variations, in order to ensure that the prescribed dose is actually absorbed
in the CTV.’
Internal Target Volume: This is the margin that must be added to the CTV to compensate for
expected physio-logical movements and variations in size, shape, and position of the CTV
during therapy.’
Organs at risk: ‘Organs at risk (OAR) are normal tissues whose radiation sensitivity may signifi-
cantly influence treatment planning and/or prescribed dose.’
A usual configuration of treatment volumes is shown in figure 2.12. For passive beam delivery
the sole enlargement of the treatment margins, such that the tumor is in the treatment field at
all times, can be an option and has successfully been used at NIRS (Nihei et al., 2006). Due to
the interplay effect the mere adaption of the margins is usually not feasible for scanned beam
delivery and has to be accompanied, e.g., by the adaption of the beam delivery, as discussed in
the following section.
Apart from the adaption of treatment margins a dedicated optimization of other treatment
plan parameters is possible. The optimization of treatment plan and beam parameters to mit-
igate small residual motion under abdominal compression or in comparable scenarios with re-
duced tumor motion will be a major focus of this work in the chapters 4–5.
2.2.3.3 Beam gating
Beam gating is the irradiation in a selected part of the breathing cycle only, the gating win-
dow (GW) (Minohara et al., 2000; Lu et al., 2006a). Typically, the rather stable and reproducible
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Figure 2.13.: Simplified diagram of the gating delivery mode with a synchrotron accelerator. The
logical gate signal is generated by applying the gating window (GW) to the motion
monitoring signal. Irradiation is only possible if the gate signal is active during beam
availability. The amount of residual tumor motion depends on the GW size.
exhale position is chosen as the center of the gating window. The extraction of the beam is con-
trolled using a motion monitoring signal (section 2.2.4). A major disadvantage of this technique
is the prolonged treatment time due to the frequent interruptions of the beam. In figure 2.13
the principle of gating is shown schematically for a synchrotron accelerator. As depicted, the
additional folding of the gate signal with the accelerator’s duty cycle results into even longer
treatment times. However, it has been shown that optimization of the synchrotron cycle is pos-
sible and can considerably limit the increase in treatment time (Tsunashima et al., 2008). The
efficiency can be further improved by the extraction of multiple beam gates per synchrotron
pulse (spill). For that purpose, so-called knock-out extraction (KO) has been implemented at a
number of facilities, including HIT (Noda et al., 1996; Heeg et al., 2004).
Gating has successfully been used for the treatment of lung and liver cancer at several centers
with passive beam delivery systems (Iwata et al., 2010; Hashimoto et al., 2006). Since the GW
has a finite size, a corresponding residual motion inevitably remains. For beam scanning this
can result into dose inhomogeneities due to the interplay effect. For this reason to date only few
gated treatments have been performed using beam scanning. The amount of residual motion
depends on the GW and is typically on the order of few millimeters and therefore comparable to
the situation of abdominal compression for liver and lung tumors. The optimization of treatment
plan parameters to mitigate residual motion effects has been proposed by Bert et al. (2009). This
is the central research topic of this work and will be dealt with in chapters 4–5. An alternative
approach is pursued by NIRS and PSI, in which additional plan robustness can be gained by
combining gating with the rescanning technique (Furukawa et al., 2007; Zenklusen et al., 2010).
2.2. Treatment of moving tumors 21
2.2.3.4 Rescanning/Repainting
The rescanning technique is a specific approach for scanned beam delivery. It aims at a statistical
leveling of the dose inhomogeneities originating from beam interference effects by performing
repeated fractional irradiation of the same volume (Phillips et al., 1992). A number of rescan
options have been proposed so far, all having their specific characteristics (Furukawa et al.,
2007; Rietzel and Bert, 2010; Zenklusen et al., 2010). The major discussed options are slice-
by-slice rescanning and volumetric rescanning. A number of groups have proposed strategies to
additionally ensure the statistical leveling of the dose after a number of rescans, namely random-
delay rescanning (Seco et al., 2009; Rietzel and Bert, 2010) and phase-controlled rescanning or
breath-sampled rescanning. In the latter two the rescans are performed equally distributed over
the respiratory cycle, resulting into fewer required rescans and increased robustness. (Furukawa
et al., 2010a; Seco et al., 2009).
In contrast to gating, rescanning requires to enlarge the treated volume to at least the envelope
of the tumor in all motion states. This may result in considerable dose to normal tissue and
constitutes a major disadvantage of the technique. Despite the breath-sampled options, the
delivery of rescanning is technically simple and does not require real-time motion monitoring
(section 2.2.4). So far, rescanning has not yet been established in patient treatments but is
planned for the future, e.g., at NIRS (Furukawa et al., 2007) and PSI (Zenklusen et al., 2010).
2.2.3.5 Beam tracking
Beam tracking was originally proposed for photon IMRT (Keall et al., 2001). The underlying
concept is to adjust the treatment beam with respect to the tumor and to establish the full
compensation of the target motion such that no additional margins will be required. Beam
tracking is clinically used in x-ray radiosurgery in the robotic Cyberknife Synchrony system
(Accuray Inc., Sunnyvale, Ca., USA) (Brown et al., 2007; Kilby et al., 2010).
A full tracking system for scanned beam delivery has been implemented at GSI. Lateral com-
pensation is performed with the two scanner magnets, while longitudinal range adjustment
requires fast energy modulation via a linear motor-driven double wedge system (Weber et al.,
2000). The correction of the beam position is performed based on a motion monitoring signal
and pre-calculated look-up tables for the compensation parameters. The system has been fully
integrated into the GSI treatment control system. Dosimetric and technical tests have proven
high precision of the system (Bert and Rietzel, 2007; Bert et al., 2010; Saito et al., 2009). Reli-
able clinical use of the system, however, requires accurate four-dimensional (4D) imaging data
and fast and precise real-time internal motion monitoring to ensure proper functioning of the
motion compensation. This is currently not feasible.
2.2.4 Motion monitoring
The application of motion monitoring in radiotherapy is manifold, ranging from passive moni-
toring over interlock generation during treatment delivery to active beam delivery control as in
the beam gating or beam tracking techniques discussed above. Motion monitoring techniques
can be grouped into those directly measuring the tumor position, as in fluoroscopic imaging
(Shirato et al., 2000; Berbeco et al., 2004) or with electromagnetic transponders (Balter et al.,
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2005), and motion surrogates utilizing body surface expansion, air flow or other secondary sig-
nals. Commercially available system, e.g., are the Varian RPM system (Varian Medical Systems,
Inc.) using infrared reflective markers in combination with a camera tracking system and the
ANZAI AZ-773V system (ANZAI MEDICAL CO., LTD) employing either laser distance or pressure
sensors attached to a waist belt (Li et al., 2006). Surrogate motion monitoring systems do not
allow for absolute measurement of organ motion. Instead, they are used to detect the motion
state of the patient relative to the respiratory cycle.
2.3 Treatment planning
Modern three-dimensional treatment planning is based on a computed tomography (CT) of the
volume of interest. The volumetric dataset is the basis for the delineation of the target volume,
nearby organs and critical structures by a physician. Other fused volumetric data sets like mag-
netic resonance imaging (MRI) or positron emmission tomography (PET) can be used in support
during the delineation process. The common definitions of the different treatment volumes have
been introduced in the last section (cf. figure 2.12 on page 20). The core task of treatment plan-
ning is the dose optimization process. That is the determination of the machine-dependent
delivery parameters needed to yield the prescribed—usually homogeneous—PTV dose coverage
for a chosen beam configuration while minimizing the dose to normal tissue. According to rec-
ommendations by the ICRU, 100% of the PTV volume should receive between 95 % and 107 %
of the planned dose (ICRU, 1993a). The dose optimization is normally performed in an iterative
computational way using a treatment planning system (TPS). Treatment planning strongly de-
pends on the employed radiation type and the beam delivery technique. The following section
will concentrate on the specifics for scanned ion beam therapy.
2.3.1 Treatment planning for scanned ion beams
In treatment planning for scanned ion beams the characteristics of the active beam delivery sys-
tem and the physical interactions of the ion radiation in the tissue have to be considered. For
heavier ions than protons the modeling of the biological effectiveness adds additional complex-
ity, due to the multiple dependencies of the RBE (section 2.1.2). Several treatment planning
systems have been developed at the different centers employing beam scanning, e.g., at PSI
(Scheib, 1993) and at NIRS (Inaniwa et al., 2008). In the following, the fundamental steps in
treatment planning with the GSI treatment planning system, TRiP98, will be briefly introduced,
as they are of further interest later in this work. A detailed description of the program and the
underlying concepts can be found elsewhere (Krämer et al., 2000; Krämer and Scholz, 2000).
The treatment planning process is aimed at the optimization of a treatment plan which is
applicable with the raster-scanner system (section 2.1.3.2) and yields a prescribed (biologically
effective) dose distribution. The plan consists of raster points in a defined order (scan path).
They are organized in slices of specific energy and beam FWHM. The optimization task is
to determine the required energies, positions and particle numbers of all superimposed pencil
beams, so that the optimal target dose distribution is obtained. The employed physical beam
model uses a pencil beam approach with a Gaussian beam profile in combination with measured
depth-dose curves in water. Lateral scattering is included based on Molière’s theory (Molière,
1948). Ion transport model calculations take into account nuclear fragmentation and yield
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secondary particle spectra in energy and atomic number. Tissue inhomogeneities are accounted
for using the planning CT dataset. The Hounsfield units (HUs) (representing x-ray attenuation,
thus, essentially the electron density) are voxel-wise2 related to a water-equivalent path length
(WEPL) using a piece-wise linear calibration curve which has been determined in dedicated
measurements with tissue-equivalent materials (Geiss et al., 1999; Jäkel et al., 2001a; Rietzel
et al., 2007). Calculation of the biological effectiveness in TRiP98 is performed using the local
effect model (section 2.1.2). Starting from the secondary particle spectra in energy and atomic
number the model is able to relate local ionization densities to a biological effectiveness at any
point in the treatment field. Dose optimization is performed iteratively and takes into account
the RBE for each target voxel. The algorithm initially distributes raster points according to the
requested raster spacing in each of the energy layers covering the target in water-equivalent
space. The subsequent least square minimization algorithm determines the required particle
fluences per raster point. The physical and biological beam models are used to calculate the
dose contributions from all raster points to each individual target voxel.
It should be noted that the modeling of the beam delivery in TRiP98 does not include any
time structure, i.e. it neglects the subsequent nature of the beam scanning process and any
target motion. The tumors treated in the GSI pilot project were mostly tumors of the brain and
pelvis which could be well immobilized. Thus, they were considered static on the time-scale of
the treatment delivery and no interference with the beam scanning had to be taken into account.
Per definition this is no longer the case for intra-fractionally moving tumors. For treatment of
this kind of tumors 4D treatment planning (4DTP) is essential.
2.3.2 4D treatment planning
It has been shown by several studies that higher tumor dose, e.g., in lung cancer, can signif-
icantly improve local tumor control rates (Rosenzweig et al., 2005; Kong et al., 2005). It is
also observed that radiation-induced complications depend significantly on the normal tissue
dose. For instance, Belderbos et al. report that the probability of acute esophagus toxicity in
treatment of lung cancer is significantly correlated with the volume receiving a dose of at least
35Gy (Belderbos et al., 2005). The objective of 4D radiotherapy (4DRT) is to increase the dose
to the moving tumor while sparing the normal tissue and can be defined as “the explicit inclusion
of the temporal changes in anatomy during the imaging, planning and delivery of radiotherapy”
(Keall, 2004). This section will concentrate on the planning aspect of 4DRT. In the following,
the technical prerequisites for 4D treatment planning will be described. Emphasis will be put on
4DTP for ion beams. Further details on 4DTP aspects will then follow in the subsequent chapter
which focuses on the development of a 4DTPS for ion beams.
2.3.2.1 Time-resolved computed tomography
The basis for 4DTP is time-resolved computed tomography (4DCT) which was developed at several
centers in the past decade and is now readily available (Ford et al., 2003; Keall, 2004; Rietzel
et al., 2005a) in clinical routine. 4DCT data acquisition is performed in dedicated protocols
which ensure that projection data of the rotating x-ray tubes are taken over a full respiratory
cycle at each couch position. The projections are assigned retrospectively to the respective state
2 A voxel is a volume element and the 3D analogon of a pixel.
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Figure 2.14.: Axial (a), coronal (b) and sagittal (c) view of the reference 4DCT phase (end-exhale)
of a lung cancer patient. The deformation field transforming it to the end-inhale
phase is visualized by the overlayed vector field. The predominant motion in SI
direction is characteristic of respiration-induced motion.
(a) (b) (c)
of motion. Time correlation between the patient motion and the time stamp of the projections
is established using a surrogate motion monitoring device (section 2.2.4). The reconstruction
process yields a time series of three-dimensional computed tomographys (3DCTs) capturing the
change of anatomy over time. Typically, on the order of ten respiratory states are acquired. The
distribution of these so-called 4DCT phases3 over the respiratory cycle depends on the employed
protocol. The 4DCT phases can, for instance, be defined using the amplitude (amplitude-based),
or the phase (phase-based) of the surrogate signal (Lu et al., 2006c).
2.3.2.2 Image registration and contour propagation
The information provided by 4DCT on the temporal changes of the anatomy can only be used
to the full extent if a spatial correlation between the individual 4DCT phases is established, i.e.
image registration is performed. Image registration establishes a voxel-to-voxel mapping from
a reference phase to any other phase of the breathing cycle. In figure 2.14 the end-exhale phase
of a the 4DCT of a lung cancer patient is shown, including the deformation fields matching
it with the end inhale phase. Usually rigid registration and deformable registration methods
are distinguished. Various registration algorithms have been published in the literature (Hill
et al., 2001; Brock et al., 2006; Rietzel and Chen, 2006b). The performance and accuracy of
some of the available algorithms has been evaluated recently in a dedicated multi-institutional
study (Brock, 2010). Brock et al. found that the registration accuracy for the majority of the
algorithms is on the order of the CT voxel size, i.e. millimeters. However, their findings also
indicate that image registration accuracy is dependent on the image contrast. It should be noted
that registration inaccuracies translate directly into further treatment planning steps, such as 4D
image segmentation.
Ideally, delineated structures on all 4DCT phases are available for the subsequent steps in
4DTP. The amount of image data in 4D imaging is increased roughly by one order of magnitude
compared to 3D imaging. Thus, manual contouring, as in a conventional work flow, is time-
consumptive and in general not feasible. Therefore, contour propagation methods are often
used to automate this procedure. An overview of the available techniques can be found in (Xing
et al., 2007). One approach is to propagate the manually contoured region of interest (ROI)
3 The terms motion phase and motion state are also used frequently in the literature and will be used synony-
mously here.
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on the reference phase to all other phases by using the deformation maps obtained by image
registration (Lu et al., 2006b). Alternatively, elastic deformable models can be employed which
locally adjust the reference phase contours to the test image by physical modeling of image
forces (McInerney and Terzopoulos, 1996).
2.3.2.3 Target volume definition and motion mitigation
As already introduced in section 2.2.3, a widely used approach to include organ motion into
the planning process is the generation of an internal target volume (ITV) which is formed by
the union of the CTV in all relevant motion phases (ICRU, 1999). Different options of this
geometrical concept have been reported for photon therapy (Rietzel et al., 2006; de Orban et al.,
2007; Wolthaus et al., 2008). For ion beams this geometrical approach is not sufficient (Moyers
et al., 2001; ICRU, 2007) and needs to be modified, taking into account range variations of
the beam. An overview of the techniques currently used for passively delivered ion beams
was published recently by Bert and Durante (Bert and Durante, 2011). For scanned ion beam
therapy an approach based on 4DCT has been proposed (Bert and Rietzel, 2007; Rietzel and
Bert, 2010). In the most recent version the full target dimensions in water-equivalent space
in the respective motion phases are considered for the design of the ITV. It should be noted
that the formation of the ITV depends on the employed motion mitigation technique. For beam
gating, for instance, ITV generation needs to be performed using the 4DCT phases in the gating
window only.
Bert and Rietzel (2007) have incorporated 4DTP functionality for gating, rescanning and
tracking into the GSI treatment planning system TRiP98. Apart from the ITV generation for res-
canning and gating, optimization of compensation parameters for beam tracking are supported.
The basic planning strategy in TRiP98 is to optimize a treatment plan on a reference 4DCT phase
and to ensure adequate dose coverage of the target volume in the other phases either by opti-
mization of compensation parameters in beam tracking or by the use of an appropriate ITV in
combination with gating or rescanning. However, as introduced in section 2.2.3, the mere use of
enlarged margins, i.e. an ITV, is not sufficient for scanned beams. Even in the case of gating or
small uncompensated target motion—as in treatments under abdominal compression—residual
motion will induce interplay effects. Bert et al. have proposed to optimize the beam’s FWHM
and the distance of iso-energy slices to mitigate the resulting dose inhomogeneities (Bert et al.,
2009). The research questions addressed in this dissertation are tying up to these investigations.
2.3.2.4 4D dose calculation and optimization
Complementary to the treatment plan optimization step 4D dose calculation is an important tool
in 4DTP. For ion beams it allows to quantify dose heterogeneities caused by interplay effects. 4D
dose calculation algorithms exploiting deformable image registration have been developed by
several groups. Depending on the 4DCT sampling technique, weighting of the individual dose
distributions is needed for photons and passive ion beam delivery (Rietzel et al., 2005a). For
scanned beams the time-structure of the sequential plan delivery has to be considered (Bert and
Rietzel, 2007; Paganetti et al., 2004). Summation of the individual dose contributions is either
done by transforming dose contributions in each phase to a common reference frame (Bert and
Rietzel, 2007) or by deforming the dose grid (Knopf et al., 2010b). The latter approach has the
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advantage that it also enables for biological dose calculation, which is particularly important for
heavy ion therapy. Based on this principle, Gemmel et al. have implemented a 4D dose algorithm
into the GSI TPS which is capable of biological and physical dose calculations (Gemmel et al.,
2011). The algorithm was validated in cell survival measurements using a dedicated phantom.
The implementation and validation of 4D dose calculation and the modelling of interplay effects
will be dealt with in further detail in the next chapter.
In contrast to the strategy of planning on a reference phase only, the full incorporation of
the complete 4DCT information into the dose optimization process seems promising. At the
time of writing no full 4D optimization has been reported for particle beams. However, several
attempts have been made for x-ray therapy. Unkelbach et al. (2009), e.g., have studied robust
treatment plan optimization based on probability distributions of patient geometries. Suh et al.
(2009) and Nohadani et al. (2010) have developed robust inverse planning techniques for IMRT
motion tracking that incorporate possible variations in the patient’s breathing cycle.
2.4 Summary
In this chapter the rationale for the clinical application of ion beam radiation has been defined
and the physical and biological properties of ions have been introduced. Their specific advan-
tages and characteristics have been described and the different existing techniques to deliver
ion beams to the tumor volume were discussed. Emphasis was put on the beam scanning tech-
nique. Furthermore, the problem of organ motion in modern radiotherapy has been illuminated
and the different existing techniques to manage organ motion effects have been introduced. In
particular, the mitigation of interplay effects for scanned beams and of the induced changes in
radiological depth has been motivated. In the last section the requirement of dedicated 4DTP for
scanned ion beams was clarified and an overview of the current state of research in the field was
given. To address the subject of this dissertation—the mitigation of residual tumor motion—a
functional 4DTPS is indispensable. The posed problem required a substantial revision of the
existing GSI 4D treatment planning functionality and its integration into a new software. The
implementation of this system will be described in the subsequent chapter.
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3 Development of a 4D treatment planning
system for scanned ion beam therapy
In the preceding chapter the principal steps required in treatment planning for static targets
were discussed for the GSI in-house treatment planning system, TRiP98 (Krämer et al., 2000;
Krämer and Scholz, 2000; Jäkel et al., 2001a). Its original design was geared to treatment
planning for head and neck tumors, thus, any effects of organ motion could safely be neglected.
The treatment of moving organs with a scanned beam introduces additional complexity in a two-
fold way. Firstly, the individual intra-fractional changes of the patient’s anatomy over time and
their impact on the relative beam position need to be considered, in order to avoid geometric
miss. Secondly, the temporal structure of the dynamic beam delivery process, its interaction
with the target motion and the negative impact on the dose coverage (interplay effect) has to
be taken into account (Bert and Durante, 2011).
This chapter will present the development of a 4DTPS, based on the TRiP98 program, named
TRiP4D in the following. The first section will review the previous efforts made in the develop-
ment of 4DTP functionality at GSI and will define the design requirements for the new software.
The second section focuses on the implementation of the respective functionality into TRiP4D.
The validation of the 4DTPS is presented in the third section. Finally, the last section discusses
the results of the software implementation and validation.
3.1 Introduction
The initial attempts made at GSI with respect to irradiation of moving tumors were focused on
the implementation of a beam tracking solution (section 2.2.3). Li et al. established a simulation
environment based on TRiP98 concentrating on 4D dose calculation for beam tracking and
uncompensated irradiation of moving targets (Li et al., 2004). Target motion was modeled
rigidly only, i.e. translational and rotational. Simulation of the dynamic beam delivery was based
on single measured beam intensity profiles which were applied cyclically and took into account
spill pauses of the synchrotron accelerator. The program was capable of 4D dose calculation
with variable time resolution for artificial and experimental water phantom setups (Groezinger
et al., 2006). The program was successfully validated in film measurements (Li et al., 2004).
However, the program’s design was not compatible with the upcoming 4DCT and deformable
registration workflows and, therefore, was not suitable for simulation of time-resolved dose
delivery in a realistic patient environment.
In a more general approach, Bert and Rietzel implemented 4DTP functionality for ion beams
in a newly developed descendant of TRiP98 (Bert and Rietzel, 2007). The design was primar-
ily led by 4DTP workflows based on 4DCT and deformable image registration, as proposed for
4D photon therapy (Keall, 2004; Rietzel et al., 2005a). The temporal changes of the anatomy
during beam delivery, i.e. the transitions through the CT phases, were determined from motion
monitoring traces. Sub-treatment plans for each 4DCT phase, containing all raster points irradi-
ated in a particular phase, were generated on the basis of the time-correlated motion trace and a
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time-resolved beam delivery sequence. 4D physical dose calculation was established by sequen-
tial 3D dose calculation for each sub-treatment plan on the respective CT phase and subsequent
transformation of the sub-distributions to the reference phase. Apart from beam tracking and
uncompensated irradiation the program also was capable of simulating rescanned and gated
beam delivery. Compared to Li et al., the time structure of the irradiation was incorporated in a
more realistic way using beam intensity courses simulated or measured over the entire delivery
time. Also, 4D optimization functionality was developed comprising the calculation of motion
compensation parameters for beam tracking and the design of ITVs in water-equivalent space
for realistic patient geometries. An improved version of beam tracking takes into account real-
time adaption of the particle numbers per raster point, in order to compensate for dose changes
caused by target rotation or deformation. Validation of the 4DTPS was performed in numerous
experiments (Bert et al., 2010; Bert, Richter et al., 2012).
The sequential nature of the TPS and the 4D dose calculation algorithm developed by Bert
and Rietzel has proven incompatible with the calculation of biologically effective dose. Since
the RBE value depends non-linearly on the full spectrum of energies and particles contributing
to the total physical dose at each point in the treatment field, it can not be determined from
the constituent physical dose distributions per CT phase. Therefore, Gemmel et al. (2011) de-
veloped a complementary program based on TRiP98. It featured a dedicated 4DCT structure
for full access during run-time and a new biological dose calculation concept considering par-
ticle spectra and dose contributions from all CT phases to the total dose at each point in the
treatment field. Furthermore, the algorithm also was capable of calculating 4D physical dose
distributions. The code has been successfully verified in cell survival measurements in the pres-
ence of target motion (Gemmel et al., 2011). It should be emphasized that the program relied
on functionality and intermediate results from the TPS of Bert and Rietzel and did not constitute
a full replacement of the latter.
Although well tested and established in experiments, the 4DTPS codes previously available at
GSI carry substantial limitations with respect to 4D treatment planning for realistic patient ge-
ometries. The existing approaches also suffer from decentralized functionality and cumbersome
workflows. Against the background that the treatment of abdominal-compressed hepatocellular
tumors at HIT has been commenced recently and other tumor sites subject to intra- and inter-
fractional motion are planned for the near future, an integrated and efficient 4DTPS is strongly
required. Considering the experiences made and the current state of research in the field of 4D
radiotherapy the following central requirements were defined for the new treatment planning
system, TRiP4D:
(1) TRiP4D is based on TRiP98 for efficient use of the well established 3D treatment planning
functionality, as well as the physical and biological beam model. New functionality is to be
integrated using existing conventions and must not impair existing core functionality.
(2) The existing functionality of the predecessor programs should be fully integrated. This
particularly includes 4D (biological) dose and detector response calculation as well as the
generation of quasi-static sub-treatment plans based on temporal correlation of a time-
resolved beam delivery sequence and motion traces.
(3) New structures are to be integrated as flexibly and efficiently as possible to meet the re-
quirements of future research, such as 4D dose optimization tasks. This specifically requires
30 3. Development of a 4D treatment planning system for scanned ion beam therapy
run-time access to all 4D structures and rules out sequential calculation procedures in sep-
arate sessions and remote access to external software as employed by Bert and Rietzel.
(4) 4D optimization and beam delivery for multiple treatment fields, as needed for typical clini-
cal treatment plans, have not been available with the previous planning systems and should
be incorporated in compliance with TRiP98’s 3D design concepts for multiple fields (Gem-
mel et al., 2008).
(5) Previous GSI planning systems were lacking dedicated structures and functionality for 4D
segmentation and deformable image registration support. Key requirements are the flexible
integration of deformation maps of various registration software packages, the propagation
of contours from a reference CT phase and their efficient handling throughout the 4D plan-
ning process. Similarly, support for 4DCT data as introduced by Gemmel et al. needs to be
significantly extended.
(6) Full compatibility of the program to the clinical treatment planning workflow at HIT and
similar facilities needs to be established. Specifically, this includes the 4DCT protocol and
motion monitoring data. In earlier implementations the integration of realistic patient mo-
tion traces was restricted to amplitude-based motion state identification (section 2.3.2). In
clinical practice motion state identification and the corresponding signal processing routines
have to be integrated into the TPS in accordance with the 4DCT protocol.
(7) The design of TRiP98 is compatible with scanned beam delivery systems similar to the one
used at GSI. Modelling of 4D beam delivery using time-resolved beam delivery sequence
data therefore should be flexible enough to ensure compatibility to the respective systems,
in particular the one used at HIT.
3.2 Implementation
The TRiP98 mother program is a command-line-based software without graphical user inter-
face. It is written in C programming language using a pseudo object-oriented structure and
natively runs on an IBM AIX operating system. The development of TRiP4D has been performed
in a development branch of TRiP98. The inherent complexity and scope of operation of the
program involves constant evolution and refinement. The information given here represents
the state of TRiP4D and its mother program TRiP98 at the time of writing and may be subject
to changes in the future. The author was the main person responsible for the development of
TRiP4D. However, the work of collaborators significantly contributed to the functionality. Their
contributions will be indicated in the respective places.
In the following, the implementation of the 4D treatment planning functionality of TRiP4D
will be discussed. The first section will concentrate on the modeling of patient anatomy changes
in TRiP4D. Subsequently, the currently pursued four-dimensional optimization strategy will be
discussed. In the last section TRiP4D’s 4D treatment simulation capabilities and the required
components are dealt with.
3.2.1 Moving patient geometry
The modeling of the moving patient geometry in the 4DTPS involves integration of 4DCT imag-
ing, motion monitoring and of 4D segmentation of anatomic structures as well as interpretation
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of deformation maps obtained by deformable image registration. This section will discuss the
development and implementation of the required modules in TRiP4D.
3.2.1.1 4D computed tomography
Imaging, characterization and quantification of the moving patient geometry can be considered
the first step in 4D treatment planning (Keall, 2004; Chen et al., 2007). Time-resolved com-
puted tomography (4DCT) has proven essential for the assessment of patient motion and 4D
treatment planning tasks, such as the design of safety margins and 4D dose calculation (Rietzel
et al., 2005b). Dedicated 4DCT structures and functionality have been implemented in TRiP4D,
in order to fully exploit its potential for treatment planning.1 Since 3DCT datasets are the
starting point for any 3D treatment planning workflow in TRiP98, corresponding structures and
extensive functionality were well established and served as a basis for the integration of 4DCT.
The 4DCT structure was implemented as a sequence of 3DCTs, mapping its real representation
as a time-correlated series of individual 4DCT phases, i.e. 3DCTs, with a distinguished reference
state CT. Individual 4DCT phases are characterized and indexed by their position in the res-
piratory cycle. The mapping of an external surrogate motion trace to the corresponding 4DCT
state at a certain time is essential for the simulation of 4D treatments and will be discussed in
the subsequent section. The reference state CT of the 4DCT structure supersedes the original
CT of the 3D workflow, e.g., for dose optimization tasks. The comprehensive and already estab-
lished 3DCT functionality, such as the computation of water-equivalent path lengths, could be
re-used efficiently for the constituent 4DCT phases. The current integration of 4DCT in TRiP4D
enables elaborate planning tasks like biological 4D dose calculation, as it provides access to the
full 4DCT information at run-time of the program. It should be noted that the data volume for
4DCT is increased by about one order of magnitude with respect to 3DCT datasets with a typical
4DCT consuming on the order of 0.5 GB of memory. The existing memory-mapping approach for
3DCTs in TRiP98 therefore has been extended to the 4DCT structures. TRiP98 supports the na-
tive data format of the VOXELPLAN planning system developed at DKFZ (Schlegel et al., 1992)
for any data input and output. The corresponding routines in TRiP4D have been extended for
compatibility with 4DCTs datasets. The usability of DICOM standard CT data is guaranteed by
a dedicated in-house DICOM converter software (appendix A.1).
3.2.1.2 Motion monitoring data
Retrospective reconstruction of 4DCT requires a surrogate motion signal to determine the respi-
ratory state of the patient throughout data acquisition (Ford et al., 2003; Rietzel et al., 2005a).
Similarly, for simulation of a 4D treatment delivery the transition of the patient through the
4DCT states over time has to be known. The latter will be discussed in detail in section 3.2.3.1.
Signal handling and processing of realistic patient motion trajectories has been integrated
into TRiP4D. Compatibility of the TPS to the ANZAI AZ-733 system (ANZAI MEDICAL CO.,
LTD) has been established, including the implementation of an interface for the acquired motion
traces. The ANZAI system provides a one-dimensional surrogate signal from either a pressure
sensor in a waist belt or a laser distance measurement. The system is used clinically for motion
1 The 4DCT functionality has been implemented in close collaboration with two master students, A. Schwarzkopf
and J. Trautmann, which were supervised by the author.
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monitoring and 4DCT acquisition at HIT and UCHD and is the designated control device for
gated treatments.
Additionally, a general motion trace format has been established supporting 3D position mea-
surements for multiple markers. It is expected that general compatibility to the format can
be easily facilitated for other commercial monitoring systems by data conversion or adaption.
The format also is compliant with the information provided by the ANZAI system. Dedicated
routines are available for automatic generation of regular sinusoidal motion traces or traces ac-
cording to Lujan et al. (1999) for experimental purposes. Additional routines for motion trace
manipulation and signal processing, such as signal-smoothing have been implemented.
In TRiP4D two different kinds of motion signals can be used in parallel, i.e. the surrogate
signal and the internal motion signal. The latter holds the true motion data to be used for
4D dose reconstruction while the former represents the observed motion signal and may, for
instance, include phase shifts or base-line drifts w.r.t. the internal motion. In this way real-time
decisions based on motion monitoring and affecting the beam delivery course, such as motion
state identification for beam tracking, can be modeled correctly.
3.2.1.3 Image registration and deformation maps
The implicit information of 4DCT data on the spatial and temporal changes of the patient’s
anatomy can be extracted with image registration which establishes the alignment between a
fixed reference state CT and a test 4DCT state. The resulting deformation maps represent voxel-
to-voxel displacements between the registered CTs and are a key prerequisite for quantitative
incorporation of 4DCT information into the treatment planning process. Various algorithms
have been published in the literature (Rietzel and Chen, 2006a; Kessler, 2006; Yang et al.,
2008). Their individual characteristics and performance is beyond the scope of this work.
The output of the registration process of a 4DCT with N states can be characterized by N − 1
transformation maps, T ri(x ), relating a distinguished reference state r and a state i 6= r. The
map relates the position of a point x ′ in state i to its position x in the reference state:
x ′ = x + u ri(x ) . (3.1)
In its simplest form the vector displacement u ri(x ) is directly given by a vector field represen-
tation of T ri(x ), however, depending on the registration software the vector field may have to
be reconstructed first from the registration output data, as in the case of a B-spline parameter
representation.
Integration of deformation maps
At the time of writing the design of TRiP4D did not include native image registration function-
ality. Since various reliable external registration software packages are available, it is sufficient
and more flexible to only integrate the interfaces to the respective programs in TRiP4D, i.e. the
input and processing of image registration output. A separate module has been implemented
in TRiP4D which supports reading and processing of deformation maps of the open source
software packages Plastimatch (Sharp et al., 2007), VTK CISG (Hartkens, 1993) and of a com-
mercial Siemens prototype software.2 VTK CISG provides binary B-spline-based parameter sets
2 The work of two master students, A. Schwarzkopf and J. Trautmann, has contributed to the discussed imple-
mentation.
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from deformable image registration while Plastimatch and the Siemens prototype deliver CT-
like volume datasets in vector field representation. Compatibility to the B-spline representation
also provided by Plastimatch has not been established so far. Priority was given to the integra-
tion of deformation maps in volume dataset representation featuring one CT-like structure per
displacement vector component and state transition r → i:
T ri(x ) =
(
T xri(x ), T
y
ri(x ), T
z
ri(x )
)
. (3.2)
This representation is compatible with both the registration output of Plastimatch and the
Siemens prototype and requires only minor pre-processing for TRiP4D. The approach of a
general implementation of CT-like deformation maps seems promising for three reasons.
(1) All registration software packages should, at least in principle, be able to deliver the reg-
istration output in this basic form, although minor differences in the data format are to
be expected. Hence, compatibility to other registration software packages can easily be
established in the future.
(2) The interpretation of the volume dataset deformation maps is simple and does not require
extensive, software-specific algorithms and calculations as, e.g., the evaluation of B-spline
parameters.
(3) The CT-like structure enables efficient use of existing and well tested basic functionality for
similar volume datasets in TRiP4D.
It should be emphasized that memory consumption of deformable registration maps in the
form of volume datasets is substantial and easily amounts to more than 1GB of memory for a
complete set of deformation maps, depending on the number of 4DCT states and the resolution
of the volume datasets. Specific steps of 4D treatment planning, e.g., contour propagation
(section 3.2.1.4), also require the inverse deformation maps, T ir(x ). In general, these have to
be obtained from a separate registration process. In order to improve memory efficiency, subsets
of the deformation maps can be selected for the respective planning tasks via the command-
line interface. Additionally, the program can handle volume dataset deformation maps at any
spatial resolution and independent from the original CT voxel spacing. Consequently, also lower
resolution deformation maps can be employed, further limiting the memory consumption.
Apart from deformable registration, rigid registration is of frequent interest in treatment plan-
ning, e.g., when modeling experimental setups. Rigid transformation maps in TRiP4D have been
implemented employing the commonly used 4×4 matrix representation and formalism (Veblen
and Young, 2005). TRiP4D supports affine deformation maps provided by VTK CISG and a
native deformation map format expected to be generally compatible with other registration
software packages delivering matrix-based rigid deformation maps. Dedicated routines have
been added for fast and convenient generation of rigid deformation maps based on regular
motion trajectories or specified parameters to suit experimental needs.
Coordinate transformation
Interpretation and evaluation of the deformation field is required in various steps through-
out 4D treatment planning and involves calculation of displacement vectors for a given source
vector and destination state. In general, the coordinate systems of TRiP4D and the respective
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registration software have to be aligned before the actual transformation. This has been im-
plemented by additional rigid transformation of the source and displacement vectors such that
(3.1) translates into:
x ′ = x + P−1u˜ ri(P · x ) . (3.3)
Here P and its inverse, P−1, denote the 4× 4 matrices transforming the respective coordinate
systems of TRiP4D and of the registration software into each other. u˜ ri is the displacement vec-
tor in the extrinsic coordinate system. The matrices P and P−1 usually depend on the employed
registration software only. However, they also can flexibly be defined by the user, if required.
Calculation of the displacement vectors, u ri(x ) = P−1u˜ ri(P · x ), is carried out depending on
the deformation map modality. For B-spline maps the corresponding parameters are employed
to reconstruct the deformation field u˜ ri at the requested position using a software-specific algo-
rithm. For volume dataset maps u˜ ri is directly given on a discrete voxel grid. To determine the
deformation vector at an arbitrary position, trilinear interpolation of u˜ ri is performed among
the neighboring voxel centers. Finally, the evaluation of rigid deformation maps at a certain
position x involves matrix multiplication with the matrix representation of the map, M ri:
x ′ = x + P−1M riP x . (3.4)
Motion assessment
Patient motion analysis is an important aspect of 4DTP. Hence, specific commands and rou-
tines have been implemented in TRiP4D to conveniently assess the extent and distribution of
patient motion on the basis of the available deformation maps. Specifically, patient motion of
certain volumes often is of interest. Therefore, the functionality is coupled to the segmentation
functionality discussed in the next section. The export of volumetric cuts of the displacement
fields has been implemented, similar to those generally used for dose distributions or CT vi-
sualization. Selected ROIs can be overlayed on demand to ease interpretation. Additionally,
differential and cumulative motion volume histograms (MVHs) of displacement vectors in se-
lected ROIs can be exported. Basic statistical parameters such as mean and median values or
standard deviations are calculated from the distributions. Figure 3.1 on the following page il-
lustrates the functionality in the example of a liver tumor and the displacement field between
the end exhale and end inhale 4DCT phases.
3.2.1.4 4D segmentation
Elaborate 4D treatment planning requires information on the spatial and temporal changes of
target volumes and organs at risk. The automatic propagation of a manually delineated refer-
ence contour is a promising and efficient approach to obtain contours on all 4DCT states (Lu
et al., 2006b; Gaede et al., 2011). The design of ITVs and other steps in the 4D treatment
planning workflow can benefit from a full integration of 4D segmentation into the treatment
planning system. Therefore, TRiP4D’s existing module for handling 3D segmentation has been
enhanced with respect to 4D treatment planning functionality. This comprises a novel 4D con-
tour data model, a contour propagation algorithm and contour manipulation functionality.3
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(a) absolute displacement (b) displacement in SI
(c) displacement in AP (d) displacement in LR
Figure 3.1.: Visualization and assessment of organ motion using deformation maps from de-
formable image registration in TRiP4D. (a) Axial cut of the reference state CT (end
exhale) and the overlayed displacement field between the extreme states, end ex-
hale and end inhale are shown. The absolute values of the displacement vectors are
shown as a contour plot, CTV contours of a liver tumor are also indicated. (b–d) His-
tograms of the displacement vector components for the two CTV volumes, liver and
lung in the SI, AP and LR direction, respectively. Organ motion is most pronounced
in the SI direction and is significantly larger in CTV(2) than in CTV(1) volume for all
vector components.
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(a) (b)
Figure 3.2.: (a) ROI conversion from a polygon contour (red solid line) into volumetric boolean
masks (VBMs) (gray areas) and re-converted polygon contours (dashed lines). Result-
ing Boolean masks are indicated for the two ROI areas and the overlap region. (b)
Contour propagation by inverse transformation from a regular grid. The propagated
ROI (dark gray) is formed from voxels with source points inside the polygon contour
(red solid line). Transformation vectors are indicated for two voxels (arrows).
4D contour data model
The segmentation module of TRiP98 relies on contour data given in the form of co-planar
polygons usually originating from the delineation process on axial CT slices. Complementary to
the CT data the VOXELPLAN format of DKFZ is supported (Schlegel et al., 1992). Compatibility
to the DICOM standard additionally has been established in the context of this work through an
external conversion software (appendix A.1). The new implementation of 4D segmentation in
TRiP4D extends the 3D functionality by integration of 4DROIs in the form of Boolean masks held
in a volume dataset structure as a single entity. This approach is based on several arguments.
Firstly, a major focus was on the design of an integrated 4D structure capable of handling ROIs
in all CT states. Flexible combination of the individual volumes should also be supported and
is particularly simple in the approach of Boolean masks. Secondly, volume datasets are well
established structures in TRiP4D and the existing functionality can be efficiently re-used. And
thirdly, contour propagation involves deformation of the ROI. In this context, a volume dataset
model offers advantages over polygonal contours.
Generation of the volumetric boolean mask (VBM) ROIs from the polygon contours is per-
formed as follows:
(1) One volume dataset per ROI is created. Usually the CT voxel spacing is sufficient to map
the polygon contour adequately, otherwise a finer lateral voxel spacing is used. The longi-
tudinal resolution corresponds to the CT slice spacing. For reasons of memory efficiency the
3 The discussed 4D segmentation functionality has been implemented by two master students supervised by the
author, A. Schwarzkopf and J. Trautmann.
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volume dimensions are determined from the spatial extension of the polygon ROI, taking
into account necessary margins due to motion.
(2) Each voxel center is tested for its position w.r.t. the polygon ROI. A point-in-polygon ray-
casting algorithm on the basis of the Jordan curve theorem is used to determine whether
the respective voxel is inside the polygon ROI (Glassner, 1989; Hales, 2007).
(3) Each voxel inside the polygon ROI is marked in the volume dataset using a bit mask. A
single bit per ROI representation and voxel is required. Consequently, different ROI states
can be held on individual bits in a single volume dataset.4
Figure 3.2a illustrates the conversion of the polygon contour into a VBM and the resulting
bit patterns for the different ROI states. In order to ensure compatibility with other software
packages, e.g., external visualization tools, the VBM datasets can be re-converted into poly-
gon contours. Contour detection routines have been implemented based on a Freeman code
chain algorithm (Freeman and Davis, 1977). The enveloping polygons of the ROI volume are
reconstructed in each axial slice of the volume dataset (dashed lines in figure 3.2a) taking into
account potential separation of sub-ROIs. Further manipulation of the 4DROIs can be per-
formed conveniently using the VBM datasets. For instance, the formation of geometrical unions
or intersections among different ROI states involves bit mask operations only and has been
implemented in TRiP4D for further 4DTP tasks (cf. section 3.2.2.1).
Contour propagation
Different methods of contour propagation have been published in the literature and are com-
monly divided into deformable registration-based (Ragan et al., 2005; Lu et al., 2006b; Shekhar
et al., 2007) and deformable model-based methods (McInerney and Terzopoulos, 1996; Montag-
nat and Delingette, 2005). Contour propagation in TRiP4D employs a deformable registration-
based approach taking advantage of the already discussed infrastructure for deformable regis-
tration maps. The underlying concept is to guide the transformation of the reference state ROIs
with the deformation fields obtained from registration of the underlying CT geometry. The use
of co-planar polygons alone poses problems in contour propagation, since the co-planar charac-
ter is in general lost under spatial transformation. For this reason triangular mesh surfaces are
used by some groups to model the transformation of the ROIs (Lu et al., 2006b; Faggiano et al.,
2011). The alternative approach in TRiP4D of employing VBM dataset structures for contour
propagation will be introduced in the following section.
The initial step of the transformation procedure of a polygonal ROI from the reference state
r to all states i 6= r starts with the conversion of the reference state contour into a VBM dataset
as described in the previous section. Let q lmn = (x l , ym, zn) denote the position of the voxel
centers. Propagation of the reference state ROI to state i is performed by inverse transformation
of each voxel center q lmn to the reference state
p = q lmn+ u ir(q lmn) . (3.5)
Here, p denotes the reference state position of q lmn. The displacement vectors, u ir(q lmn), are
obtained from the inverse deformation maps, T ir(x ), as discussed earlier in section 3.2.1.3.
4 The maximum number of ROI states depends on the size of the data type used, e.g., 32 states for a 32 bit
integer per voxel.
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(a) (b)
Figure 3.3.: (a) View of an axial slice of a VBM dataset for a liver ROI. The different ROI states are
indicated by a gray shading, the red solid line is the overlayed polygon contour of
the reference state. (b) Coronal cut of liver contours for the reference state (exhale,
yellow markers) and the propagated inhale state (red markers). The contours are
overlayed on the inhale CT phase.
The procedure is illustrated in figure 3.2b. The position of p w.r.t. the reference state contour is
tested using the point-in-polygon ray-casting algorithm described in the last section. The voxel
positions having a source point inside the polygonal reference contour are marked in the vol-
ume dataset as a Boolean mask using separate bits for the different states (figure 3.2a). After
repetition of the procedure for each state i and each q lmn the VBMs for all ROI states are con-
tained within a single dataset (figure 3.3a). It should be noted that the described propagation
algorithm does not require transformation of the reference state VBM-ROI. Instead, it makes
direct use of the polygonal reference state contour to obtain the VBM-ROIs in all states.
The performance of the contour propagation algorithm has been assessed by visual inspec-
tion. Figure 3.3b shows the result of a liver contour propagation driven by the deformation
maps obtained from image registration of a 4DCT. The liver contour was propagated from the
reference end exhale state (yellow markers) to the end inhale state (red markers) and shows
good agreement with the underlying anatomy depicted in the inhale CT phase.
3.2.2 4D treatment plan optimization strategy
Common 4D treatment planning strategies for ion beams have been introduced in section 2.3.2.
At the time of writing treatment plan optimization for all motion mitigation techniques in
TRiP4D is performed on a reference 4DCT state only, as reported by Bert and Rietzel (Bert
and Rietzel, 2007).
Depending on the employed motion mitigation technique (section 2.2.3) optimization of the
target volume, i.e. ITV generation, and technique-specific parameters are required to ensure
adequate dose coverage. These parameters, for instance, comprise the optimization of motion
compensation parameters in the case of beam tracking or the gating window size in beam gating.
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This section briefly introduces the design of ITVs and the optimization of beam tracking and dose
compensation parameters in TRiP4D. The functionality predominantly has been implemented
by colleagues and is mentioned here for the sake of completeness. The optimization of beam
parameters for the compensation of residual motion will be discussed later in chapter 4, since it
does not require specifically implemented functionality.
3.2.2.1 Internal target volume design
ITVs are formed from the CTVs in all relevant 4DCT phases (ICRU, 1999). Rescanning, for
instance, requires the formation of an ITV over all respiratory states, while for gating only the
states inside the gating window are relevant. In ion beam therapy the mere use of a geometrical
union is not sufficient for the design of ITVs, since range variations in the beam path need to be
considered (ICRU, 2007). For scanned ion beam therapy a water-equivalent approach has been
proposed by Rietzel and Bert (Rietzel and Bert, 2010) and has been implemented into TRiP4D
(Graeff et al., 2012). The method makes use of the 4D segmentation functionality of TRiP4D
to form the geometric union of the target volume as a first step. For a specific beam incidence
the composite target volume in water equivalent space is then calculated laterally and longitu-
dinally, taking into account motion-induced density variations. Further treatment planning is
then performed on the water-equivalent ITV. The latter also can be re-converted to geometrical
space, if needed. It shall be emphasized again that due to the density variations in the beam path
the ITV is port-specific. Consequently, the unique geometric target volume required for dose op-
timization on multiple-field ITVs has to be related to multiple water equivalent representations,
depending on the beam port.
3.2.2.2 Optimization of real-time beam adaption parameters
In beam tracking the beam position is adjusted to the tumor motion in real-time (Groezinger
et al., 2006). During beam delivery pre-calculated correction vectors are applied to the planned
beam position according to the current motion state of the patient. A more elaborate version
of beam tracking additionally compensates for potential dose changes of tumor areas with re-
spect to the reference treatment plan, caused , e.g., by target rotations, and is called real-time
dose compensation combined with beam tracking (RDBT) (Bert and Rietzel, 2007; Lüchtenborg
et al., 2011). The optimization of position and dose compensation parameters has been inte-
grated into TRiP4D by Lüchtenborg et al. (Lüchtenborg et al., 2011). In brief, the deformation
maps obtained from image registration (section 3.2.1.3) are used to calculate lateral and lon-
gitudinal correction parameters for each raster point and in all motion states relative to the
planned position in the reference state. The correction parameters are stored in a look-up table.
During beam delivery the lateral position adaptation is realized via the scanner magnets. The
longitudinal correction corresponds to a modulation of the water-equivalent range via the beam
energy using a fast double-wedge system (Weber et al., 2000). For real-time dose compensa-
tion the look-up table of correction vectors is extended by the motion state-dependent dose
contributions of each raster point to all other raster points. The dose compensation parame-
ters enable correction of the applied particle numbers in real-time, in order to compensate for
motion-induced dose changes.
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3.2.3 Simulation of 4D treatment delivery
Dose deposition for moving targets in scanned ion beam therapy is determined by the double-
dynamic nature of the system, also representing the origin of the interplay effect. Firstly, the
beam delivery process itself is time-dependent, since the beam is scanned over the target. Sec-
ondly, the effective beam position is affected by the target motion. Both contributing aspects
have to be modeled adequately in the TPS, in order to enable simulation of 4D treatments. It has
been shown with earlier versions of the GSI 4DTPS that simulation of dose delivery subsequent
to treatment is well feasible for experimental setups (Li et al., 2004; Gemmel et al., 2011; Bert,
Richter et al., 2012).
TRiP4D has been extended for simulation of clinical 4D treatment delivery in realistic pa-
tient environments. This particularly includes irregular surrogate motion trajectories, 4D dose
calculation using transformation maps obtained from deformable image registration and time-
resolved beam delivery sequence data compatible with clinically used accelerators, e.g., HIT.
In the following sections the integration of clinical motion monitoring data and the time struc-
ture of the beam delivery process into TRiP4D are described. Temporal correlation of these
two components finally enables simulation of physical and biological 4D dose deposition which
considers the specific motion characteristics at treatment delivery time. The implementation of
these aspects will be discussed in the last section.
3.2.3.1 Motion state identification
In section 3.2.1.2 the principal incorporation of motion monitoring data into TRiP4D was dis-
cussed. The simulation of 4D treatments in TRiP4D requires information on the transition of
the patient through the 4DCT phases over time. Surrogate motion monitoring data acquired
concurrently to beam delivery can provide this information, given that the identification of the
motion state is performed in agreement with the 4DCT reconstruction process (Ford et al., 2003;
Rietzel et al., 2005a).
Motion state identification is a central functionality of TRiP4D’s motion trajectory module. Dif-
ferent methods are available based on: (i) the absolute signal amplitude, (ii) the signal phase
and (iii) the relative signal amplitude. The latter is needed in particular for use in conjunction
with the ANZAI system. In contrast to amplitude-based (AB) motion state identification, the
methods (ii)–(iii) require dedicated signal pre-processing prior to motion state identification.
For phase-based (PB) identification the signal phase is computed using the Hilbert transform
of the original signal (Lyons, 2010). The Hilbert transform is obtained by external fast Fourier
transform routines (Frigo and Johnson, 2005). Figure 3.4 shows an original patient trajectory
and the corresponding Hilbertian phase component. For relative-amplitude-based (RB) iden-
tification the original signal is converted into a normalized trajectory with a fixed amplitude
range. This is done based on a search for the maximum and minimum position in each respi-
ratory cycle and subsequent normalization of the signal to the amplitude range in each exhale
(negative slope) and inhale branch, respectively (figure 3.4).
After signal pre-processing, motion state identification at a specific time along the trajectory
is performed as follows:
(i) The limits on the pre-processed signal for the respective motion states are configured either
automatically or by the user. The limits should be in agreement with the distribution of the
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Figure 3.4.: Motion state identification in TRiP4D. Depending on the employed method the orig-
inal signal (AB), its Hilbertian phase component (PB) or the relative amplitude (RB) is
discriminated against motion state limits (gray dashed lines). The relative amplitude
is obtained from the normalized signal by flipping over the exhale branches at each
maximum and normalizing to 100 %.
motion states over the respiratory cycle as defined during reconstruction of the 4DCT. This
step is independent from the input time and usually done only once during a treatment
planning session.
(ii) If necessary, the pre-processed signal is interpolated linearly between the neighbouring
supporting points.
(iii) The motion state is determined by discrimination of the interpolated signal value against
the motion state limits. In contrast to AB identification the inhale/exhale status is also
considered for the RB and PB methods.
3.2.3.2 Beam delivery sequence and time structure
In raster scanning the individual dwell time per raster point depends on the requested particle
fluence and the intensity delivered by the accelerator. Due to the complexity of the system, the a
priori modeling of the time structure of beam delivery is challenging, especially if beam pauses
caused by gating or by the synchrotron are to be considered. However, the time structure,
called beam delivery sequence (BDS) in the following, can be measured during irradiation. The
procedure to obtain the BDS can be considered highly facility dependent. Nevertheless, several
general beam delivery events (BDEs) can be expected to be accessible at any scanning facility.
Table 3.1 summarizes the types of BDEs and the possible transitions between them.
TRiP4D provides the interface to a generally defined table format for BDS input files describ-
ing the chronology of BDEs. The tables have to be compiled externally according to the specific
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event type characterization possible transition to
BON beam on BOF, NXP
NXP end of a raster point NXP, EOP, BOF
EOP end of iso-energy slice BOF
BOF beam off BON
Table 3.1.: Types of general beam delivery events (BDEs). The chronology of BDEs defines the
beam delivery sequence (BDS).
conditions of the respective machine and the data acquisition system used. In contrast to the
data model used in previous 4D versions of TRiP98, only the basic information needed for sim-
ulation of 4D dose deposition is integrated into the TPS in an efficient way. No measured beam
intensity profiles or memory-consumptive intensity courses are needed. The automatic gener-
ation of simulated BDS tables for 4D treatment simulation purposes has not been integrated
into the TPS, since this is a highly facility dependent task. External software is used to model
the beam delivery time structure at GSI and HIT. An example of a simulated beam delivery
sequence is shown in figure 3.5.
3.2.3.3 4D dose deposition
4D dose deposition is fully determined by the treatment plan, the time structure of the beam
delivery and the patient motion. In order to account for dose contributions to each dose voxel
in consideration of target motion, knowledge is required on which raster points were fully or
partly irradiated in a certain motion state. This information is obtained from the combined time
courses of the BDS and the surrogate motion trajectory. This section will discuss the necessary
steps to model the dose deposition in 4D treatment simulations based on measured or simulated
surrogate motion traces and beam delivery sequences.
Time correlation
The treatment control system and the motion monitoring device are usually independent med-
ical products of different manufacturers, hence, beam delivery and motion monitoring naturally
do not share the same data acquisition and system clock. At the time of writing, the integra-
tion of motion monitoring into the HIT treatment control system is not sufficient to allow full
base data acquisition for 4D treatment simulation.5 Similar situations are to be expected for
other facilities. Therefore, temporal alignment of the BDS and the surrogate motion trace, i.e.
the identification of the time offsets between the different acquisition systems, is mandatory.
Figure 3.5 illustrates the time-correlated motion trajectory and the respective BDS. Temporal
correlation is performed with external tools and the determined time offsets then are commu-
nicated to TRiP4D. For this purpose, user-specified offset values for both the native BDS and
motion trace input files are supported. Time stamps are handled with micro-second precision
and any time resolution larger than one micro-second is supported for the surrogate monitoring
and BDS input files.
5 Nevertheless, a dedicated interface for gated beam delivery with the ANZAI AZ-733 system exists.
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Figure 3.5.: Visualization of an example 4D beam delivery course. The lower graph visualizes
the beam delivery sequence comprising the beam status (BON/BOF events, cf. ta-
ble 3.1) shown as a logical signal (black line) and the irradiated raster points (NXP
events) as red markers. Due to their temporal clustering, the single raster points can
not be resolved in this graphical representation. The upper graph depicts the time-
correlated motion trajectory (blue line) and the distribution of motion states as they
were detected for the irradiation of each raster point (black diamonds) according to
RB motion state identification. The motion states are encoded as integer numbers
with ’0’ marking the end exhale position (minimum). The presented kind of graphi-
cal visualization of 4D beam delivery courses is part of the TRiP4D functionality.
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Generation of quasi-static sub-treatment plans
Temporal correlation of the motion surrogate with the beam delivery sequence enables iden-
tification of the motion state in which each of the treatment plan’s raster points was irradiated.
The original treatment plan is split into quasi-static sub-treatment plans, according to Bert and
Rietzel (2007). Each plan comprises all raster points fully or partly irradiated in the respective
4DCT phase. Sorting of the points into the associated sub-treatment plans is performed using
either amplitude-based, phase-based or relative-amplitude-based motion state identification, as
discussed above. Let it be emphasized again, that the motion state identification method ideally
should match the one used for 4DCT reconstruction.
The generation of sub-treatment plans has been fully re-implemented to integrate the func-
tionality developed by Bert and Rietzel (2007), RDBT according to Lüchtenborg et al. (2011)
and new functionality developed within the scope of this thesis. The implemented algorithm
will be described in the following.6
The temporal sequence of beam delivery events first is complemented by identification of the
valid motion state for each event. The different types of BDEs and their valid transitions are
recalled in table 3.1. Additional events which mark a change of the 4DCT phase, so-called mo-
tion state change (MSC) events, are then generated and inserted into the BDS at the respective
times. Determination of the temporal position of the MSC events is performed by nested tempo-
ral interval searches in-between subsequent BDEs using the functionality provided by TRiP4D’s
motion trace module. The extended BDS constitutes the basis for sub-treatment plan genera-
tion. Note that any temporal misalignment of the motion trajectory and the BDS will result into
an entirely different mapping of the motion states to the respective BDEs (see also figure 3.5).
Generation of the sub-treatment plans is performed by sequential processing of the linked list
of BDEs. A flow chart of the algorithm is given in figure 3.6. In contrast to earlier implemen-
tations, the algorithm employs a state machine approach to more effectively handle transitions
between BDEs and reliably intercept invalid event transitions being inconsistent with table 3.1,
e.g., if resulting from defective data. The irradiation of each raster point is traced over time and
the nominal fluence is sub-divided and allocated to the respective sub-treatment plans. For this
purpose specific actions are triggered upon detection of the different BDE types, as illustrated
in the flow chart. Start of irradiation for a raster point is triggered by the BON event in the case
of the first point of an iso-energy slice and by the NXP event otherwise. Stop of irradiation of
a point is communicated via the subsequent NXP event. After the start of irradiation of a point
has been triggered, the subsequent motion state changes are buffered in a temporal list of MSC
events. Beam pauses occurring during irradiation of the point are also registered. At stop of
irradiation the coordinates and particle fluence of the respective point are obtained from the
3D treatment plan, maintaining the irradiation order. If simulation of beam tracking has been
requested, the raster point coordinates are adapted according to the provided tracking look-up
table (Bert and Rietzel, 2007). In the case of RDBT the particle fluences are adapted according
to Lüchtenborg et al. (2011).7 In order to maintain consistency between the simulation and the
actual beam delivery, the same routines are also used in the treatment control system. Beam
tracking and RDBT both rely on motion monitoring for real-time calculations. Miscorrelation
of the true tumor motion and the monitored motion, such as phase shifts, can be simulated
using a dedicated motion monitoring trajectory for all real-time tasks. The subsequent eval-
uation of the fractional particle fluences is independent from the motion mitigation modality
6 The integration of RDBT predominantly has been carried out by R. Lüchtenborg (Lüchtenborg et al., 2011).
7 The dose compensation functionality can also be used stand-alone and independent from beam tracking.
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Figure 3.6.: Flow chart of the generation of quasi-static sub-treatment plans after temporal cor-
relation of BDS and motion surrogate. The linked list of BDEs (cf. table 3.1) is pro-
cessed event by event keeping track of all MSC events during irradiation of a raster
point. Particle fluences are linearly sub-divided and allocated to the sub-treatment
plans according to the relative time spent in the respective motion state during ir-
radiation. The examples show typical configurations for the irradiation history of
raster points with and without beam pause.
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Figure 3.7.: Example of 4D dose and film response calculation with TRiP4D for a sinusoidally
moved film along the x axis in free air. Figures (a–e) break down the total 4D film
response (f) to the individual dose contributions in each of the five motion states.
All distributions are shown in the reference state coordinate system and are normal-
ized to their individual maximum in optical density. The 3D treatment plan covers a
homogeneous square on the stationary film (g).
and also applies for uncompensated irradiation. The fractional particle fluences are determined
using the buffered list of MSC events. The beam intensity is assumed to be constant over the
time-scale of a raster point irradiation (several milliseconds). This is a valid approximation for
treatment conditions at HIT and GSI. The nominal particle fluence then is sub-divided according
to the relative weight of the irradiation time span in the respective motion state, taking poten-
tial beam pauses into account. Two typical configurations of fractional raster point irradiation
and the resulting fluence sub-division are illustrated in figure 3.6. The procedure is repeated
until all raster points of the 3D treatment plan have been processed. Note that solely for beam
tracking and RDBT specific steps need to be taken. In all other cases the treatment modality
characteristics of the beam delivery are communicated by the BDS only.
4D dose calculation
The quasi-static sub-treatment plans discussed in the last section are the starting point for 4D
dose calculation. The dose calculation algorithm of Gemmel et al. was implemented in TRiP4D
and is capable of both biological and physical dose calculation. For details the reader is referred
to the respective publication (Gemmel et al., 2011). In brief, the dose contributions of all raster
points of the respective sub-treatment plan to each dose voxel are collected in every motion
state. For this purpose, the voxel position is transformed accordingly, using TRiP4D’s deforma-
tion map module (section 3.2.1.3) and taking into account the radiological density distribution
of the respective 4DCT phase. The algorithm therefore is fully compatible with transformation
maps obtained from deformable image registration of patient 4DCTs. The total physical dose is
computed by summation of the dose contributions from all motion states in the reference state
(figure 3.7). For biological dose calculation the particle spectra in energy and atomic number
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are also accumulated over all motion states in consideration of the transforming dose grid. The
total spectra finally are used as the input for the calculation of the relative biological effective-
ness and the resulting biologically effective dose using the LEM (Krämer and Scholz, 2000).
Accordingly, TRiP98’s capabilities to calculate non-linear dose response of radiographic films in
dependence of the local particle and energy spectra using a model similar to the LEM (Spiel-
berger et al., 2003) have been extended to 4D. Additionally, calculation and output of dose
and detector response distributions in individual motion states is supported. An example of a
4D film response simulation including the state-resolved sub-distributions is given in figure 3.7.
Finally, TRiP4D provides calculation of dose volume histograms for ROIs in all motion states in
conjunction with the 4D segmentation module (section 3.2.1.4).
3.3 Verification
TRiP4D is a newly designed 4DTP extension to the established GSI treatment planning system
TRiP98. The integration of the 4D functionality required substantial changes of the existing pro-
gram structure and source code. Systematic testing is required to assure that core functionality
of TRiP98 is not impaired. Moreover, the 4D planning functionality combines newly imple-
mented features and re-implementations based on earlier programs. Both demand elaborate
validation, especially considering the program’s possible future application in clinical routine.
The consistency of TRiP98’s core functionality in TRiP4D has been verified successfully using
the comprehensive test suit delivered with the mother program and will not be discussed here.
The predecessors of TRiP4D were repeatedly tested in various dedicated experiments (Li et al.,
2004; Gemmel et al., 2011; Bert, Richter et al., 2012). Within the scope of this thesis selected
tests were re-iterated and TRiP4D’s performance was benchmarked against the experimental
results and the predecessor programs. Additionally, new water phantom experiments were de-
signed and conducted, in order to test the program’s combined functionality at a high level of
complexity.
3.3.1 Radiographic film response simulations
The 4D treatment simulation capabilities of TRiP4D were tested in simulations of the dose
response of radiographic films moved during irradiation. The simulations were verified against
the experimental results obtained by Bert, Richter et al. (2012) and were compared to previous
simulations of the 4D detector response by the same authors.
3.3.1.1 Materials and methods
The experimental setup of the radiographic film measurements is summarized here in brief.
For a detailed description the reader is referred to the original publication by Bert, Richter
et al. (2012). Irradiation was performed at GSI with a carbon ion beam and a single-slice
treatment plan. The plan was designed to cover a 110× 110mm2 field with a homogeneous
dose. Radiographic films were used as detectors and mounted on a motorized sliding table
in free air. The films were moved sinusoidally during irradiation in left-right direction w.r.t.
BEV. Different motion amplitudes, periods and initial phases were chosen and adjusted via the
sliding table. The radiographic films were developed and digitized according to Spielberger
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et al. (2003). The film trajectories were measured with sub-millimeter precision and recorded
during irradiation with a calibrated camera system tracking an infrared LED at an acquisition
rate of 40 Hz. The beam delivery sequence, i.e. the irradiation times of all raster points and
the start and stop times of the beam extraction, were measured in a separate data acquisition
system (DAQ) via TTL pulses generated from the control system. In order to establish temporal
correlation between target motion and the beam delivery sequence, the beam status signals
were additionally recorded with the motion monitoring DAQ.
The simulations of the optical film density were carried out using the 4D extensions to the
TRiP98 program by Bert and Rietzel (TRiPB) on the one hand and those of TRiP4D on the
other. According to section 3.2.3.3 the simulations were divided into two steps: (i) the genera-
tion of sub-treatment plans and (ii) the calculation of the 4D detector response on the basis of
the sub-treatment plans. The two simulations steps were performed with either of the two pro-
grams and in all possible combinations to assess the origin of possibly differing performance.
Due to the different working principles of the programs rigid transformation maps (cf. sec-
tion 3.2.1.3) were created on the basis of the measured film trajectories for TRiP4D, while for
TRiPB the displacement vectors were determined directly from the trajectories. Simulations
were performed for 20 motion states and amplitude-based motion state identification. Calcu-
lation of the expected optical density of the films in response to the local deposited dose for
both programs is based on the model of Spielberger et al. and the resulting particle-specific film
responses (Spielberger et al., 2003). The same set of depth-dose and particle spectra base data
was used in all simulations to guarantee comparability (Krämer et al., 2000).
The agreement of the simulations with the respective measurement for each of the motion
parameter sets was assessed by statistical analysis of the differential optical density distributions.
The rigid registration of the coordinate systems of the measured films and the simulations was
used as determined by Bert, Richter et al. (2012). The analysis was restricted to a region of
interest of 155× 135mm2 and pixels with optical densities S > 0.01. These criteria establish
an individually adjusted analysis mask for each case to prevent domination of the background
outside the irradiated area. The relative mean deviation in optical density and its standard
deviation were computed and chosen as a figure of merit to evaluate the agreement.
3.3.1.2 Results
Table 3.2 lists the results of the statistical analysis for the 14 measured parameter combina-
tions. Peak-to-peak motion amplitudes range from 8–20 mm for motion periods between 3 and
7s. The initial phases were 0°, 90°, 180° and 270°, depending on the case. In the table, the
analyzed simulation combinations are denoted by the identifiers for the programs used in each
of the two simulation steps, TRiPB (B) and TRiP4D (R), respectively. The comparison of the
results for the unmixed configurations RR and BB reveals that the mean relative deviation µ of
simulated and measured optical densities is closer to zero for all 14 cases in the full TRiP4D
simulations. The largest differences are obtained for cases (a)–(d) with a 20 mm peak-to-peak
amplitude (> 2%). For case (d) the absolute decrease in µ exceeds 7 % and amounts to about
2% for the other 13 cases. Similarly, the standard deviation σ is reduced for all cases except
case (j). The largest decrease for σ is observed for the 20mm amplitude cases (a)–(d). For
case (d) the absolute decrease is larger than 50 % and larger than 7 % for cases (a)–(c). An
absolute decrease of around 6% is yielded for cases (l)–(n), only minor decreases are observed
for cases (e)–(i) and (k) (< 1%) and a negligible increase for case (j) (< 0.1%).
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motion parameters BB RR BR RB
case A[mm] T[s] φ[°] µ[%] σ[%] µ[%] σ[%] µ[%] σ[%] µ[%] σ[%]
(a) 20 5 90 −5.03 20.64 −2.14 12.98 −4.76 20.35 −2.42 13.66
(b) 20 5 0 −7.32 21.52 −3.73 13.23 −7.28 21.66 −3.88 13.35
(c) 20 7 0 −4.80 21.76 −1.46 9.72 −4.76 21.92 −1.59 9.66
(d) 20 7 90 −9.84 68.98 −2.19 12.68 −8.96 56.94 −2.24 12.21
(e) 15 3 0 −1.85 10.78 −0.55 10.48 −1.70 10.71 −0.68 10.54
(f) 15 3 90 −0.89 11.53 0.37 10.84 −0.77 11.50 0.24 10.92
(g) 15 4 0 −3.50 12.06 −2.13 11.68 −3.36 11.96 −2.24 11.68
(h) 15 4 90 −4.39 11.19 −2.89 10.73 −4.21 11.04 −3.06 10.87
(i) 15 5 0 −5.40 14.99 −4.06 14.55 −5.19 14.66 −4.17 14.66
(j) 15 5 180 −5.74 12.74 −4.43 12.78 −5.65 12.86 −4.53 12.65
(k) 15 5 270 −6.46 16.09 −5.11 16.01 −6.38 16.31 −5.21 15.82
(l) 8 5 0 −2.24 18.53 0.12 12.78 −1.04 12.94 −1.02 18.11
(m) 8 4 0 −2.83 15.56 −0.88 9.43 −2.69 15.53 −1.00 9.47
(n) 8 3 0 −2.98 16.92 −1.11 10.93 −2.75 15.71 −1.21 10.89
Table 3.2.: Results of the statistical analysis of the agreement between simulated and measured
optical film densities for all 14 motion parameter sets (A = amplitude, T = period,
φ = initial phase ). In the four columns the mean relative deviation µ of the simu-
lated from the measured densities and its standard deviation σ are reported for all
studied program combinations in the two successive simulation steps: generation of
sub-treatment plans and 4D detector response calculation. B and R denote the used
program for each step, TRiPB and TRiP4D, respectively. The red highlighted column
indicates the results of the full TRiP4D simulation (RR).
Results for the mean optical density and standard deviation for the mixed simulation RB are
comparable to those obtained for simulation RR in most cases. Absolute differences for mean
and standard deviation values between RB and RR are below 1 %. Only for case (l) differences
of about 1 and 5% are observed for the mean and standard deviation, respectively.
Comparing simulations BR and BB, both using TRiPB to generate the sub-treatment plans,
the changes in the mean and standard deviation w.r.t. BB are much less pronounced than those
between simulations RB and RR. Only cases (d) and (l) show significant improvements in the
mean value (> 0.8%) and the standard deviation (> 5%).
3.3.1.3 Discussion
The data in table 3.2 show that the major improvement in simulation accuracy results from the
new algorithm for the generation of sub-treatment plans in TRiP4D. These improvements could
be traced back to the more consistent handling of beam delivery sequences in TRiP4D compared
to TRiPB. The state machine approach discussed in section 3.2.3.3 proves less error-prone, in
particular in the case of corrupted beam delivery sequence data. For the cases (a)–(d) the de-
fective data resulted from timing issues of the data acquisition at the time of the experiments
and could be resolved retrospectively. Using TRiP4D for the 4D dose calculation step instead of
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TRiPB had a small impact on the agreement of the simulated optical density distributions with
the measurements. The small improvements gained over TRiPB for mean value and standard
deviation predominantly result from additional interpolation steps needed for the summation of
individually transformed state dose cubes in the reference state for TRiPB. The larger deviations
obtained for cases (d) and (l) result from high sensitivity of these cases w.r.t. minor differences
in the applied displacements vectors. Specifically, small film displacements (<2 mm) orthogo-
nal to the motion direction, i.e. up-down BEV, have been neglected for TRiP4D calculations, as
they are affected by large relative errors of the position measurement. On average, the mea-
sured optical density distributions are reproduced by the full TRiP4D simulations RR to about
(−2± 12)%. Hence, the calculated optical densities in general are slightly overestimated by
TRiP4D. Regarding the accuracy of around 10% to be expected from film response calculations
for ion beams (Spielberger et al., 2003), the simulations otherwise are in good agreement with
the measurements.
3.3.2 Water phantom experiments and simulations
Predecessor versions of the GSI 4D treatment planning system have been tested repeatedly in
experiments. So far, 2D target motion, with and without range changes introduced by ab-
sorbers were studied (Li et al., 2004; Bert, 2006; Bert and Rietzel, 2007; Bert et al., 2009).
In preparation of extensive patient treatment planning studies and future clinical application,
more elaborate tests of TRiP4D were carried out in water phantom experiments at the Heidel-
berg Ion-Beam Therapy Center using a robotic setup with 3D target motion and gated beam
delivery. TRiP4D simulations were compared to absolute 4D dose measurements.
3.3.2.1 Materials and methods
The experiments were part of a measurement series with and without gated beam delivery. The
details given here on the experimental setup will focus on the specifics for gated beam delivery.
Further details on the data acquisition and instrumentation will be given later in chapter 4 in
the context of residual motion experiments using a largely identical setup.
An ellipsoidal target volume of 82cm3 was irradiated in a static water phantom with gated
beam delivery. The absorbed dose was measured with an array of 24 pinpoint ionization cham-
bers (ICs), as reported by Karger et al. (1999). 3D sinusoidal motion of the IC array was
facilitated using a robotic arm (Steidl, Richter et al. 2012). Peak-to-peak motion amplitudes
of 20mm in left-right BEV and 10mm in the remaining dimensions were chosen. Additionally,
non-gated static reference irradiations were performed. Beam control and the adjustment of
the gating window were established using the ANZAI AZ-773V system (ANZAI MEDICAL CO.,
LTD). The gating window (GW) was configured based on the signal of a laser distance sensor
which monitored the LR projection of the IC array motion. The GWs were adjusted to result
in residual motion amplitudes of 2–10mm around the maximum amplitude in LR BEV. Target
motion, raster point irradiation times and beam status signals were acquired with a dedicated
data acquisition system (section 4.2.1).
Treatment plans were optimized with the GSI reference 3D treatment planning system
TRiP98. 18 different combinations of lateral grid spacing (2 and 3mm), iso-energy slice spacing
(1, 2, 3 and 4mm water-equivalent), beam FWHM (6, 8 and 10 mm) and two different ripple-
filters (section 2.1.3.2) were chosen. Apart from the standard ripple-filter (RiFi) with 3 mm
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effective Bragg-peak width (RiFi3), two orthogonally crossed 3mm RiFis were used, approxi-
mately corresponding to a 4mm RiFi (RiFi4). The plans were optimized for a homogeneous
target dose of 2Gy.
Simulations were performed based on the nominal 3D target trajectory as the motion surro-
gate, the reference treatment plan and the respective BDS according to section 3.2.3.3. The
BDS was obtained by combined evaluation of the measured signals from the treatment and ac-
celerator control systems over time. The temporal alignment procedure will be explained in
detail in section 4.2.3.1. Generation of the sub-treatment plans (cf. section 3.2.3.3) was based
on the nominal target motion trajectory generated by TRiP4D. The individual initial phases for
each measurement due to the gated beam delivery were taken into account (section 4.2.3.2).
4D physical dose calculations were performed for 22 phases of a computer-generated 4DCT and
phase-based motion state identification (section 3.2.3.1). The transformation maps for rigid
target motion were generated with TRiP4D based on the target motion trajectory.
The agreement of the simulations with the respective measurements was assessed by statistical
analysis of measured and calculated dose values at the ionization chamber positions. A dedi-
cated program has been developed within the scope of this thesis to extract dose values from
calculated dose distributions for a given ionization chamber array geometry (appendix A.2).
Dose extraction is based on trilinear interpolation among neighbouring dose voxel centers. For
the analysis of the individual measurements the mean relative difference
∆D =
N∑
i
(
Dcalci − Dmeasi
)
/ Dmeasi (3.6)
of measured (Dmeas) and calculated (Dcalc) dose values and its standard deviation, σD, has been
calculated for N = 22 of the 24 ionization chamber positions per measurement. The remaining
two ionization chambers were neglected for analysis, since they were located close to the target
volume boundary (figure 3.8). Additionally, a bivariate linear regression model was fitted to the
ensemble of measured and simulated dose values for the individual ICs using JMP (version 9.0,
SAS Institute Inc., Cary, NC, USA):
Dmeas ≈ α · Dcalc+ β ·
(
R3
R4
)
(3.7)
The model assumes a linear relationship between the measured and simulated dose and ad-
ditionally allows for individual systematic and dose-independent contributions R3,4, of the
employed RiFi3 and RiFi4 ripple filters. α and β are free parameters. The results of the bi-
variate regression are reported as the coefficient of variation, R2, and the root-mean-square
error (RMSE) of the model.
3.3.2.2 Results
For each plan three to four irradiations with different motion amplitudes, distributed in the
range of 2–10mm, and one static measurement were performed, resulting in a total of 82
measurements, 64 of them with gated beam delivery. 4D simulations were performed for 52
of the gated irradiations. The remaining 12 cases were removed from the analysis because of
gross measurement errors, predominantly due to missing or deficient beam delivery sequence
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Figure 3.8.: Bird’s eye view section of simulated dose distributions through the center of the
target volume for static (left) and gated (right) irradiation with the same treat-
ment plan (lateral grid spacing: 2 mm, iso-energy slice spacing: 3 mm, beam FWHM:
10 mm, 3 mm RiFi. The 4D dose distribution was transformed to the reference phase
(scale in mGy). The IC positions used for dose extraction are indicated by the white
and black (neglected for analysis) crosses.
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Figure 3.9.: Agreement of simulated and measured 4D dose distributions for the 52 gated and
the 18 static cases (open symbols). Mean and standard deviation of the relative
difference between simulated and measured dose values of the 22 ionization cham-
bers are drawn versus the measurement index. The RiFi3 (circles) and RiFi4 (squares)
measurements exhibit a different systematic deviation from zero, indicated by the
respective fits (red dashed lines).
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Figure 3.10: Scatter plot of the mea-
sured (Dmeas) versus the
simulated dose values
(Dcalc) at the individ-
ual IC positions for all
stationary and gated
irradiations. The linear
fits determined with
the regression model
in equation (3.7) are
overlayed for RiFi3 (red
solid line) and RiFi4 (blue
dashed line). simulated dose [Gy]
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data. Figure 3.8 shows a section through the simulated dose distributions for the static and
a representative gated irradiation using the same treatment plan. A gating window of 50 %
was used in this case, corresponding to 10 mm peak-to-peak residual motion for the major
(LR) motion component. The IC positions used for dose extraction and comparison with the
measured data are also indicated in the figure. As expected, the dose distribution for the gated
irradiation exhibits significant dose inhomogeneities due to interplay effects. Figure 3.9 reports
the mean relative dose difference and standard deviation between simulated and measured dose
values at the 22 IC positions for all 52 gated measurements, drawn versus the measurement
number. The graph is split for 3 and 4mm effective Bragg-peak width, i.e. RiFi3 and RiFi4,
respectively. Two separate fits for the average agreement of all respective measurements are
given. The simulations for RiFi3 and RiFi4 on average agree with the measurements within
about (−1± 4)% and (−3± 4)%, respectively. A detailed overview of the mean and standard
deviation for all 52 gated and 18 static cases is given in table B.1 in the appendix. For both
RiFi configurations all cases had standard deviations smaller than 8%, for about 80 % of the
cases values smaller than 5% were found. Simulations of the static reference irradiations on
average reproduced the measurements within (−2± 2)% for the RiFi3 and (−3± 1)% for the
RiFi4 treatment plans. Figure 3.10 summarizes the results of the linear regression according to
the model in equation (3.7). By construction, depending on the RiFi two different linear fits are
obtained. Measured and simulated dose values exhibit an explained variance of R2 = 0.81 with
a RMSE of the model of 3.4% (p < 10−4). The systematic difference in the intercept for the two
RiFis also was statistically significant at the p < 10−4 level.
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3.3.2.3 Discussion
In summary, good overall agreement of the measurements and the 4D simulations was found
for both the analysis for the group of 22 ICs per case and the linear regression for the individual
ICs over all cases. The RiFi4 data showed a slight systematic deviation in the mean relative
dose difference relative to the RiFi3 data of about 1.5%. This is consistent among gated and
stationary experiments and was also reproduced in the fits of the linear regression model. The
additional systematics found for the RiFi4 data can most likely be attributed to larger uncertain-
ties in the depth-dose base data (Krämer et al., 2000) in these cases. Furthermore, very small
mean deviations of the static from the moving cases of below 1 % were observed (figure 3.9)
which possibly originate from small setup errors which have less impact on the stationary re-
sults, due to the smaller gradients. The residual deviations of about 1–2% observed for the
RiFi3 cases are well within the expected systematic uncertainties of 3–3.4 % in absolute ioniza-
tion chamber dosimetry for heavy ion radiation (Karger et al., 2010). With standard deviations
of less than 5% for most cases the simulations agree well with the measured dose distributions.
The increase of about 2 % in standard deviation for the moving relative to the static cases can be
attributed to the much higher complexity of the simulations which are subject to numerous in-
fluencing factors. For instance, additional uncertainties for the employed setup can be expected
from the measured beam status signals, since, for technical reasons, these were not coupled to
the beam monitoring system and feature minor unknown and systematic temporal shifts. Also,
signal fluctuations were an issue during data taking. Although most measurements exhibiting
the problem were disregarded, residual degradation of the beam delivery sequence data could,
for instance, have an impact on the calibration of the initial motion phase.
3.3.3 Biological dose calculation
Biological 4D dose calculation is indispensable for realistic 4D treatment planning in heavy ion
therapy. Cell survival experiments have been conducted by Gemmel et al. (2011) using a ded-
icated phantom to validate the 4D dose calculation algorithm implemented in a predecessor
version of the 4DTPS. This algorithm has been integrated into TRiP4D and cell survival and bi-
ologically effective dose (BED) calculations have been re-iterated for one particular experiment
(experiment 1 in the original publication). The results were compared to the measurement and
the simulation results reported by Gemmel et al.
3.3.3.1 Materials and methods
The experimental setup, data acquisition and cell processing are introduced here in brief. The
reader is referred to the original publication for a detailed description (Gemmel et al., 2011).
A biological phantom with Chinese hamster ovary cells (CHO-K1) in a medium was positioned
on a sliding table and irradiated with a carbon ion beam. The treatment plan was optimized
for a homogeneous BED of 6 Gy (RBE) in a cuboid volume of (28× 23× 45)mm3. During ir-
radiation the table was moved sinusoidally with a 40 mm peak-to-peak amplitude in left-right
BEV to induce interplay effects. Changes of the radiological depth were introduced by a sta-
tionary ramp-shaped absorber in front of the phantom. Motion monitoring, acquisition of the
beam delivery sequence and temporal correlation of table motion and irradiation progress were
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performed as described for the radiographic film experiments discussed in the previous section.
After irradiation, 10 cell samples were chosen for further analysis. Absolute cell survival was
determined according to Puck and Markus (Puck and Marcus, 1955) and was converted to BED.
The 4D BED and cell survival calculations were performed based on the recorded beam deliv-
ery sequence and the motion monitoring data using both the program of Gemmel et al. (TRiPG)
and TRiP4D. Simulations were performed in two steps, similar to the radiographic film response
simulations in the previous section: (i) generation of sub-treatment plans and (ii) calculation of
the 4D biological dose on the basis of the sub-treatment plans. Since TRiPG relies on the TPS of
Bert and Rietzel, TRiPB, for the generation of sub-treatment plans, step (i) was performed with
the latter and TRiP4D, respectively. The resulting sub-treatment plans then were used as input
to either TRiPG’s and TRiP4D’s BED calculation in step (ii). The same computer-generated 4DCT
with 11 motion states as used by Gemmel et al. were employed for all calculations. Biological
dose calculation was carried out according to section 3.2.3.3 and (Gemmel et al., 2011). The
physical dose was computed with either a standard pencil beam algorithm and an advanced
algorithm including multiple scattering effects. The rigid deformation maps for TRiP4D and
TRiPG were created based on the acquired motion monitoring data. Additional 4D pseudo-
static simulations were performed with both programs using identity deformation maps. These
serve to decouple the deformation of the dose grid and the accumulation of the particle spectra
over all motion states from each other. In this way 3D dose calculation is mimicked. The result-
ing pseudo-static dose distributions were compared to the static dose distribution obtained for
the treatment plan with the TRiP98 mother program. The same set of depth-dose and particle
spectra data (Krämer et al., 2000) as well as the same LEM version (Elsaesser et al., 2008) was
used in all 3D and 4D simulations to guarantee comparability. The measured BED from Gemmel
et al. was compared to the corresponding simulated BED for the cell samples. The difference
in BED was calculated for each sample i: ∆Di = Dmeasi − Dcalci . The mean difference ∆D and
its standard deviation σD were determined to assess the agreement of the different simulations
with the measurement.
3.3.3.2 Results
Table 3.3 lists the results of the statistical analysis of the differences in measured and simulated
BED. The simulation results for the pencil beam dose algorithm (PB) are consistent for all three
simulations and independent from the program used for generation of the sub-treatment plans.
For the multiple scattering algorithm (MS) and simulation BG the results published by Gemmel
et al. were reproduced. Simulations BR and RR using TRiP4D’s BED calculation, however, show
a significant systematic discrepancy of about 310 mGy (RBE) for the mean difference in BED
w.r.t. simulation BG. Table 3.4 summarizes the observed maximum dose differences between
the 4D pseudo-static and the static reference dose distribution. Here, for the MS algorithm the
comparison of the pseudo-static dose distribution attained with configuration BG and the static
TRiP98 dose distribution reveal maximum absolute dose differences per voxel, |∆Dmax|, of more
than 750mGy (RBE). In contrast, for simulation BR, differences of less than 10−2 mGy (RBE)
were found. Moreover, visual inspection of the MS pseudo-static dose distributions revealed
less dose contributions lateral to the target volume for the BG compared to the BR simulation,
indicating a different impact of multiple scattering. For algorithm PB, however, the respective
dose distributions agreed within less than 10−2 mGy (RBE) for both the BG and BR simulations.
Finally, the comparison of the static reference dose distributions for algorithms PB and MS on
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algorithm PB algorithm MS
simulation ∆D±σD[mGy (RBE)] ∆D±σD[mGy (RBE)]
BG −676±642 −298±500∗
BR −676±641 −614±533
RR −679±647 −617±538
Table 3.3.: Mean difference∆D and standard deviation σD of measured and calculated BED for
the cell samples. B, R and G denote the programs TRiPB, TRiP4D and TRiPG used for
generation of sub-treatment plans or 4D biological dose calculation, respectively. For
each configuration a standard pencil beam (PB) and a multiple scattering (MS) algo-
rithm were tested for physical dose calculation. The red highlighted row indicates the
results for the full TRiP4D simulations (RR). The starred result was originally published
by Gemmel et al. (2011).
algorithm PB algorithm MS
simulation |∆Dmax|[mGy (RBE)] |∆Dmax|[mGy (RBE)]
BG 1.67 · 10−3 757
BR 1.67 · 10−3 1.43 · 10−3
Table 3.4.: Maximum deviations in BED, |∆Dmax|, of the 4D pseudo-static dose distributions from
the static reference dose distribution for the two dose algorithms, PB and MS. Iden-
tity transformation maps were used to mimic 3D dose calculation. The static reference
dose distributions were obtained with TRiP98.
average showed about 70mGy (RBE) (≈ 1%) less dose in the target region in the case of MS,
due to lateral scattering. The differences in dose of around 60 mGy (RBE) found between the
two algorithms in the BR simulations (cf. table 3.3) are in agreement with this fact. For the
target dose of 6Gy (RBE) the mean deviation of (617± 538)mGy (RBE) from the measurement
for the TRiP4D simulation translates into a relative deviation of (10± 9)%. The average BED
error propagated from the cell survival measurement error was estimated to about 24 %. Thus,
the simulation results are well compatible with the measurement.
3.3.3.3 Discussion
Even though the agreement with the measurement is better for configuration BG, the performed
tests indicate that TRiPG’s dose calculation algorithm is inaccurate when using the multiple scat-
tering physical dose calculation algorithm. The 4D pseudo-static dose calculations provide the
possibility to assess the performance of the 4D dose calculation independent from the dose grid
transformation and allow for comparison with the static reference dose distributions. In these
simulations the static dose distributions could be reproduced by TRiP4D to a high level of preci-
sion with both the PB and MS algorithm. Since the implementation of biological dose calculation
is decoupled from the implementation of the PB and MS physical dose calculation algorithms
and only used downstream of these calculations, the issues observed for the MS algorithm most
likely do not originate from the specific calculations performed to determine the BED. This is
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supported by the fact that for the PB dose algorithm the results are comparable to those ob-
tained with TRiPG. In contrast to the radiographic film experiments no significant improvement
could be achieved using TRiP4D for the generation of sub-treatment plans (configuration RR).
The reason for this is that the BDS in this case was not affected by any data acquisition issues,
thus, TRiP4D’s more robust algorithms did not yield an advantage over TRiPB w.r.t. simulation
accuracy.
3.4 Summary and discussion
This chapter has presented the development and implementation of TRiP4D, a 4D treatment
planning system for scanned ion beams. The program is based on the GSI in-house treatment
planning system TRiP98 which has been used successfully for clinical treatment planning during
the GSI pilot project (Krämer et al., 2000; Jäkel et al., 2001b). The main objective of this
work was the integration of previous 4DTP efforts and developments made at GSI and the
further advancement of the program towards a clinically serviceable 4DTPS. Previous treatment
planning developments of Bert and Rietzel (2007) and Gemmel et al. (2011) in parts have
served as prototypes. The new TPS enables realistic clinical treatment planning with multiple
fields and is compatible with the treatment planning workflow used at HIT and UCHD.
4D treatment planning in TRiP4D is based on 4DCT, deformable image registration and 4D
segmentation to model the moving patient anatomy. These tools have become well established
over the past years not only in 4DTP for photon therapy (Keall et al., 2005; Rietzel et al., 2005a)
but also for particle therapy (Engelsman et al., 2006; Kang et al., 2007; Zhang et al., 2008).
Hence, emphasis was put on a flexible integration of these instruments to explicitly allow for
realistic patient treatment planning. Interfaces to several image registration software packages
have been implemented and permit quantitative assessment of 4DCT data based on the resulting
deformation maps. The corresponding structures were developed with a focus on principal
compatibility with a wide range of registration algorithms and programs. The use of additional
registration software packages in the future, thus, is expected to be manageable with a minimum
effort. Furthermore, 4D segmentation functionality has been newly implemented. A novel
4D contour data model has been introduced which employs the representation of contours as
volumetric boolean masks, i.e. the ROIs are stored in a bit-wise fashion using a CT-like structure.
This enables to store 4D segmentation data as a single entity and avoids the use of multiple
incoherent sets of polygonal contours. Additionally, a 4D contour propagation algorithm based
on deformable image registration has been implemented which is capable of creating a full 4D
segmentation dataset, starting from a manually contoured reference phase. Many other groups
have made efforts on the implementation of 4D contour propagation algorithms. Commonly,
the approaches are divided into registration-driven (Lu et al., 2006a; Rietzel et al., 2005a) and
deformable model-driven (McInerney and Terzopoulos, 1996; Montagnat and Delingette, 2005)
techniques. In the first the deformation field gives guidance to the contour deformation while
in the second a physical model is used to iteratively match the contours to the image features.
TRiP4D relies on the former approach, since the available deformation maps can be efficiently
re-used. As described in section 3.2.1.4, the contour propagation algorithm employs the inverse
deformation maps and the reference phase contour to establish the ROIs in each 4DCT phase as
VBMs. An alternative strategy has, for instance, been published by Lu et al. (2006a). They have
used triangular meshes to model the surface of the ROIs. After surface deformation the polygon-
based contours for all 4DCT phases are generated by performing sections of the surface model
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with the image plane of interest. A drawback of TRiP4D’s propagation algorithm is the necessity
to generate both, the original (needed for 4D dose calculation) and the inverse deformation
maps. Since the registration process can be sufficiently automated, this does not constitute a
major limiting factor. It can be anticipated that the use of VBMs is more memory consumptive
compared to, e.g., triangular meshes. Whilst the VBM contour model has the advantage that
contours can be easily combined and manipulated, e.g., for ITV generation, the resolution of
the contours is forced to the regular CT grid, causing a loss of precision. However, since the
usual lateral CT voxel spacing as well as the expected registration accuracy are on the order
of millimeters (Brock, 2010), no significant impact is expected. Nevertheless, also up-sampled
VBM datasets can be used in TRiP4D at the expense of memory consumption.
4D treatment plan optimization in TRiP4D implies the appropriate design of a target vol-
ume, depending on the beam delivery technique, and the dose optimization on the CT reference
phase. In the case of beam tracking or RDBT additional optimization of position or dose compen-
sation parameters is performed (Lüchtenborg et al., 2011). Water-equivalent ITV optimization
has been incorporated into TRiP4D (Graeff et al., 2012) based on the 4DCT and 4D segmenta-
tion functionality and the concept proposed by Rietzel and Bert (2010). For scanned ion beams
so far no alternative concept has been proposed. Similar approaches were made in the liter-
ature for passively delivered ion beams. Engelsman et al. have studied the design of ITVs for
proton therapy. They optimized treatment plans on the individual CT phases and combined
the respective compensators to account for motion-induced range changes (Engelsman et al.,
2006). In a simpler approach Koto et al. have investigated the formation of effective ITVs for
passive carbon ion therapy of lung tumors by manipulation of the CT HU values. They combined
a lateral margin with the extension of the tumor volume in the SI direction by replacing lung
tissue with GTV HU values (Koto et al., 2004). Apart from the mere optimization on a reference
phase CT more elaborate techniques can be thought of. At the time of writing initial implemen-
tations of 4D optimization algorithms in TRiP4D by colleagues already take into account more
than one CT phase for dose optimization. These developments benefit decisively from TRiP4D’s
newly implemented 4DCT and 4D segmentation infrastructure. Similar 4D dose optimization
concepts have been investigated for IMRT, e.g., by Nohadani et al. (2010). Unkelbach et al.
(2009) have investigated 4D treatment planning incorporating robustness considerations. 4D
dose optimization techniques, however, are significantly more memory and time consumptive
and can quickly deplete the available computing resources. It can be expected, however, that
the rapid development in the computing sector will compensate for this in the future.
In this chapter particular emphasis was put on TRiP4D’s 4D treatment simulation functional-
ity. The 4D dose deposition is modeled in two steps. First, sub-treatment plans are generated
according to Bert and Rietzel (2007). The procedure is based on beam delivery sequence tables,
which carry the time-structure of the beam delivery, and its correlation with the patient motion
via surrogate motion traces. A general and flexible implementation of the beam delivery time
structure via externally compiled tables was introduced. The implementation allows to model
all commonly proposed motion mitigation techniques, including rescanning, gating, tracking
and possible combinations of these. A module has been designed which is capable of handling
patient breathing trajectories acquired with motion monitoring devices. Based on the motion
trace, amplitude and phase-based identification of the patient’s respiratory state are supported
and can be performed in compliance with the 4DCT data acquisition used at HIT and UCHD.
After sub-treatment plan generation 4D dose calculation is carried out, taking into account the
4DCT and the deformation maps. The 4D (biological) dose calculation algorithm developed
3.4. Summary and discussion 59
by Gemmel et al. (2011) has been incorporated into TRiP4D and permits to perform detailed
4D dose calculation for realistic patient motion using TRiP4D’s deformable registration module.
The dose algorithm additionally was extended to 4D detector response calculation. To deter-
mine the non-linear biological effect, the algorithm accumulates all dose contributions to a dose
voxel over all CT phases under consideration of the deformation field. That is, the dose grid is
deformed instead of the the raster grid. This concept has been used for physical dose calculation
and proton beam scanning by other groups as well (Paganetti et al., 2005; Knopf et al., 2010a).
Inaniwa et al. (2010) have integrated a biological dose calculation algorithm into their treat-
ment planning system for scanned ion therapy. So far, they did not report a 4D version of the
algorithm. 4D treatment simulation for scanned beams was investigated by few other groups.
Furukawa et al. from NIRS have performed 2D simulations to study the mitigation of interplay
effects using gating and rescanning. However, they did not attempt direct comparisons of their
simulations with the measured dose distributions (Furukawa et al., 2010a). Knopf et al. (2011)
have performed treatment planning studies at PSI for scanned proton treatments of liver tumors
using rescanning. Apart from 4D dose calculation (van de Water et al., 2009) they also included
a model of the temporal structure of the pencil beam scanning. So far, they have considered
liver tumors and rigid patient motion only, hence, neglecting all density changes. For passive ion
therapy and photon therapy 4D dose calculation usually is realized by time-weighted averaging
of the dose distributions in each phase, taking into account their distribution over the respira-
tory cycle(Rietzel et al., 2005b; Kang et al., 2007). 4D treatment planning including 4D dose
optimization and calculation is already commercially available for photon therapy with the Cy-
berknife Synchrony system (Accuray Inc., Sunnyvale, Ca., USA) (Sarfaraz et al., 2009; Accuray,
2011). The treatment planning strategy is based on 4DCT and deformable image registration.
TRiP4D’s 4D simulation functionality has been extensively tested in verification experiments.
The preceding sections have presented results of the verification of the full 4D treatment sim-
ulation chain, including 4D dose and detector response. Where applicable, the performance of
TRiP4D was compared to the respective predecessor programs. The simulation of 4D film re-
sponse showed a significant improvement w.r.t. the planning system of Bert and Rietzel in those
cases where BDS data was defective and the more robust algorithms of TRiP4D could handle
these issues appropriately. The measured optical film densities could be reproduced with an
accuracy of around 10%. This corresponds to the expected level of accuracy as reported by
Spielberger et al. (2003). The results of the biological dose calculation tests revealed good
agreement with the planning system of Gemmel et al. for one of the two tested algorithms
used for the physical dose calculation part. Significant discrepancies were found for the second
algorithm which takes into account multiple scattering. Comparisons with TRiP98, however,
suggest that the observed differences solely originate from defective calculation of multiple
scattering contributions in the predecessor program and are not caused by differences in the
biological dose calculation. Reasonable agreement with the measured dose values was found
for the TRiP4D calculations. Moreover, new elaborate water phantom experiments were con-
ducted to test TRiP4D’s simulation capabilities for 3D target motion, gated beam delivery and a
large number of plan parameters and motion configurations. The comparison of measured and
simulated dose values showed good agreement with standard deviations smaller than 5 % in
most cases. It can be concluded that 4D simulations subsequent to treatment delivery are well
feasible in experimental setups, provided all necessary parameters are known, i.e. in particular
the time structure of the beam delivery process and the target motion during delivery. How-
ever, simulation prior to treatment delivery is very challenging even for simple setups and well
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known target motion. Synchrotron accelerator systems like those used at GSI and HIT are sub-
ject to significant variability of beam availability and to the delivered intensity on a sub-second
time-scale (Haberer et al., 1993). These parameters significantly affect the 4D dose deposi-
tion, while being difficult to model. Intensity-controlled beam extraction for synchrotrons is a
promising development to reduce this kind of uncertainty (Furukawa et al., 2005). For patient
treatments additional complexity is introduced, since prediction of the target motion in general
is not feasible on a time-scale beyond several hundred milliseconds (Sharp et al., 2004; Ruan
and Keall, 2010). Hence, a reliable prediction of the delivered dose prior to treatment is difficult
to achieve. Nevertheless, 4D treatment simulation offers great potential for 4DTP and quality
assurance. It may, for instance, provide the opportunity to monitor the success of the plan de-
livery, provided the beam delivery time structure and the patient motion during treatment are
measured. Furthermore, in-advance treatment planning simulations can be performed for many
different scenarios. Even though the patient motion and the time structure of the beam delivery
are not known, simulations of a wide range of parameter settings, such as different breathing
patterns or beam delivery schemes, can be performed and yield a spectrum of possible treatment
outcomes. These simulations also can be used to assess plan robustness or define parameters
needed as input for the respective treatment delivery technique, such as the number of required
rescans or the gating window size. Simulation studies of this nature will be the subject of the
following chapters, using experimental and realistic patient setups. It should be emphasized
that from a technical point of view there is no principal difference between in-advance simula-
tions in TRiP4D and those performed subsequent to treatment. The uncertainty and value of
4D treatment simulations solely depends on the reliability of the input data. It is important to
realize that the accuracy of any 4D treatment planning attempt based on 4DCT and deformable
image registration depends decisively on the validity and reproducibility of the input data, in
particular between the time of imaging and treatment delivery (von M. Siebenthal et al., 2007;
Mori et al., 2009; Case et al., 2010). The variability and accuracy of these are a separate field
of study and beyond the scope of this thesis.
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4 Beam parameter optimization for the
mitigation of residual motion
4.1 Introduction
The preceding chapters have repeatedly highlighted the challenges of organ motion for treat-
ment planning and beam delivery of scanned ion beams. The interference between the moving
beam and the tumor motion can lead to clinically unacceptable under- and overdosage and to
an increased exposure of surrounding normal tissue (section 2.2.2). These shortcomings so far
have prevented the application of beam scanning for moving tumors in clinical routine. Gating
(Minohara et al., 2000) and irradiation under abdominal compression (Wunderink et al., 2008)
are promising candidates to reduce the effective tumor motion for lung and liver tumors to few
(<10) millimeters (Berbeco et al., 2005, 2006; Eccles et al., 2011). Gating has been used suc-
cessfully for treatment of lung and liver tumors with passively delivered ion beams (Iwata et al.,
2010; Chiba et al., 2005). Abdominal compression and beam gating lately have been brought
to clinical application for scanned beams at HIT. However, even when using these mitigation
techniques, residual tumor motion can induce a degradation of the dose homogeneity.
Bert et al. (2009) have proposed to use an increased lateral and longitudinal overlap of pencil
beams, in order to gain robustness w.r.t. organ motion. The basic concept is depicted in fig-
ures 4.1 and 4.2. In the lateral dimension the static configuration of overlapping pencil beams
to achieve a homogeneous dose is extended either by increasing the beam’s full width at half
maximum (FWHM) or by decreasing the lateral raster spacing. The dose at each target point
is, thus, determined by a larger number of pencil beams and a relative displacement between
pencil beams will have a smaller effect on the dose homogeneity. The lateral overlap factor
shall be introduced as:
flat =
beam FWHM
∆s
, (4.1)
∆s denoting the lateral raster spacing (figure 4.2). The standard parameters used for stationary
irradiation at GSI and HIT are ∆s = 2mm and a beam FWHM of 6mm, i.e. a lateral overlap
factor of flat = 3. While the lateral raster spacing can be set as desired in the treatment planning
system, the beam FWHM is restricted to the energy-dependent beam focus settings available in
the accelerator library (Schardt et al., 2010).
In the longitudinal direction an increased pencil beam overlap can be obtained either by a
decreased iso-energy slice spacing, ∆z, or by an increased effective Bragg peak width using
dedicated ripple-filters (section 2.1.3.2).1 The longitudinal overlap factor shall be defined as:
flng =
effective Bragg peak width
∆z
. (4.2)
1 The effective Bragg peak width corresponds to the sigma of the Gaussian depth-dose profile that the ripple-filter
is optimized for (Weber and Kraft, 1999).
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Figure 4.1.: (a) The pristine Bragg peaks are broadened in depth by the use of ripple-filters.
(b) Standard longitudinal beam overlap as used for treatment of stationary targets
at GSI and HIT. Increased longitudinal beam overlap is facilitated by a larger Bragg
peak width (c), or by a decreased IES spacing (d).
Typically, a 3 mm RiFi and a ∆z = 3mm is used for stationary targets at GSI and HIT, thus,
flng = 1. In analogy to the lateral beam overlap an increased longitudinal overlap results in a
larger number of pencil beams contributing to the dose at a certain point. This should provide
enhanced robustness w.r.t. residual range variations introduced by target motion. In practice,∆z
and the effective Bragg peak width can only be varied within limits. The former is determined
by the energy steps available from the accelerator (1mm steps in water at HIT) and the latter is
defined by the mechanical design of the RiFi.
Bert et al. have studied increased lateral and longitudinal pencil beam overlap in separate
experiments and simulations using radiographic films and gated irradiation (Bert et al., 2009).
Their results indicate that motion-induced interplay effects can be effectively reduced by both
increased lateral and longitudinal overlap. The portability of the concept to a more complex and
realistic setup with 3D target motion has been studied at GSI for both gated and ungated irradi-
ation. The investigations with regard to gating were carried out by Steidl (2011). The presented
complementary study addresses the mitigation of residual motion for ungated irradiation.
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Figure 4.2.: (a) Lateral beam overlap as used for stationary targets at GSI and HIT. (b) Increased
lateral beam overlap by a decreased raster spacing (∆s). (c) Increased lateral beam
overlap using an increased beam FWHM.
Interplay patterns are very sensitive to the motion characteristics, including the motion am-
plitude and the initial motion phase. Considering that all beam parameters may also be varied
independently, the parameter space of interest is highly multi-dimensional. Due to the vast
amount of beam time needed, a purely experimental approach is impractical. Instead, a sub-
space of the parameter space has been investigated experimentally and the data were used to
validate the 4D treatment simulation capabilities of TRiP4D which were discussed in detail in
the last chapter. As the interplay patterns are very unique to the specific motion configuration
and beam delivery sequence at the time of the 4D dose measurements, the agreement between
sparsely sampled simulations and the respective measurements strongly suggests the general va-
lidity of the simulation environment. Starting from this premise, TRiP4D can be used to expand
the parameter space in large-scale simulations.
4.2 Materials and methods
4.2.1 Experimental setup and conduct
The experiments for the dosimetric parameter study were conducted on three different days
at the quality assurance cave at HIT. The first two measurement series were accomplished on
two subsequent days. The third series constituted a repetition of the original experiment for a
subset of the parameters several months thereafter. Due to other measurements occupying the
cave, the setup had to be re-positioned each day. The figures 4.3a and 4.3b show a photograph
and a schematic illustration of the experimental setup, respectively. An array of 24 pinpoint
ionization chambers (ICs) was attached to a robotic arm and was positioned inside a water
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(a) (b)
Figure 4.3.: Photograph and sketch of the experimental setup. In the sketch on the right the
data acquisition and the data communication between the systems is illustrated. As
indicated, data on the scanner progress (point irradiation times) and on the beam
status are acquired separately with the TCS and the experimental DAQ.
phantom (MP3 phantom, PTW, Freiburg, Germany). The setup is similar to the one routinely
used for quality assurance measurements (Karger et al., 1999), but was extended by robotic
motion. The implementation of the robotic motion is described in detail in (Steidl, Richter et al.
2012). The IC array moved sinusoidally in all three dimensions:
aLR(t) = 0.50 · ALR · sin
(
2pi
T
t
)
aUD(t) = 0.25 · ALR · sin
(
2pi
T
t +
pi
2
)
aBF(t) = 0.25 · ALR · sin
(
2pi
T
t +
pi
2
)
.
(4.3)
Here aLR denotes the motion direction in LR and aUD and aBF are the motion components in the
up-down (UD) and back-front (BF) direction w.r.t. BEV, respectively. A motion period of T = 3s
was used for all measurements and the peak-to-peak amplitude ALR was varied from 0 to 10mm
to mimic residual tumor motion. As shown in equations (4.3), the major motion component was
set along the LR direction. In the remaining dimensions the motion amplitudes were set to 50 %
of the LR amplitude. Additionally, a 90° phase shift was applied to both components w.r.t. to the
LR motion, such that the array moved along the path of a tilted ellipse. The start of the IC array
motion was triggered on the irradiation start with an initial motion phase of φ0 = 0°. The LR
motion component was monitored using a laser distance sensor (figure 4.3). The beam status
signal was acquired via a transistor-transistor logic (TTL) signal provided from the accelerator
control system. Additionally, a Geiger counter was used to acquire a second and independent
beam status signal. Motion monitoring data and the two beam status signals were recorded with
the same experimental data acquisition system (DAQ) at a temporal resolution of 1 ms with a
Beckhoff EtherCAT system (Beckhoff Automation GmbH, Frankfurt, Germany). In parallel, the
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raster point irradiation times were logged via the routinely provided beam records of the TCS
with a resolution of 1 µs. The 6D robotic motion was monitored and logged with dedicated
software. The absorbed dose in the ICs was measured with two multi channel dosemeters with
12 channels each (MULTIDOS, PTW, Freiburg, Germany).
Daily calibration of the beam monitoring chambers controlling the delivered particle numbers
per raster point (cf. figure 4.3) and of the dosimeters was performed. Specifically air density
corrections were taken into account. The corrections involved calibration measurements with a
reference ionization chamber at a defined position (iso-center) according to Karger et al. (2010).
Due to the large setup, these calibration measurements could not be performed at the iso-center
but 38mm closer to the beam exit window. As a result, subsequent correction of the measured
dose needed to be performed, taking into account the geometric divergence of the beam. Details
on the correction procedure were reported by Steidl (2011).
In order to assess the beam quality, a radiographic film was irradiated with single beam spots
at representative beam energies and a homogeneous field prior to each measurement series.
Similarly, the treatment records were analyzed with respect to the stability of the beam position
and beam spot size.
4.2.2 Treatment plan parameters and optimization
An ellipsoidal internal target volume (ITV) of 82cm3 and half axes of 28mm in LR BEV, 35mm
in BF and 20 mm in UD direction was irradiated in the water phantom at a depth of 125mm with
a carbon ion beam. The treatment plans were optimized and conformed to the ellipsoidal target
volume using the GSI reference 3D treatment planning system TRiP98. 18 combinations of lat-
eral raster spacing (2 and 3mm), iso-energy slice spacing (1, 2, 3 and 4mm water-equivalent),
beam FWHM (6, 8 and 10mm) and RiFis were selected. Apart from the standard RiFi opti-
mized for a 3 mm IES spacing, an additional combination of two orthogonally crossed 3 mm
ripple-filter was used. At the beam energies used in the experiment the latter produces an effec-
tive Bragg peak width of about 4 mm. The FWHM of the beam spot at each focus level remained
approximately constant over the selected energy range of the experiment (≈216–298MeV/u) .2
Thus, a single focus level could be requested for each treatment plan. The plans for all 18 com-
binations were optimized for a homogeneous target dose of 2Gy. Table 4.1 gives an overview
of the beam parameter combinations used for the treatment plans.
4.2.3 4D dose reconstructions
To assess TRiP4D’s ability to simulate the time-dependent dose delivery for the described exper-
imental setup and the different combinations of beam parameters, dose reconstructions were
performed according to section 3.2.3 and compared to dosimetric measurements. The vali-
dation of the simulation environment constitutes the prerequisite for further simulations with
TRiP4D using a larger parameter space. 4D dose reconstructions were accomplished based on
the measured beam status signal, the treatment records provided from the TCS, the nominal sur-
rogate motion trajectories of the LR target motion component and a computer generated 4DCT
of the water phantom with 22 phases. Dose calculations were performed on an isotropic 1 mm
2 By trend the FWHM of the beam spot increases for decreasing beam energy, due to scattering in the beam line.
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plan parameters [mm] peak-to-peak amplitude ALR [mm]
RiFi ∆s ∆z FWHM FL static 2 3 4 5 6 7 8 10
series/day one
3.0 2.0 2.0 6.1 2 × × – × – × – × ×
3.0 2.0 2.0 8.3 3 × – × – × – × – ×
3.0 2.0 2.0 10.1 4 × – × – × – × – ×
3.0 2.0 3.0 6.1 2 × × – × – × – × ×
3.0 2.0 3.0 8.3 3 × – × – × – × – ×
3.0 2.0 3.0 10.1 4 × – × – × – × – ×
3.0 3.0 1.0 10.1 4 × – × – × – × – ×
3.0 3.0 2.0 10.1 4 × – × – × – × – ×
3.0 3.0 3.0 10.1 4 × – × – × – × – ×
series/day two
4.0 2.0 2.0 6.1 2 × × – × – × – – ×
4.0 2.0 2.0 8.2 3 × – × – × – × – ×
4.0 2.0 2.0 10.1 4 × – × – × – × – ×
4.0 2.0 3.0 6.1 2 × × – × – × – – ×
4.0 2.0 3.0 8.2 3 × – × – × – × – ×
4.0 2.0 3.0 10.1 4 × – × – × × – – ×
4.0 2.0 4.0 10.1 4 × – × – × – × – ×
4.0 3.0 2.0 10.1 4 × – × – × – × – ×
4.0 3.0 3.0 10.1 4 × – × – × – × – ×
series/day three
3.0 2.0 2.0 6.1 2 × – – – × – – – ×
3.0 2.0 2.0 8.3 3 × – – – × – – – ×
3.0 2.0 2.0 10.1 4 × – – – × – – – ×
3.0 2.0 3.0 6.1 2 × – – – × – – – ×
3.0 2.0 3.0 8.3 3 × – – – × – – – ×
3.0 2.0 3.0 10.1 4 × – – – × – – – ×
3.0 3.0 2.0 10.1 4 × – – – × – – – ×
3.0 3.0 3.0 10.1 4 × – – – × – – – ×
4.0 2.0 2.0 10.1 4 × – – – × – – – ×
4.0 2.0 3.0 10.1 4 × – – – × – – – ×
Table 4.1.: Table of the measured beam parameter combinations and motion amplitudes. ALR
denotes the peak-to-peak amplitude of the major motion component (left-right in
BEV). The motion amplitudes for the remaining components were: A⊥ = 0.5× ALR.
Each treatment plan was optimized for a combination of ripple-filter (RiFi), lateral
raster spacing (∆s), IES spacing (∆z) and beam focus level (FL). The corresponding
average FWHM of the beam spot for each FL is also given.
68 4. Beam parameter optimization for the mitigation of residual motion
Figure 4.4.: Bird’s eye view section of simulated dose distributions for the static (left) and a mov-
ing target (right) and a representative beam parameter combination (dose in mGy.
The 4D dose is mapped to the reference phase (extreme left position in BEV). The IC
positions are indicated by the white and black crosses (neglected for analysis).
voxel grid. The robotic target motion was modeled using rigid deformation maps generated
with TRiP4D, based on the nominal 3D target motion trajectories (cf. section 3.2.1.3).
4.2.3.1 Beam delivery sequence data
As discussed in section 3.2.3.2, 4D dose calculations in TRiP4D require beam delivery se-
quence (BDS) input tables. The measured data of the beam status signals and of the raster
point irradiation times were used to generate BDS tables reflecting the individual characteristics
of the beam delivery at the time of each of the measurements. For technical reasons, raster point
irradiation times and beam status signals were not acquired with the same DAQ (cf. figure 4.3).
As a consequence, temporal correlation of the two systems and combination of the data into
BDS tables for TRiP4D was needed. For this purpose, dedicated software was used which was
developed within the scope of this thesis (appendix A.3). The inputs to the program are the
measured beam status signals from the experimental DAQ and the TCS treatment records. The
underlying principle of the calibration procedure is as follows. The beam is switched off rapidly
(1ms) by the control system at the end of a beam gate or spill (BOF event, using the nomen-
clature introduced in section 3.2.3.2) or after completion of the last raster point of an IES (EOP
event). Temporal alignment is established by mapping the BOF events, as defined by the beam
status signal, to the matching EOP events from the treatment records:
(1) Beam-on (BON event) and BOF events are generated by discrimination of the analog beam
status signal against suitable thresholds. The EOP events are obtained from the treatment
records using the completion time of the last raster point in each IES.
(2) A rough initial alignment is established by mapping the last EOP event to the last BOF event.
Subsequently, corresponding pairs of BOF and EOP events are determined in a regional
search in time around each EOP event.
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Figure 4.5.: (a) Visualization of a BDS after temporal alignment. The raster point index is drawn
vs. the respective irradiation time. The falling edges of the aligned beam status
match the completion time of the last raster point in each IES. (b) Correction of the
initial phase shift originating from the starting delay (∆t). The initial phase (φ0) is
determined via a fit of a sinusoid to the motion trajectory (red dashed curve).
(3) Due to the lower sampling resolution of the beam status signal (1ms), the initial alignment
may lead to raster points located outside beam gates. To maintain causality, a fine-tuning of
the temporal alignment is performed by relative shifting of the time axes of the two systems
such that all raster points are located within spills.
A graphical visualization of an example BDS table resulting from the alignment procedure is
depicted in figure 4.5a. Note, that the accuracy of the alignment depends on the number of
supporting points available for calibration, i.e. the number of iso-energy slices, and is on the
order of few milliseconds in the presented case.
4.2.3.2 Correction of the initial motion phase
Instead of the measured motion trajectories, the nominal sinusoidal trajectories were generated
using TRiP4D’s motion trace module (cf. section 3.2.1.2) and were used in the 4D simulations.
Due to technical limitations, the robotic motion exhibits a significant starting delay w.r.t. the
trigger at irradiation start (Steidl, Richter et al. 2012). This delay effectively corresponds to
a non-negligible initial phase shift of the measured motion trajectory relative to the planned
initial motion phase. In order to ensure adequate agreement of the dose reconstructions with
the measurements, this phase shift was determined in a signal analysis of the measured motion
trajectory and the beam status signal. For each measurement a sinusoid was fitted to the mea-
sured motion trajectory. The initial motion phase then was obtained as the phase of the sinusoid
at irradiation start and was considered for generation of the sinusoidal motion trajectory with
TRiP4D. The correction procedure is illustrated in figure 4.5b showing the relation of the initial
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phase, φ0, to the starting delay, ∆t, and the resulting sinusoidal motion trajectory used in the
simulations (dashed red line).
4.2.3.3 Analysis of measured and reconstructed dose distributions
The accuracy of the 4D dose reconstructions with TRiP4D was assessed by a statistical analysis
of simulated and measured dose values at the respective geometrical positions of the ionization
chambers. A software was developed which is capable of extracting dose values from a 3D
dose distribution using a given geometry of pinpoint ICs (appendix A.2). The mean relative
difference of measured and simulated dose values
∆D =
N∑
i
(
Dcalci − Dmeasi
)
/ Dmeasi (4.4)
and the standard deviation, σD, was calculated for N = 22 ICs. The remaining two ICs were
neglected for analysis because they were positioned close to the target volume boundary (fig-
ure 4.4) and exhibited significantly larger dose fluctuations compared to the other detectors.
Furthermore, the agreement between measured and simulated dose at the individual IC po-
sitions was assessed using bivariate linear regression. The same regression model as given in
equation (3.7) was used (see section 3.3.2 for details). This model assumes a linear relationship
between measured and calculated dose, modified by a systematic and dose-independent contri-
bution of the two different ripple-filters. The analysis was carried out using JMP (version 9.0,
SAS Institute Inc., Cary, NC, USA). The results of the bivariate regression are reported as the
coefficient of variation R2 and the root-mean-square error (RMSE) of the model.
4.2.4 4D dose simulations
4.2.4.1 Parameter space expansion
The validation of the simulation environment using the dose reconstructions discussed in the
previous section was the basis for additional 4D simulations in the same setup. The sparse
sampling of the motion parameter space in the experiments was extended by a finer graduated
scan of the parameter space, including the initial motion phase and amplitude. Furthermore, the
impact of the beam delivery sequence (BDS) on residual motion interplay effects was studied.
To assess the full spectrum of the expected dose inhomogeneities for the given target geometry
and the selected beam parameter combinations, the initial target motion phase was varied from
0° to 360° in 12 steps of 30°. Four motion amplitudes of 0.5, 3, 5 and 10 mm were chosen for the
major motion component in the LR direction. In analogy to the experimental configuration, the
amplitudes for the remaining dimensions were reduced to 50% of the LR value. For practical
reasons a motion period of three seconds was used for all simulations.
To study the impact of the temporal structure of the beam delivery on the interplay effects,
the BDS data measured during the experiments were used as input to the 4D simulations. They
were assumed to represent a realistic spectrum of the HIT beam delivery characteristics over
time. Since the BDS is specific to a particular treatment plan, between one and ten different
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BDS tables (93 in total) were available for each of the beam parameter combinations listed
in table 4.1. For every sequence the full spectrum of four amplitudes and 12 starting phases
was simulated, amounting to a total of 4464 dose distributions. The simulation workflow and
infrastructure is identical to the one used for the dose reconstructions, including the 4DCT and
target geometry. The motion parameters were used as input to TRiP4D to generate 3D target
motion trajectories and the associated rigid deformation maps (section 3.2.1.3). Initial motion
phase correction, as described above, did not apply.
4.2.4.2 Analysis of simulated dose distributions
The analysis of the simulated dose distributions was based on a statistical evaluation of the
dose inside a CTV. It is common practice to obtain the ITV from the CTV by an appropriate
definition of margins (section 2.2.3.2). In the presented case the limited amount of beam time
only allowed for a single treatment plan to an ITV per beam parameter combination. There-
fore, the CTV was constructed from the ITV using TRiP4D’s 4D segmentation functionality
(section 3.2.1.4). In brief, the ITV was transformed to all 4DCT phases based on the inverse
rigid deformation maps for the respective target motion. The CTV was obtained by subsequent
formation of the intersection volume over all ITV phase representations. For reasons of simplic-
ity and comparability, only the smallest possible CTV, i.e. for the 10 mm motion amplitude, was
constructed and selected for analysis of all dose distributions. In figure 4.4 the reference phase
CTV and ITV are depicted as cross sections through the ITV center.
To assess the dose homogeneity inside the CTV as a function of the beam parameters and
the motion amplitude, the mean dose and standard deviation, D and σD, and the minimum and
maximum dose, Dmin and Dmax, were computed. Furthermore, the differential dose distributions
to the static case were computed, including the mean dose and standard deviation, the minimum
and the maximum dose inside the CTV. Also, dose volume histograms (DVHs) were calculated
and analyzed for all dose distributions. A dose homogeneity index (HI) was defined as:
HI=
D5− D95
Dp
. (4.5)
Here, D5 and D95 denote the dose covering 5 % and 95 % of the CTV, respectively. Dp is the
prescribed dose. The conformity of the dose to the ITV was measured using two different dose
conformity indices. The so-called conformation number (CN) was adopted from van’t Riet et al.
(1997) and Feuvret et al. (2006) and is defined as:
CN=
(
V T95
VT
)
×
(
V T95
V95
)
, 0≤ CN≤ 1 . (4.6)
Here, VT is the volume of the ITV and V
T
95 is the ITV volume receiving at least 95% of the
prescribed dose. Finally, V95 denotes the overall volume receiving at least 95 % of the prescribed
dose. Hence, the target coverage is balanced with the exposure of the surrounding volume. As
a second figure of merit the dose conformity index (CI) according to Steidl (2011) was used:
CI=
∫
ITV
D(x , y, z)dV∫
D(x , y, z)dV
, 0< CI< 1 . (4.7)
That is, the fraction of the integral dose deposited in the ITV.
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focus level 2 focus level 3 focus level 4
series/
day
FWHMx FWHMy FWHMx FWHMy FWHMx FWHMy
µ±σ[mm] µ±σ[mm] µ±σ[mm] µ±σ[mm] µ±σ[mm] µ±σ[mm]
1 6.0±0.4 5.7±0.3 8.2±0.7 8.0±0.3 10.3±1.0 10.4±0.3
2 5.6±0.2 5.8±0.2 7.5±0.1 8.1±0.2 9.2±0.2 10.4±0.3
Table 4.2.: Mean measured FWHM of the beam spot and standard deviation for the lateral di-
mensions (x,y) at the different focus levels. The data were extracted from the TCS
treatment records of the first two measurement series. Differences between days
originate from an accelerator hardware failure.
4.3 Results
A total of 99 measurements with target motion were performed. Between two and five motion
amplitudes per treatment plan were driven with the robot, some of them were measured mul-
tiple times. Additionally, 29 static reference irradiations were performed. An overview of the
amplitudes measured per beam parameter combination is given in table 4.1. Due to a hardware
failure on day one, beam conditions were not stable over the first two measurement series. Ta-
ble 4.2 summarizes the results of the statistical analysis of the TCS treatment records regarding
the FWHM of the beam. Compared to day two, beam spots on day one had a larger mean di-
ameter in the x dimension (≈10%) and also exhibited larger fluctuations on the same order of
magnitude in this dimension. The planned values of beam FWHM are given in table 4.1 for each
treatment plan. Deviations of the measured beam FWHM from these values are smaller than
10% on both days. Apart from the beam FWHM, beam positions were also less stable on day
one. The standard deviation of the mean difference to the planned beam position was deter-
mined to 0.9 mm and 0.2mm in x and y , respectively. This compares to 0.2 mm and <0.1mm
for x and y on day two, respectively.
Since all measurement with RiFi3 were performed on day one (cf. table 4.1) and were affected
by the fluctuation in the beam spot size and position, the respective parameter combinations
were repeated in the third measurement series. A smaller number of RiFi4 combinations was
also measured for comparison. Beam conditions were stable during these measurements.
4.3.1 4D dose reconstructions
4D dose reconstructions were carried out using the nominal target trajectories with an individ-
ual initial phase determined from the measured motion trajectory and the acquired beam status
data, as discussed above. Six of the measurements were disregarded for dose reconstruction,
due to missing or deficient BDS data. On the first two measurement days the robot showed
an average starting delay w.r.t. the trigger on the first beam-on of ≈1160 ms. For the selected
motion period of 3 s this translates into an initial motion phase shift of ≈−139°. After improve-
ments in the start-up behaviour of the robot for the third measurement series, the initial motion
phase shift was reduced to −29°, corresponding to a delay of ≈240ms. However, for all cases
correction of the initial phase shift turned out to be necessary, in order to satisfactorily reproduce
the measured IC doses in the simulations.
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Figure 4.6.: Agreement of simulated and measured dose values for the first two (a) and the third
measurement series (b). The mean relative dose difference over the 22 IC positions
and standard deviation is drawn vs. the measurement number. Static reference
irradiations are indicated with open symbols. Separate fits are given for the RiFi3
and RiFi4 cases.
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Figure 4.7.: Scatter plot of measured (Dmeas) versus simulated dose values (Dcalc) for the indi-
vidual ICs in all moving and stationary cases of series one and two (a), and series
three (b). The fits determined by bivariate linear regression for RiFi3 and RiFi4 are
indicated for each ensemble, including the R2 and RMSE.
In figure 4.6a and 4.6b the results for the comparison of reconstructed and measured dose
values at the IC positions are given for all measured cases, including the static reference irradia-
tions. Separate graphs are shown for the first two and the third measurement series, comprising
47(19) and 21(19) irradiations with(without) target motion, respectively. The graphs are split
for the RiFi3 and RiFi4 combinations, including separate fits to the data. The average agree-
ment of the 4D simulations with the measurements for the first two series is (−1± 5)% and
(−3± 5)% for RiFi3 and RiFi4 cases, respectively. Standard deviations are below 8% for more
than 90% and below 5% for about 60 % of the cases. For the third measurement series the
average agreement is (−2± 2)% and (−4± 2)% for the RiFi3 and RiFi4 cases, respectively.
Standard deviations are below 3 % for all cases. For the static reference irradiations the simu-
lations agree with the measurements of the first two series within (−2± 1)% and (−4± 1)%
for RiFi3 and RiFi4 cases. Similar values of (−2± 1)% and (−3± 1)% were obtained for the
third series. A systematic difference in the mean value of about 2% was consistently observed
between RiFi3 and RiFi4 treatment plans over all measurement series. Detailed results of the
dose reconstructions for all cases are listed in tables B.2 and B.3 in the appendix.
The results of the bivariate linear regression using the model in equation (3.7) are summarized
in figures 4.7a and 4.7b. The analysis was performed separately for the first two and the third
measurement cohort and the respective simulations. The scatter plots show the correlation
of measured and simulated dose values at the individual IC positions for all considered cases
with and without target motion. The linear fits for the two ripple-filters are drawn on top.
The resulting coefficient of variation, R2, and RMSE for the model are given for both data
ensembles. Compared to the first two series (figure 4.7a), the third cohort of measured and
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simulated dose values exhibits a 50 % larger explained variance R2 and a significantly smaller
RMSE (figure 4.7b). The systematic dosimetric difference between RiFi3 and RiFi4 cases was
statistically significant at the p < 10−4 level.
4.3.2 4D simulation results
The following sections will present the results of the 4D simulations concentrating on the influ-
ence of the various beam parameters on the target dose homogeneity and the dose conformity.
Since several of the investigated parameters turned out to be strongly correlated, only a subset
of the parameters is considered here, namely the standard deviation of the mean dose in the
CTV, σD, and the conformity indices, CI and CN. σD exhibited a large sample correlation co-
efficient, r, w.r.t. the homogeneity index, HI (r ≈ 0.99, p < 0.05), and Dmax − Dmin (r ≈ 0.96,
p < 0.05). Since variations of the static dose inside the CTV were negligible, the mean differ-
ential dose and standard deviation were strongly correlated to the respective non-differential
parameters (r ≈ 1.0, p < 0.05). Thus, they were not investigated any further.
4.3.2.1 Dose homogeneity
Variation of the beam spot size
In figure 4.8 bird’s eye view cross sections of two 4D dose distributions for 6 and 10mm beam
FWHM, a medium LR motion amplitude of 5 mm and a selected initial motion phase are shown.
On the right hand side the corresponding DVH bands for the CTV are given for three motion
amplitudes. The bands represent the spread of one standard deviation around the average DVH
characteristic. Both were determined using all simulations of the respective beam parameter
combination, i.e. initial phases and several beam delivery sequences.3 In the presented case the
overdose to the CTV (pink areas in figures 4.8a,c) is reduced for the 10 mm beam spot size.
The corresponding DVH bands feature a narrower shape and steeper slope. Target coverage is
gradually improved for smaller motion amplitudes.
Figure 4.9 on page 78 shows the amplitude dependence of the target dose homogeneity (stan-
dard deviation relative to the planned dose) for the four beam parameter combinations with
∆s = 2mm in which different beam FWHM of 6, 8 and 10 mm were used. The indicated mark-
ers and error bars represent mean values and standard deviation calculated over all simulations
at the respective amplitude, i.e. the 12 initial motion phases per beam delivery sequence (grey
markers). The curves represent linear fits to the data, including the stationary irradiations. Me-
dian values are also shown (open symbols) to visualize the asymmetry of the distribution of
standard deviation values, where applicable. A linear dependence of the dose homogeneity on
the motion amplitude is observed at all beam spot sizes. Likewise, the spread increases approx-
imately linear with amplitude and becomes increasingly asymmetric towards large values of
relative standard deviation. For all combinations but (∆z = 2mm, RiFi3) the dose homogeneity
on average increases with a larger beam FWHM, in particular for the (∆z = 3mm, RiFi3) com-
binations. However, the error bars for the different beam spot sizes overlap to a large extent at
all amplitudes.
3 Potentially resulting band ranges overshooting 100% or undershooting 0% of the volume were clipped to
100% and 0 %, respectively.
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Figure 4.8.: Horizontal dose cuts and DVH bands for 6 mm (a-b) and 10 mm (c-d) beam FWHM,
∆s = 2mm,∆z = 3mm and RiFi3. Dose scale is in percent of the planned dose.
Variation of the lateral raster spacing
A varying lateral raster spacing could be studied at a beam FWHM of 10 mm only, as smaller
beam spots were not combined with a ∆s of 3mm in the treatment plans (see table 4.1). The
relative standard deviation versus the motion amplitude is depicted in figure 4.10 on page 79 for
varying ∆s of 2 and 3mm and four combinations of ∆z and RiFi. The presentation is identical
to figure 4.9. The linear fits exhibit a slightly shallower slope for ∆s = 3mm and RiFi3. For
RiFi4 the larger homogeneity of ∆s = 3 is diminished at a ∆z = 3mm (figure 4.10d) and
for ∆z = 2mm the situation is inverted w.r.t. to RiFi3. The error bars for different parameter
combinations overlap with each other at most amplitudes.
Variation of the iso-energy slice spacing
The variation in target dose homogeneity with the IES spacing is depicted in figure 4.11
on page 80 for six combinations of beam FWHM, ∆s and RiFi. For RiFi3 and ∆z = 2mm
(figures 4.11a,c) dose homogeneity on average is improved compared to ∆z = 3mm at a beam
FWHM of 6mm and 8 mm (the latter is not included in the figure). No difference between 2 and
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Figure 4.9.: Relative standard deviation of the CTV dose versus the residual motion peak-to-peak
amplitude for varying beam FWHM and several combinations of lateral raster spac-
ing (∆s), IES spacing (∆z) and RiFis. The grey markers indicate different initial mo-
tion phases. For clarity, markers are drawn with a horizontal offset.
3mm slice spacing is observed for a beam FWHM of 10 mm, the same holds for ∆s = 2mm and
RiFi4 (figures 4.11b,d). The curve for ∆z = 4mm shows a significantly decreased homogeneity
compared to the other IES spacings (figure 4.11d). For ∆s = 3mm and RiFi3 differences are
small between all IES spacings, including ∆z = 1mm (figure 4.11e). The respective RiFi4
combination on average exhibits a smaller slope for the larger IES spacing.
Variation of the ripple filter
In figure 4.12 on page 81 the relative standard deviation is drawn versus the motion amplitude
for varying ripple-filters. For ∆s = 2mm and ∆z = 2mm differences between RiFis are small at
all beam spot sizes (figures 4.12a,c). For∆z = 3mm the RiFi4 curves tend to have smaller slopes
than the respective RiFi3 curves, in particular for a beam FWHM of 6 and 8 mm. The graphs for a
beam FWHM= 8mm were omitted in the figure. At∆s = 3mm only for∆z = 2mm a significant
difference (separation by more than one standard deviation) in the average characteristic is
found (figure 4.12e). In this case the RiFi4 curve features larger dose homogeneity w.r.t. RiFi3.
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Figure 4.10.: Relative standard deviation of the CTV dose versus the residual peak-to-peak mo-
tion amplitude for varying lateral raster spacing (∆s) and several combinations of
IES spacing (∆z) and RiFis.
Variation of the beam delivery sequence
The results in the previous sections were reported for simulations based on the full spec-
trum of BDSs. The variations observed in target dose homogeneity as a function of the
BDS are illustrated for a representative beam parameter combination (∆s = 2mm, ∆z = 3mm,
FWHM = 8mm, RiFi3) in figure 4.13. Comparable results were obtained for most of the other
combinations. On the right hand side of figure 4.13, the relative standard deviation is shown as
a function of the residual motion amplitude for different BDSs. On the left hand side the DVH
bands for the corresponding ensemble of dose distributions are given. For clarity, only three
BDSs are depicted. These represent the worst (BDS 1), best (BDS2) and a medium (BDS 3)
case example w.r.t. to dose homogeneity at the particular parameter combination. The relative
standard deviation for the best and worst case BDS differ from the overall fit (black solid line)
by about ±30%. The green solid line constitutes the overall fit obtained for a smaller ∆z of
2mm instead, i.e. a larger longitudinal overlap factor. For the parameter combination in ques-
tion the largest improvement in dose homogeneity using a decreased IES spacing was found
(cf. figure 4.11). Hence, the best case BDS for∆z = 3mm and the average curve for∆z = 2mm
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Figure 4.11.: Relative standard deviation of the CTV dose versus the residual peak-to-peak mo-
tion amplitude for varying IES spacing (∆z) and several combinations of beam
FWHM, lateral raster spacing (∆s) and RiFis.
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Figure 4.12.: Relative standard deviation of the CTV dose versus the residual peak-to-peak mo-
tion amplitude for varying RiFi and several combinations of beam FWHM, lateral
raster spacing (∆s) and IES spacing (∆z).
4.3. Results 81
dose [%]
60 80 100 120 140
vo
lu
m
e 
[%
]
0
20
40
60
80
100 static
BDS 1
BDS 2
BDS 3
residual motion amplitude [mm]
0 2 4 6 8 10
re
la
tiv
e 
st
an
da
rd
 d
ev
ia
tio
n 
[%
]
0
2
4
6
8
10
12
14
16
18
z = 2 mm, overall fit∆
z = 3 mm, overall fit∆
beam delivery seq.:
z = 3 mm)∆BDS 1 (
z = 3 mm)∆BDS 2 (
z = 3 mm)∆BDS 3 (
s = 2 mm, FWHM = 8 mm, RiFi3∆
Figure 4.13.: Relative standard deviation versus the residual motion amplitude (right) and corre-
sponding DVH bands (left) for three different beam delivery sequences (BDSs) at a
selected beam parameter combination (∆s = 2mm, ∆z = 3mm, FWHM = 8mm,
RiFi3). The overall fits for ∆z = 3mm and ∆z = 2mm on the basis of all BDSs are
shown for comparison (black and green solid lines). DVH bands are drawn for a
10 mm motion amplitude.
exhibit a comparable dose homogeneity. The different beam delivery sequence also show sig-
nificant differences w.r.t. the spread in relative standard deviation (note, for instance, the grey
and blue error bars). The DVH bands shown on the left of figure 4.13 represent the spread of
one standard deviation around the average characteristic (dash-dotted lines) at a 10 mm mo-
tion amplitude. The three shown BDSs exhibit differences in the general shape and width of
the bands, also asymmetries are observed (BDS 3). The widths and average characteristics of
the DVH bands qualitatively correspond to the mean values and spreads found for the relative
standard deviation.
4.3.2.2 Dose conformity
The results for the conformity indices CI and CN are presented here for a representative beam
parameter combination only (∆s = 2mm, ∆z = 3mm, FWHM = 6mm and RiFi3), since very
similar results were obtained for the other combinations. Figures 4.14a–c summarize the results
for the dose conformity index (CI). The CI did not show dependencies on any of the beam
parameters with exception of the beam FWHM. The horizontal dose cuts in figures 4.14a–b
illustrate the lateral increase of dose deposition outside the ITV for a beam FWHM of 10 mm
compared to a FWHM of 6mm for a static target. In figure 4.14c the CI is drawn versus the
motion amplitude. While mean values are independent of the amplitude, the standard deviation
increases approximately linearly.
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Results for the conformation number (CN) are presented in figures 4.14d–f for the same
beam parameter combination. In analogy to figure 4.13, curves for three different BDSs are
shown. All BDSs on average exhibit an exponential decay of the CN with the motion amplitude,
accompanied by an increasing standard deviation. Depending on the BDS the CN fluctuates by
up to 50 % around the mean value. For a medium motion amplitude of 5 mm representative
cross sections of the dose distributions for the initial phases, φ, with the best (φ = 210) and
worst (φ = 30) CN and BDS 2 are depicted in figures 4.14d,e. The 95 % iso-dose areas entering
into equation (4.6) for the CN are framed with a solid black line and show large differences
w.r.t. to target coverage. To compare this with the dependence of the CN on the beam FWHM,
the average CN characteristic for a 10mm FWHM has been included in figure 4.14f (red solid
line). It can be seen that the CN is dominated by the fluctuations due to interplay effects for
amplitudes ¦ 3mm. Comparable results were also obtained for the other beam parameter
combinations.
4.4 Summary and discussion
The purpose of the experimental and simulation studies presented in this chapter was to assess
the impact of an increased beam overlap on residual motion interplay effects, in particular with
respect to the target dose homogeneity and dose conformity. Experiments and simulations were
performed in a water phantom setup with 3D target motion.
Measurements and 4D dose reconstructions
Several series of 4D dose measurements were conducted at HIT with a robotically moved IC
array. The results of the absolute 4D dosimetry were compared to the subsequently executed
4D reconstructions with TRiP4D. Although beam positions and beam FWHM were not fully
stable on the first two days of the measurements (cf. table 4.2), a good agreement of the 4D
simulations with the respective measurement was found in most cases. The mean relative dose
difference and standard deviation over all ICs (equation 4.4) was used to evaluate the simu-
lation accuracy. For about 50% of the more than 40 cases the standard deviation was smaller
than 5 %. This is to be compared to standard deviations of less than 3 % determined for the
static dose. Standard deviations of less than 3 % for all moving and less than 2% for all static
cases were obtained for measurements performed on the third day. A systematic offset of −2 %
of the calculations w.r.t. the measurements was found for the cases using the standard 3 mm
RiFi. This is within the expected level of systematic uncertainty in absolute dosimetry of ion
radiation (Karger et al., 2010). An additional systematic deviation of around −2% in the mean
value was found for the cases with two crossed ripple-filters (see, e.g., figure 4.6), including the
static measurements. This difference may be attributed to inaccurate beam base data employed
for dose optimization and calculation with TRiP4D. These data are not as well tested as those
for the standard RiFi optimized for a 3mm IES spacing. The agreement of the simulations with
the measurements has additionally been tested with a bivariate linear regression model. For the
third measurement series the introduced model is capable of explaining 94 % of the observed
variance at a RMSE of 1.7 % (p < 10−4). A smaller R2 of 0.61 was obtained for the measured and
simulated data of the other two series (cf. figure 4.7a). Furthermore, the slope of the obtained
fit which relates measured and simulated dose values is considerably smaller than the expected
bisecting line. Differences are likely to have been introduced in the measurements rather than
the simulations, since the simulation environment was the same for all considered cases. For
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example, uncertainties were introduced by the varying beam conditions on the first two days
(see table 4.2). The beam FWHM in one dimension showed average deviations of ≈10% be-
tween days one and two and deviations in the beam position had standard deviations of about
1mm. Also, since the setup had to be re-positioned each day, systematic position uncertainties
on the order of 1–2mm may have been introduced. These affect the required location of dose
extraction points in the simulated dose distributions. While for the static dose distributions only
a minor impact is expected, this is critical for 4D dose distributions which often exhibit strong
dose gradients. Thus, even small shifts may lead to significantly different dose values. Further
improvement of the agreement with the measurements might be gained by an analysis of simu-
lated dose values near the nominal dose extraction point, to compensate for the unknown setup
shift. However, considering the static agreement as a limit, the average improvements will prob-
ably not exceed 1–2%. Additional uncertainties are to be expected from the measured beam
status signals, since, for technical reasons, these could not be directly related to the time the
beam reached the cave but may be slightly shifted in time. In some cases also signal fluctuations
compromised the simulation accuracy. Although most measurements exhibiting these kind of
problems were disregarded, residual degradation of the beam delivery sequence data must be
expected and may have a particular impact on the calibration of the initial motion phase (sec-
tion 4.2.3.2). From the experiences made, the ideal solution for the acquisition of beam delivery
sequence data is the combination of beam status and point completion signals into a single DAQ
with a sampling time of less than a millisecond, i.e. well below typical point irradiation times.
This configuration inherently provides temporally correlated data without the need for major
post-processing introducing additional uncertainties. At the time of the presented experiments
such a solution was not available.
Simulation studies
The validated simulation environment enabled extensive 4D simulations using the same wa-
ter phantom setup. In more than 4400 simulations with various motion amplitudes and initial
phases the impact of a varying lateral raster spacing, IES spacing, beam FWHM, RiFi and beam
delivery sequence was investigated. The target dose homogeneity in the CTV and the dose con-
formity inside the ITV were determined for all dose distributions. Among other parameters, the
relative standard deviation and two conformity indices were considered. With regard to target
dose homogeneity in the CTV the motion amplitude had the strongest influence. The mean
relative standard deviation of the average CTV dose exhibited a linear increase with the ampli-
tude for all studied beam parameters. Furthermore, the standard deviation of the homogeneity
increases approximately linearly with the amplitude, as well. For a particular treatment plan
the relative order of the initial phases with respect to the homogeneity remains the same at all
amplitudes, i.e. the modulation of the interplay pattern by the initial phase is the same. This
can be understood when considering the fact that at a fixed motion period the target travels
a larger distance in the same span of time and the same relative relation of target motion and
beam scanning is maintained. Thus, interplay patterns and the related standard deviation are
scaled as the amplitude increases. It can be deduced from the results that the principal interplay
pattern is decisively determined by the particular BDS and drives the standard deviation signif-
icantly. In the example given in figure 4.13 differences in the spread of the relative standard
deviation of more than 400 % have been found between different BDSs, independent of the
motion amplitude. Similarly, variations in the mean value of ±30 % were found. Although the
effect was less pronounced for some of the analyzed treatment plans, variations in the average
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value and the spread of the relative standard deviation exceeded 20% in most cases. Against
this background, the results obtained for the various plan parameters have to be interpreted.
These have been obtained taking into account all beam delivery sequences for the respective
treatment plan. The average characteristics for the beam parameters in question were com-
pared. Due to the large number of measurements, the standard errors on the mean values are
very small in most cases, such that trends in the average homogeneity may be deduced. How-
ever, due to the substantial spread of the homogeneity distributions—even considering a single
BDS only—exploiting these trends for a general improvement of the target dose homogeneity is
difficult. Although the increase of the beam FWHM from 6–10 mm yielded an average decrease
in the relative standard deviation by up to 30 %, an inappropriately chosen initial phase can
invalidate this advantage. Apart from the effect of the beam spot size, which can be attributed
to the gained robustness at an increased lateral beam overlap, results for the other beam param-
eters are difficult to interpret, as trends are not consistent. For instance, the use of a decreased
IES spacing, i.e. an increased longitudinal overlap, on average did either increase or decrease
the dose homogeneity, depending on the employed RiFi. For a RiFi3 and ∆s = 2mm reductions
of the relative standard deviation by 20 % and 30% were found for a beam FWHM of 6 and
8mm, respectively. In contrast, for RiFi4 and a ∆s = 3mm the larger IES spacing showed a
30% improvement (compare e.g. figures 4.11a,f). Similarly, results for the lateral raster spacing
obviously can not be understood with the overlap concept alone, since a 3 mm spacing showed
better homogeneity at a beam FWHM of 10mm compared to the smaller spacing in three out
of four cases (see e.g. figures 4.10a,c). However, the differences were smaller—a maximum
decrease in relative standard deviation by 20% for ∆z = 2mm and RiFi3.
Apart from the dose homogeneity, the dose conformity has been investigated as a function of
the target motion amplitude and various beam parameters for the ITV. The dose conformity
index (CI) on average did not show a dependence on the residual motion amplitude and only
exhibited differences with respect to the beam spot size. By construction, the inhomogeneous
distribution of interplay patterns is neglected. The spread of the CI is dependent on the ampli-
tude and the beam spot size. The spread is most likely caused by dose transferred outward or
inward w.r.t. the ITV, due to target motion. In contrast, the conformation number (CN) con-
siders both the target coverage and the exposure of the surrounding volume (van’t Riet et al.,
1997). As the 95 % iso-dose volume of the ITV enters geometrically into expression (4.6), the
CN is strongly interplay-dependent. As has been shown in figure 4.13f, even for beam deliv-
ery sequences which generate a small spread in CN (e.g. BDS1 , open circles), the fluctuations
predominate the effect of a decreased dose conformity due to a larger beam FWHM at motion
amplitudes larger than 3mm.
In the presented study, the ITV volume has been used for calculation of the CN, in order to be
more sensitive to dose deposition outside the treated volume. If the CTV volume had been used
instead, the CN would have been dominated by the dose deposited inside the ITV. However,
from a clinical point of view, this dose was accepted by the therapist and it can therefore be
argued that it should not enter into the CN calculations. On the other hand, the ITV is not
designed to receive the full treatment dose but to ensure adequate CTV coverage. Thus, to
assess the target dose conformity, the CTV is the relevant volume. To incorporate both of these
aspects, a modified conformation number is proposed here:
CN′ =
(
VCTV95
VCTV
)
×
(
V ITV95
V95
)
, 0≤ CN′ ≤ 1 . (4.8)
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V ITV95 denotes the volume of the 95 % iso-dose volume inside the ITV. An analogous definition
holds for the PTV, if used.
A possible explanation for the heterogeneous results obtained for the different beam parame-
ter combinations is that lateral and longitudinal beam overlap effects are not entirely indepen-
dent, as it was assumed in the presented study. The reduced impact of the IES spacing w.r.t.
the dose homogeneity for an increasing beam spot size may be an indication that an increased
longitudinal overlap can not improve the dose homogeneity beyond a certain level, if a large
lateral overlap has already been applied. Against the background of the findings reported here
w.r.t. the large variations in dose homogeneity and conformity introduced by varying BDSs, it
also seems likely that the BDS may have a systematic impact on the target dose homogeneity for
certain combinations of beam parameters. An increased lateral or longitudinal raster spacing,
for instance, involves larger particle numbers per raster point in order to yield the same dose.
This may have an impact on both the scan speed and the choice of intensity levels by the con-
trol system. Depending on the specific correlation between target and beam motion, resonance
effects with large variations of the homogeneity as a function of the initial motion phase could
be more or less likely. To improve the understanding of these aspects, further studies in this
area are proposed by the author. For several of the studied BDSs with a tendency towards large
relative standard deviations a comparably inhomogeneous distribution of particles over the CT
phases has been observed, presumably driving the dose homogeneity accordingly. Also, the dis-
tribution of the ratio of the delivered particle number and the respective irradiation time—being
a measure for the beam intensity—in some cases varied significantly between BDSs. Above that,
considerable differences between treatment plans were observed. Furthermore, variations in
the accelerator cycle, i.e. the pattern of the beam pauses in relation to the target motion, could
have an impact on the correlation between scanning and target motion.
Very similar simulation studies to the presented one were carried out by Steidl (2011) with
regard to residual motion in a gating window. The same setup and simulation environment was
used. However, Steidl employed simulated BDSs as opposed to measured ones. He reports qual-
itatively similar results for an increased lateral overlap using a larger beam FWHM. However, a
larger reduction of the relative standard deviation of 60–80 % from the smallest to the largest
focus was observed. With respect to a smaller IES spacing, Steidl reports a similar behaviour
for beam FWHM of 6 and 8mm and a RiFi3 in the same order of 20–30 % improvement of
the homogeneity for the smaller slice spacing. For most other combinations of FWHM and RiFi
a similar behaviour was found, in contrast to the findings here. Similar to the results in this
work he also observed slightly improved dose homogeneity for the 3mm lateral raster spacing
compared to the 2 mm spacing. Finally, the impact of the RiFi on the target dose homogeneity,
as reported here, in most cases is comparable to the results of Steidl with regard to the mag-
nitude of the effect of about 0–10 %. However, for some combinations the effect was observed
in the opposite direction. The differences observed between the two simulations can be due to
several reasons. The principal structure of the BDS for gating differs significantly from the one
of uncompensated delivery. For gating more beam pauses are introduced and irradiation is per-
formed in a part of the motion cycle only. As a result, the impact of the initial motion phase and
resonance effects between target and beam motion is likely to be suppressed and variations in
dose homogeneity and conformity will be reduced. Finally, the accelerator constitutes a complex
system which is challenging to simulate. Resulting BDSs therefore may be subject to additional
uncertainties which can have an impact on the simulation results.
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Bert et al. (2009) have studied lateral and longitudinal beam overlap in separate experiments
using radiographic films. They found a linear dependence of the acceptable motion amplitude
on the beam FWHM. For a 10 mm beam spot they report a maximum tolerable motion amplitude
of 2 mm at an acceptable level of 5% deviation from the static dose and a lateral raster spacing
of 2 mm. When using an 8 mm beam spot, the accepted amount of motion is reduced to about
0.5 mm. These values can be compared to figure 4.9, assuming an acceptable relative standard
deviation of 5%. This results into acceptable motion amplitudes of 4 and 5.5 mm at a ∆z of
3mm, a ∆s of 2mm, RiFi3 and a beam FWHM of 10 and 8 mm, respectively. Steidl (2011)
have stated accepted motion amplitudes of 2.5 and 4 mm for the same parameter combinations,
respectively. Hence, in both cases the robustness w.r.t. residual motion is larger compared to
the results of Bert et al. However, in general, a direct comparison between absolute dose and
film response can not be made (Spielberger et al., 2003) but it can be concluded that the same
overall trend is observed in all studies.
It should be emphasized that the results of the 4D simulations presented in this chapter are
not directly transferable to patient geometries. The observed large impact of the initial motion
phase, as well as possible resonance effects between target motion and beam scanning are
likely to be diminished for more irregular target geometries and motion patterns, since relative
correlations between the two will not exist over a longer period of time. For this reason, the
next chapter will focus on systematic treatment planning studies on patient data.
Apart from the concept of increased beam overlap, other approaches have been published.
Furukawa et al. (2007) have proposed to use rescanning in combination with gating to reduce
the residual motion interplay effects, PSI plans to use the same approach (Zenklusen et al.,
2010). Above that, a combined approach of both techniques seems promising.
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5 4D treatment planning studies
5.1 Introduction
In the previous chapter the concept of increased beam overlap to mitigate dose inhomogeneities
due to residual motion interplay effects has been studied in a simplified geometry. However,
treatment planning studies with patient data are essential to explore the dosimetric effects
in a more realistic scenario. The studies will also be indispensable if conclusions shall be
drawn for the clinical applicability of the concept. At the time of writing, HIT has already
commenced to use scanned carbon ions for the treatment of hepatocellular carcinoma (HCC).
Tumors of the liver can be subject to a significant amount of respiratory-induced motion. For
instance, Case et al. (2010), have reported an average liver motion amplitude of 8mm in the
superior-inferior (SI) direction, however, with a large range of up to 18.8 mm. Adequate motion
management for these tumors is of great importance, especially for treatments using scanned
ion beams. Two possible strategies to effectively reduce tumor motion in the liver are abdom-
inal compression (figure 5.1a) and beam gating (section 2.2.3.3). For abdominal compression,
Eccles et al. (2011) report an average reduction of the motion amplitude of 2.4 mm in the SI
direction. Abdominal compression is in clinical use at HIT since summer 2011. Using beam
gating, respiratory-induced motion can effectively be reduced to few millimeters, depending on
the gating window (GW) size (Berbeco et al., 2005; Fuji et al., 2009). Several centers have suc-
cessfully employed gating in combination with passive beam delivery (section 2.1.3.1) for the
treatment of lung and liver tumors (Minohara et al., 2000; Lu et al., 2007). The world’s first pa-
tient treatment with gating and scanned carbon ions was conducted in December 2011 at HIT.
Other tumor sites subject to organ motion are planned for treatment in the future. The use of
enhanced beam overlap is a promising candidate to complement both abdominal compression
and gated beam delivery by further mitigating residual motion effects.
In this chapter the results of a treatment planning study will be presented in which the concept
of enhanced lateral and longitudinal beam overlap has been used for realistic patient geome-
tries. For this purpose, the data of the first patients treated under abdominal compression and
with beam gating at HIT were used. Based on the results discussed in the last chapter, partic-
ular emphasis was put on the analysis of the dosimetric consequences when using an enlarged
beam spot size. In addition to these treatment simulations, 4D dosimetric reconstructions of
the original patient treatments have been performed for two of the patients. These reconstruc-
tions are based on motion monitoring data and beam delivery sequence (BDS) data acquired
during treatment delivery and utilize the 4D treatment simulation functionality of TRiP4D, as
introduced in chapter 3.
89
5.2 Materials and methods
5.2.1 Patient cohort
For the treatment planning study eight patients with hepatocellular carcinoma (HCC) were se-
lected. Six of these patients were treated with scanned carbon ions at HIT. For the remaining
two patients the treatment was planned but was finally cancelled for medical reasons. One of
the patients was irradiated using gated beam delivery. Another four patients were irradiated
under abdominal compression and one patient was treated without any motion mitigation tech-
nique. Table 5.1 lists the 11 clinical target volumes volumes in the eight patients, including the
average CTV motion amplitudes. Tumor motion is most pronounced in the superior-inferior (SI)
direction with SI amplitudes ranging between 0.1 mm and 13.3mm. The tumor motion ampli-
tudes were estimated using deformable image registration. Further details on the analysis and
supplementary results are given in section C.1 in the appendix. In the context of the presented
study all eight patients were re-planned with TRiP4D.
While patients A1–A4 were planned for treatment under abdominal compression, patients
G1–G4 were considered for gated treatment. For patients A2 and G2, 4D dose reconstructions
of the original treatments at HIT were carried out based on measured data and the clinical
treatment plans.
5.2.2 Treatment planning
In the presented study two different treatment planning procedures were used. Clinical treat-
ment planning was performed with a commercial TPS in preparation of the actual treatment.
Also 4D dose reconstructions were carried out based on the clinical treatment plans. The simula-
tion study w.r.t. enhanced beam overlap involved re-planning with TRiP4D for all patients. The
agreement of the two planning systems was assessed by comparison of static dose calculations
for the clinical treatment plans. Physical and biologically effective dose calculations were in
very good agreement of on average (0± 1)%. Details are given in section C.2 in the appendix.
5.2.2.1 Clinical treatment planning
For each patient a 4DCT and a free-breathing planning CT scan were acquired. For three of the
gating candidate patients (G2–G4) an additional breath-hold CT scan was performed in the end-
exhale position. According to the HIT protocol, the ANZAI waist belt motion monitoring system
(AZ-773V, ANZAI MEDICAL CO., LTD) was interfaced to the CT scanner to facilitate reconstruc-
tion of eight 4DCT phases. For patients G2 and G3 additional 4DCT phases were reconstructed
to cover the respiratory cycle around the end-exhale position in 10 % steps of the relative mo-
tion amplitude (cf. figure 3.4 on page 42). Figure 5.1b illustrates the distribution of the eight
and 14 4DCT phases over the breathing cycle, respectively. All patients were immobilized prior
to the CT scans using a vacuum mattress. For patients A1–A4 abdominal compression was ap-
plied using a compression plate mounted to a carbon frame (figure 5.1a). The target volumes
and organs at risk (OARs) were delineated by a physician, either on the free-breathing CT or
the breath-hold CT (patients G2–G4). The clinical treatment plans were created by a medical
90 5. 4D treatment planning studies
mean motion amplitude and SD [mm]
patient CTV V[cm3] |A| SI AP LR
ab
do
m
in
al
co
m
pr
es
si
on A1
TA1 9.3 9.3±1.1 −9.1±1.1 −2.2±0.3 0.2±0.1
TA2 62.5 1.8±0.9 −1.8±0.9 −0.3±0.2 0.0±0.1
A2 TA3 81.1 11.4±3.2 −10.9±3.6 −2.5±1.4 −0.9±0.7
A3 TA4 39.2 0.9±0.4 0.1±0.5 −0.7±0.2 0.2±0.3
A4 TA5 118.2 10.1±3.5 −9.4±3.7 −3.2±1.2 −1.2±0.6
ga
ti
ng
G1
TG1 6.8 9.7±0.5 −9.2±0.5 −3.0±0.4 −0.8±0.2
TG2 65.0 12.5±1.2 −11.6±1.1 −4.5±0.7 −1.5±0.3
TG3 14.2 15.6±1.6 −13.3±1.1 −7.1±1.2 −4.1±0.5
G2 TG4 75.5 8.2±2.0 −7.4±1.9 −3.4±0.8 −0.4±0.5
G3 TG5 46.2 8.9±1.1 −8.6±1.1 −2.1±0.3 0.0±0.4
G4 TG6 17.7 8.9±1.1 −8.0±1.2 −3.9±0.3 0.0±0.1
Table 5.1.: Volumes and motion amplitudes determined for the 11 CTVs in the eight selected
patients. Mean motion amplitudes and standard deviation (SD) are given for the
superior-inferior (SI), anterior-posterior (AP) and left-right (LR) direction, respectively.
|A| denotes the length of the motion vector. The values were determined from de-
formable registration of the end-inhale and end-exhale phases of the 4DCT.
(a)
(b)
Figure 5.1.: (a) Patient immobilization for liver treatments under abdominal compression at HIT.
Abdominal pressure is applied via a plate mounted to a carbon frame and an ad-
justable screw. (b) Schematic illustration of the 4DCT phase distribution over the
breathing cycle for the 4DCT with eight (HIT standard) and 14 phases.
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physicist using a commercial TPS. A single left-lateral carbon ion field was employed. For treat-
ment of HCC at HIT a lateral overlap factor (section 4.1) of flat ≈ 4 is routinely applied, using
a 10 mm beam spot combined with the standard lateral and longitudinal raster spacings of 2
and 3 mm, respectively. ITV margins were estimated on a patient-specific basis in 3D, using the
4DCT. Planning target volume (PTV) margins of 5mm in the lateral and 7mm in the longitu-
dinal direction were added to the ITV. The PTV was planned to receive a biologically effective
dose of 32.4 Gy (RBE) in four fractions of 8.1 Gy (RBE). The fractionation scheme is based on a
protocol for treatment of HCC at NIRS (Tsujii et al., 2007, 2008).
5.2.2.2 Treatment planning with TRiP4D
For re-planning with TRiP4D, non-rigid registration with the Plastimatch software package
(Sharp et al., 2007) was used to match the free-breathing planning CT and the end-exhale
phase of the 4DCT. In a second step, non-rigid registration of all 4DCT phases was established,
using the end-exhale phase as the reference phase. The contours were propagated to the 4DCT
phases using TRiP4D and the resulting deformation maps (section 3.2.1.4).1 For patients G2
and G3, registration and contour propagation were performed for both 4DCT sets with eight
and 14 phases, respectively. ITVs including range changes were optimized with TRiP4D based
on the 4D contours of the CTV and the eight phase 4DCT according to section 3.2.2.1. For
abdominal compression the ITVs were generated using the full respiratory cycle. For gating,
only the CT phases around end-exhale were taken into account, approximately corresponding
to a 50 % gating window (GW) (cf. figure 5.1b). For reasons of comparability the ITV optimized
for the 50 % GW was also used for the 30 % GW. Since no setup uncertainties were consid-
ered in the simulations, no additional PTV margins were added to the ITVs. Dose optimization
was performed on the ITV in the reference phase (end-exhale). According to recommendations
of the ICRU, 100 % of the ITV volume was required to receive between 95 % and 107% of
the planned dose (ICRU, 1993a). The beam port configuration and the fractionation scheme
(8.1Gy (RBE) per fraction) of the clinical liver treatments at HIT were adopted for all patients.
At HIT the LEM-I model (section 2.1.2) and corresponding RBE tables are used in combination
with a commercial treatment planning system. The respective RBE tables were adopted for dose
calculation in TRiP4D. Depth-dose tables and any other required beam base data (Krämer et al.,
2000) were employed in accordance with the data used clinically at HIT.
12 different treatment plans per patient were optimized using various combinations of lateral
raster spacing (2 and 3 mm), iso-energy slice spacing (2 and 3 mm water-equivalent) and beam
spot FWHM (6, 8, 10 and 15mm).2 The combinations of beam FWHM and lateral raster spacing
resulted in lateral overlap factors (section 4.1) of 3 ® flat ® 7.5. A lateral overlap factor of
flat ≈ 3 is typically used for stationary targets at HIT. A RiFi optimized for 3 mm IES spacing
was considered for all treatment plans. Other RiFis could not be used because the required
particle spectra data needed for biological dose calculation with TRiP4D were not available.
1 Deformable registration and contour propagation was kindly provided by N. Saito.
2 Note, that the precise values for the beam FWHM depend on the requested beam energy and by trend are
larger for smaller energies, i.e. shorter penetration depths.
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5.2.3 4D treatment reconstructions
4D treatment reconstructions were carried out for patients A2 (abdominal compression) and G2
(gating). Motion monitoring data were acquired with the ANZAI waist belt motion monitoring
system during treatment delivery. For patient G2 the ANZAI system was also employed to de-
fine the gating window and communicate the beam requests to the TCS. The gating window
was adjusted asymmetrically around the end-exhale position, covering 30 % of the amplitude
range in exhale and 70 % in inhale, respectively. Raster point irradiation times were recorded
via the treatment records routinely provided from the TCS. The beam status was logged using
the ANZAI system. Data analysis revealed unexpected timing inaccuracies of the ANZAI system,
increasing proportionally with the acquisition time. For the patient treatments temporal dis-
crepancies of up to 500ms were observed. For this reason, the ANZAI beam status data could
not be used to generate the required BDS input data for TRiP4D (section 3.2.3.2). Instead, man-
ual temporal correlation between the TCS treatment records and the ANZAI motion data had
to be performed. For patient A2 the global time offset between the two systems was extracted
from a synchronous read-out of the respective system clocks after irradiation. For patient G2
the system time stamps marking the end of the first beam gate were used for temporal corre-
lation. The beam delivery sequence (BDS) input data for TRiP4D were generated based on the
TCS treatment records only. The missing beam status data was incorporated as follows: To a
good approximation beam-off signals could be assumed to coincide with the completion of the
last raster point in each beam gate. Beam-on signals were established by using a fixed irradia-
tion time of the first raster point in each beam gate. A constant irradiation time of 15ms was
estimated from the treatment records.
The treatment reconstructions were performed based on the BDS data, the clinical treatment
plans, the patient’s 4DCT and related deformation maps, as well as the motion monitoring data
recorded during treatment (section 3.2.3). The target point for the clinical treatment plan was
mapped from the free-breathing planning CT to the 4DCT reference phase, using the transfor-
mation maps resulting from deformable registration. Motion state identification was based on
the relative amplitude of the ANZAI motion trace and was performed in correspondence with
the 4DCT data acquisition (see section 3.2.3.1), thus, taking into account the irregular respira-
tion of the patient. 4D dose calculations were based on eight 4DCT phases for patient A2 and on
14 phases for patient G2.3 To assess the robustness of the delivered 4D dose and to incorporate
the uncertainties of the ANZAI system timing and the temporal alignment procedure, two ad-
ditional reconstructions were performed for each fraction, considering temporal displacements
∆t of −250ms and +250 ms between the motion trajectory and the BDS. For patient A2 all four
fractions were reconstructed. As a possible treatment outcome, a total dose distribution has ex-
emplarily been calculated for patient A2 by direct summation of the nominal constituent dose
distributions (∆t = 0ms). For technical reasons, only three fractions could be reconstructed for
patient G2. Therefore, no total dose distribution could be calculated.
3 For all calculations TRiP4D’s APDB pencil beam algorithm was used. The algorithm includes geometrical beam
divergence effects and neglects multiple scattering effects.
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5.2.4 4D treatment simulations
4D treatment simulations were performed for all patients based on the optimized treatment
plans for varying lateral and longitudinal beam overlap, the 4DCT data and the related defor-
mation maps. Since the major purpose of this study was to assess the effect of optimized beam
parameters on the 4D dose distribution, variations in the patient breathing patterns were not
considered. Regular patient motion according to Lujan et al. (1999) was assumed. Two rep-
resentative breathing periods of 3.6 and 5.4 seconds were used. The fractional numbers were
chosen for technical reasons. Additionally, a spectrum of initial motion phases was considered.
For patients A1–A4 (abdominal compression) six equally distributed initial phases (60° steps)
were chosen. For gated treatment, two gating windows covering 30% and 50% of the relative
amplitude range around the end-exhale position were defined, as illustrated in figure 5.1b. Due
to the synchronization of BDSs for gating at HIT after few beam gates, the initial motion phase
is expected to have less impact on the 4D dose distribution. Therefore, six initial phases were
simulated for patient G2 only. For the remaining three patients two initial phases were selected
(center and start of the GW). Simulations were based on the standard 4DCT with eight phases
for all patients. Additional simulations for the same treatment plans and a 4DCT with 14 phases
were performed for patients G2 and G3. BDS data were generated using a dedicated software
developed within the scope of this work. Assuming a rectangular beam extraction profile, the
program is able to generate BDS data for a gated or ungated treatment course. The simulation
is based on the treatment plan, the motion trajectory and realistic HIT accelerator timing in-
cluding an appropriate choice of intensity levels (Naumann, 2011). 4D treatment simulations
were performed according to section 3.2.3. Motion state identification was carried out based on
the relative motion amplitude (section 3.2.3.1).
5.2.5 Data analysis
Dose parameters
For both treatment reconstructions and simulations the dose delivered to the CTV was assessed
for each dose distribution by calculating dose volume histograms (DVHs) and the volumes re-
ceiving 95% (V95) and 107 % (V107) of the prescribed dose. Additionally, the dose homogeneity
index (HI), as defined in equation (4.5), was used to evaluate the dose homogeneity. The dose
conformity to the CTV was analyzed using the conformation number (CN), as introduced in
equation (4.6). Mean and standard deviation of V95, V107, HI and CN over all initial motion
phases and motion periods were analyzed as a function of the beam FWHM and the various
raster spacing combinations. The correlation of V95 and HI with the CTV motion amplitude was
investigated using the Pearson correlation coefficient (PCC), r. The exposure to lung and liver
was assessed for all patients by calculation of DVHs and of the maximum and the mean dose
deposited in the respective organ.
Statistical analysis
In the context of the beam overlap parameter study a statistical analysis of the dose homogene-
ity as a function of the beam and tumor motion parameters was performed using univariate and
multivariate linear regression. The investigated influencing variables were the beam FWHM, the
median CTV motion amplitude components Axx in left-right (xx=LR), anterior-posterior (AP),
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and superior-inferior (SI), the median length of the CTV motion vector, |A|, the longitudinal
and the lateral raster spacings, ∆z and ∆s, and the CTV volume, V . The analysis was per-
formed separately for abdominal compression and each of the two gating windows. Due to the
non-normal distribution of V95 and V107, the variables were tested against HI only. All variables
were screened in univariate regression, and if found significant at the p < 0.05 level were also
entered in a multivariate regression model:
HI(v1, . . . ,vN )≈
N∑
i
αi · v i +
i 6= j∑
i j
βi j v i · v j + γ . (5.1)
That is, a multilinear superposition of the influencing variables v i was used in combination with
non-linear cross terms (coefficients βi j). γ denotes a constant term. The multivariate model was
identified through step-wise regression. The results of this multivariate regression are reported
as the coefficient of variation R2. To judge the contributions of the single variables to the overall
regression, a series of regression models were computed, starting with the strongest single con-
tributor and subsequently entering more variables until the complete model as resulting from
the step-wise regression was reached. Finally, also the cross-terms of all entered variables were
considered (βi j 6= 0). All analyses were carried out using JMP (version 9.0.3, SAS Institute Inc.,
Cary, NC, USA).
5.3 Results
5.3.1 4D treatment reconstructions
A total of 12 dose reconstructions were performed for patient A2 and the four treatment frac-
tions. Additionally, the static dose and an exemplary total dose distribution were calculated
(direct sum). Resulting dose distributions and DVH bands are given in figure 5.2. Dose cross
sections through the CTV are shown for the static dose, total dose and a selected fractional dose
distribution in the CT reference phase. The displayed slice and fractional dose were chosen as a
worst case example of the obtained dose distributions. The DVH for the total dose is drawn on
top of the DVH bands (red dash-dotted line). The total dose exhibits improved target coverage
(V95) and overdose (V107) compared to the majority of single fraction dose distributions, visible
in the steeper DVH. Table 5.2 lists the resulting dose parameters of all 12 simulated treatments.
While the mean dose to the CTV is stable (≈±1%), V95 and V107 show larger variability between
76–97% and 2–27%, respectively. Within the same fraction, differences of up to ≈10% for the
V95 and of up to 20 % for the V107 occur for different temporal shifts. The analysis of the dose
to normal tissue showed that the mean lung dose increased by about 25% w.r.t. to the static
dose distribution (see also the blue band in figure 5.2d). 4D dose delivery had no impact on
the mean liver dose. Details on the values for individual fractions are given in table C.3 in the
appendix. For both lung and liver the maximum dose to the respective organ in a single fraction
increased by about 1–2 Gy (RBE), compared to the static case. The average exposure of liver
and lung for the exemplary full treatment increased by about 3 and 0.5Gy (RBE), respectively.
A worst case dose distribution (lowest V95) and the DVH bands, based on the nine single
fraction dose distributions for patient G2, are shown in figure 5.3. The detailed results for the
analyzed dose parameters for each fraction are listed in table 5.3. The original treatment has
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Figure 5.2.: Results of dose reconstructions for patient A2. Axial cross sections of the static
dose (a), a single fraction dose (b), and the exemplary total dose distribution (c)
are shown. Contours are overlayed for the PTV (white), the CTV (cyan) as well as
lung and liver (black). The DVH bands encompass all 12 single dose distributions.
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dose
distr.
dose in % prescribed dose volume in %
∆t [ms] mean±SD HI min max V95 V107 CN
static — 101.0±0.8 2.8 94.7 106.0 100.0 0.0 0.30
fraction 1
−250 101.0±4.6 15.2 83.5 117.7 90.9 8.5 0.28
+0 101.2±6.8 22.2 80.4 121.0 80.4 21.3 0.24
+250 101.3±7.7 24.5 76.1 123.9 76.8 27.0 0.22
fraction 2
−250 101.4±7.5 24.3 74.7 127.9 78.1 23.7 0.22
+0 101.1±6.6 22.0 75.9 123.0 81.7 18.0 0.24
+250 100.2±4.2 13.8 83.1 120.5 88.0 5.0 0.27
fraction 3
−250 101.2±7.4 22.8 79.6 128.0 76.1 23.3 0.22
+0 100.3±6.5 21.3 81.6 120.9 77.8 16.0 0.22
+250 99.7±3.9 12.8 81.7 112.8 87.6 1.6 0.27
fraction 4
−250 102.0±4.7 15.2 83.8 119.1 95.8 16.1 0.31
+0 101.7±4.3 14.4 82.4 116.5 93.8 10.3 0.30
+250 101.6±3.6 12.1 83.6 119.0 96.5 6.4 0.31
total — 101.1±3.9 12.4 88.3 114.1 92.8 4.6 0.29
Table 5.2.: Results of the treatment reconstructions for patient A2. Three dose distributions for
varying time offsets ,∆t, between BDS and motion monitoring data were calculated.
The total dose was calculated by direct summation of the distributions for∆t = 0ms.
dose
distr.
dose in % prescribed dose volume in %
∆t [ms] mean±SD HI min max V95 V107 CN
static — 100.2±1.2 3.9 95.4 104.4 100.0 0.0 0.19
fraction 2
−250 100.1±4.3 14.2 84.8 113.7 88.2 5.9 0.17
+0 99.7±4.8 15.9 82.9 114.4 83.4 6.9 0.15
+250 100.1±3.9 12.9 84.8 113.5 91.5 4.8 0.18
fraction 3
−250 100.8±4.3 14.4 86.8 117.6 92.6 8.6 0.17
+0 100.7±4.0 13.1 87.9 114.2 94.0 7.1 0.17
+250 100.5±3.1 10.4 88.7 113.6 97.0 2.9 0.18
fraction 4
−250 100.9±2.5 8.4 89.3 111.0 98.8 0.9 0.18
+0 100.5±2.7 8.9 89.2 111.9 97.2 0.5 0.18
+250 100.5±4.0 13.3 87.8 121.5 92.9 5.7 0.18
Table 5.3.: Results of the treatment reconstructions for patient G2. Three dose distributions for
varying time offsets ,∆t, between BDS and motion monitoring data were calculated.
For technical reasons, the data of the missing first fraction could not be analyzed.
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Figure 5.3.: Results of dose reconstructions for patient G2. (a) Axial cross section of the worst
case single fraction dose distribution. Contours are overlayed for the PTV (white),
the CTV (cyan) and the liver (black). (b) DVH bands encompass all nine calculated
single dose distributions.
been performed with a gating window ranging from 30 % of the relative amplitude in exhale
to 70 % in inhale. V95 values are above 90 % for all but two dose distributions and V107 values
remain below 10%. The mean lung dose remains small and comparable to the static case
(+0.2 to +0.3 Gy (RBE)). A small increase < 0.8Gy (RBE) in the maximum liver dose is also
observed. The mean liver dose exhibits a slight increase by about 0.2Gy (RBE). This is also
indicated in figure 5.3b (green band). Compared to the static simulation, the maximum liver
dose is on average about 1Gy (RBE) smaller. Detailed results on the normal tissue exposure are
given in table C.4 in the appendix.
5.3.2 4D treatment simulations
5.3.2.1 Dose coverage and homogeneity
Impact of beam parameters on the dose coverage
The CTV dose coverage was assessed using the V95 of the simulated dose distributions. In
figures 5.4 and 5.5 the V95 is shown as a function of the beam spot FWHM for abdominal com-
pression and gating, respectively. The data for different lateral raster and IES spacings are
visualized with different colors and markers. The markers represent the mean and standard
deviation of V95, resulting from the various initial motion phases and periods. For clarity, mark-
ers for different raster spacing combinations are drawn with a horizontal offset to each other
(0.2mm). For the gated cases the colored markers represent mean and standard deviation of
V95 for simulations with a 50% GW. Data for the 30 % GW are drawn as black triangles with
a second smaller horizontal offset (0.08mm). With respect to the 50% GW, an approximately
linear increase in the average V95 with the beam FWHM is found for all CTVs and both mitiga-
tion techniques. The overall trend is indicated by the gray dash-dotted lines which have been
determined by linear fits to the data. The increase in V95 on average amounts to about 6–10 %
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(c) CTV TA3 (pat. A2), |A| =  11 mm
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(e) CTV TA5 (pat. A4), |A| =  10 mm
Figure 5.4.: V95 as a function of the beam spot FWHM for the five CTVs in patients A1–A4 with
abdominal compression. |A| denotes the motion amplitude for each CTV volume.
The dash-dotted lines are linear fits to the data.
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Figure 5.5.: V95 as a function of the beam spot FWHM for the six CTVs in patients G1–G4 with
gating. |A|50(30) denotes the motion amplitude in the 50 % and the 30 % GW, respec-
tively.
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per millimeter beam FWHM, relative to the initial difference in V95 w.r.t. the static case at a
6mm beam spot.
Four out of five CTVs with abdominal compression exhibit mean V95 values larger than 90%
for all raster spacing combinations and a beam FWHM of 15 mm. At the same beam spot size
five out of six gated CTVs have average V95 values larger than 95 %. Two of them reach values
comparable to the static level (TG3 and TG5) at all raster spacing combinations. For abdominal
compression CTVs TA2 and TA4 (figures 5.4b,d) show similarly large values at the largest beam
spot size. The two volumes, however, have only very small tumor motion amplitudes (<2mm).
For the gated CTVs a direct relation between the motion amplitude and the magnitude of V95 is
not observed. Considering, for instance, the volumes TG3 and TG4, it can be seen that TG3 has a
6mm larger tumor motion amplitude at a 50% GW, but V95 values are consistently smaller than
for TG4 (see figures 5.5c,d). For abdominal compression similar motion amplitudes on average
seem to yield comparable V95 values, as can be seen in figures 5.4a,c,e. On the basis of figure 5.5
no systematic differences in the mean V95 are observed between the two gating windows. Only
for CTV TG3 consistently larger V95 values are obtained for the 30 % GW (figure 5.5c). In few
cases significant differences in V95 are observed between the two IES spacings of 2 and 3mm,
in particular for TA5 and TG4, where data points are separated by more than one standard
deviation at a FWHM of 8mm. Based on the presented data no difference in the V95 for different
lateral raster spacings is found.
V107 values have also been studied and show a linear decrease with the beam spot FWHM. The
average decrease in V107 amounts to about 8–12 % per millimeter beam FWHM, relative to the
initial difference to the static V107 at 6mm FWHM. At a FWHM of 15 mm, mean V107 values are
below 5 % for all gated CTVs and four out of five CTVs with abdominal compression. Significant
differences (separation of more than one standard deviation) in V107 for different IES spacings
are observed in one case (TA5). For the lateral raster spacing no effect is observed. For one
gated case (TG3) systematically lower values of the mean V107 and small standard deviations
were found for the 30 % GW compared to the 50 % GW. Detailed results are given in figures C.3
and C.4 in the appendix.
Impact of beam parameters on the dose homogeneity
Figure 5.6 displays axial cross sections of examplary dose distributions for a fixed lateral
and longitudinal raster spacing and beam spots of 6 and 15 mm FWHM. On the right hand
side the corresponding DVH bands are depicted. The bands encompass all single DVHs for the
varying initial motion phases and the two motion periods. Dose distributions were calculated
for patient A2 with abdominal compression. DVH bands for the CTV at the 15 mm beam spot
are narrower in shape, i.e. less variability is observed among the respective dose distributions.
Furthermore, they feature an increased steepness, indicating improved dose homogeneity com-
pared to the 6 mm beam spot. The thresholds of 95% and 107% of the prescribed dose, as
recommended by the ICRU, are drawn as dash-dotted lines for comparison. The illustrated ef-
fect was also observed at FWHM of 8 and 10 mm and showed a gradual increase with the beam
spot size.
In figures 5.7 and 5.8 the dose homogeneity index (HI) is shown as a function of the beam
FWHM for abdominal compression and gating, respectively. The data presentation is identical
to figures 5.4 and 5.5. For all CTVs a linear decrease of the HI with the beam FWHM is observed
which is equivalent to an increase of the dose homogeneity. The gray dash-dotted lines have
been fitted to the data to indicate the trend. On average the homogeneity index decreases by
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Figure 5.6.: Axial dose cuts through the CTV and DVH bands for varying beam FWHM at a fixed
lateral (∆s = 2mm) and longitudinal (∆z = 3mm) raster spacing (dose in percent of
the prescribed dose). DVH bands are the envelope to all single DVHs.
about 5–7% per millimeter beam FWHM, relative to the initial difference to the static case at a
6mm beam spot. Standard deviations also decrease for increasing beam spot size. Data points
for CTV TG3 show systematically smaller mean HI values for the 30 % than for the 50 % GW
(separation larger than one standard deviation). For all other CTVs no systematic difference
between the two gating windows is observed. From figure 5.7 it can be seen that for most of
the CTVs there is a general trend of the larger 3mm IES spacing (open markers) towards larger
HI values, compared to the 2mm spacing (see e.g. figures 5.7a,e). Differences are on the order
of 10–30%. The effect is particularly pronounced for CTV TA5 (≈50 %). For the gated CTV TG4
differences of ≈20 % in the mean HI are found between the two IES spacings. However, error
bars overlap in most cases, so a clear advantage of a smaller IES spacing can not be ascertained.
From figures 5.7 and 5.8 no difference in the HI is observed w.r.t. the lateral raster spacing.
Impact of the CTV motion amplitude
In figure 5.9 the dependence of the HI on the CTV motion amplitude in the superior-inferior
(SI) and the anterior-posterior (AP) direction is shown for a fixed combination of beam param-
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(d) CTV TA4 (pat. A3), |A| = 1 mm
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(e) CTV TA5 (pat. A4), |A| = 10 mm
Figure 5.7.: Homogeneity index as a function of the beam spot FWHM for the five CTVs in pa-
tients A1–A4 with abdominal compression. |A| denotes the motion amplitude for
each CTV volume. For clarity, data points are shifted against each other in the ab-
scissa.
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Figure 5.8.: Homogeneity index as a function of the beam spot FWHM for the six CTVs in pa-
tients G1–G4 with gating. |A|50(30) denote the motion amplitude in the 50 % and
30 % GW, respectively.
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Figure 5.9.: Homogeneity index as a function of the motion amplitudes in (a) superior-inferior
(SI) and (b) anterior-posterior (AP) direction for∆z = 2mm,∆z = 3mm and a beam
FWHM of 8 mm. Markers and error bars represent mean and standard deviation of
the HI and r denotes the Pearson correlation coefficient (PCC).
eters. The gray dash-dotted line has been determined by a linear fit to the data. An average
increase of the HI with the motion amplitude is observed. The HI exhibits a stronger corre-
lation with the mean AP motion amplitude than with the SI component, although AP motion
amplitudes are significantly smaller (<4mm). The Pearson correlation coefficients (PCCs), r,
calculated in both cases are given in the figures for comparison. Similar correlation has consis-
tently been found for all studied beam parameter combinations. The average r and standard
deviations for the SI and AP motion components were 0.50± 0.06 and 0.68± 0.06, respectively.
Hence, the overall correlation found between the HI and the motion amplitude is low and about
0.18 larger for the AP motion component.
The same analysis was also performed with regard to the V95, showing an average decrease
with the motion amplitude. A low level of overall correlation and no significant differences
w.r.t. the two motion components were found. The average r and standard deviations were
−0.46± 0.08 and −0.45± 0.09 for the SI and AP directions, respectively. The detailed re-
sults for all beam parameter combinations are given in table C.5 in the appendix. CTV motion
amplitudes for abdominal compression and in the two gating windows were determined from
the 4DCT using deformable registration. Details on the method and the results are given in
section C.1 in the appendix.
Statistical analysis
Of the investigated variables, the amplitude components, the amplitude vector length |A|, the
beam FWHM, the CTV volume V , and ∆z showed a significant contribution to HI (all p<0.01).
Only for the 50 % gating window, |A| was not significant. The volume V showed a high correla-
tion to the motion variables and was thus excluded from the model to avoid statistical artifacts.
In step-wise regression, the AAP component, the beam FWHM and ∆z were identified as mu-
tually independent contributors to HI and remained highly significant also in the multivariate
model. All multivariate models showed considerably increased explained variance R2 in com-
parison to the strongest univariate predictor (AAP for abdominal compression, the beam FWHM
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R2 (p < 0.05)
model variables/terms abdominal compr. 50% GW 30% GW
1 |A| 0.49 n.s. 0.04
2 AAP 0.54 0.08 0.27
3 FWHM 0.16 0.33 0.35
4 ∆z 0.06 0.02 0.01
5 AAP+ FWHM 0.7 0.41 0.64
6 AAP+ FWHM+∆z 0.76 0.42 0.65
7 AAP+ FWHM+∆z
+AAP× FWHM
0.83 cross terms
n.s.
0.69
8 AAP+ FWHM+∆z
+AAP× FWHM
+∆z× FWHM
+∆z× AAP
0.86 cross terms
n.s.
0.71
Table 5.4.: Results of the uni- and multivariate analysis of the HI for abdominal compression and
the two gating windows. The coefficient of variation, R2, is tabulated for the uni-
variate (1–4) and the multivariate models (5–8). p < 0.05 was considered statistically
significant. |A| and AAP denote the length of the motion vector and the AP motion
component, respectively.
for both gating models). The addition of cross-terms in the model resulted in further strong
increases in R2 for abdominal compression and the 30% GW, but not for the 50% GW. The
final models explained 86, 42 and 71 % of the observed variance for abdominal compression,
the 50% and the 30 % GW, respectively, see table 5.4.
Impact of the 4DCT phase sampling
In figure 5.8 the expected advantage of a 30 % over the 50% GW regarding dose homogeneity
was observed only for CTV TG3 (figure 5.8c), which exhibited the largest difference in the
estimated motion amplitudes between the two gating windows of about 8 mm. Likewise, the
results for the V95 and V107 have shown no significant benefit of the 30% GW for most patients.
The impact of the 4DCT sampling on the dose distributions was studied for two patients by
re-iteration of the dose calculations using 14 instead of eight CT phases. The former provided
a more adequate coverage of the GW in 10% steps of the relative amplitude. Figure 5.1b
illustrates the distribution of CT phases in both cases. In figure 5.10 resulting DVH cohorts for
patient G2 are compared for 4D dose calculations on the two 4DCT sets. As seen in figure 5.5
before, only small differences between the 50% and the 30 % GW are observed for the smaller
4DCT set which was used for most patients. For 14 CT phases the DVH curve for the 30% GW
exhibits a significantly increased steepness w.r.t. the larger gating window. Also, less overdose is
present for both GWs compared to the 4DCT set with eight phases. Similar results were obtained
for the comparison of the two 4DCT sets of patient G3.
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Figure 5.10.: Comparison of DVHs for patient G2. Dose calculations were based on eight (a) and
14 4DCT phases (b). Dashed-dotted lines represent ICRU dose thresholds of 95 %
and 107 % of the prescribed dose, respectively.
5.3.2.2 Dose conformity
Dose conformity of the treatment plans with and without target motion was evaluated using the
CN. The results for a subset of the patients with a single CTV volume are shown in figure 5.11.
The data presentation is identical to figures 5.7 including the respective trend lines for target
motion (gray dash-dotted line) and the static treatments (black dash-dotted line). The depen-
dence on the gating window was not analyzed, since the dose optimization was done on the
same ITV for both gating windows. Static CN values exhibit an approximately linear decrease
with the beam spot FWHM. The slopes are different for each tumor volume. Extreme cases are
shown in the figure for CTV TA5 and CTV TG5 (figures 5.11b,d) with decays of the CN of about
5% and 30 % over the studied FWHM range, respectively. In the presented example of CTV TA5
the CN amounts to only 75–80% of the static conformity at the smallest beam spot size with
standard deviations of about 15 %. Reduced standard deviations are observed for all CTVs with
increasing beam spot size, especially at 15mm. For CTVs TA3 and TA5 the average conformity
under target motion increases with the beam FWHM and gradually approaches the static values
(see figure 5.11b). Differences of more than one standard deviation between different IES spac-
ings are seen for CTVs TA5 and TG4. The lateral raster spacing did not exhibit a relevant impact
on the CN. Likewise, a clear dependence of the CN on the tumor motion amplitude was not
observed. For instance, despite a comparable amount of tumor motion CTVs TG4 and TG5 have
significantly different CN characteristics. For CTV TG4 larger standard deviations and a decreas-
ing average deviation from the static values is observed for increasing FWHM. In contrast, CN
values for CTV TG5 are close to the static reference at all FWHM.
5.3.2.3 Normal tissue exposure
The exposure of the liver and lung was analyzed as a function of varying beam parameters
for all patients, as far as the respective contours were available. As a representative example,
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Figure 5.11.: Conformation number as a function of the beam spot FWHM for CTVs TA3 and TA5
with abdominal compression (a–b) and CTVs TG4 and TG5 with gating (c–d). The
static CN values and trend are drawn for comparison.
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Figure 5.12.: Mean and maximum dose in liver and lung as a function of the beam spot size for
patient G1. The data points for static irradiation are drawn for comparison.
figure 5.12 shows the results for the dose to the liver and lung in patient G1. The various raster
spacing combinations are visualized by different markers. Mean dose values for both organs
increase with the beam spot FWHM. However, only for the lung a difference between static
and moving irradiation is observed. The mean dose to the lung in this case increases by about
10% per millimeter beam spot. The same qualitative behaviour of the mean dose was found for
most patients. A gradual decrease of the the maximum dose to the lung and liver relative to the
static case is observed with increasing beam spot size, in particular for the liver (figure 5.12b).
The decrease in the maximum dose amounts to about 20 % over the studied range of FWHM.
Comparable results have also been found for the other patients. Differences from this behaviour
were observed for patient A2, in particular. The CTV for this patient is located close to the lung
volume boundary. Range overshoots into the lung, due to organ motion, in this case lead to a
systematically increased maximum dose w.r.t. the static irradiation (see also figure 5.6). From
figure 5.12 it can also be seen that there is no relevant difference in the mean and maximum
dose to the two organs with regard to different lateral or longitudinal raster spacings.
Due to different volumes of the lung covered by the CT scans, absolute comparisons of the
mean lung dose among different patients could not be made. In summary, maximum lung dose
values of 0–10 Gy (RBE) were determined, depending on the individual location of the tumor.
For the liver the mean received dose is between 0.7 and 2.0Gy (RBE) for most patients. Only
for patient G3 values up to 3 Gy (RBE) were found. Maximum dose values for the liver range
between 9 and 13Gy (RBE). Detailed results are listed in tables C.6 to C.13 in the appendix.
5.4 Summary and discussion
In this chapter the results of 4D treatment planning studies for eight patients with HCC were
presented. A major focus of these studies was to investigate the potential of the concept of
enhanced pencil beam overlap, in order to mitigate residual motion interplay effects. Most of
the analyzed patients had received treatment with scanned carbon ion therapy at HIT before.
During treatment, the patient motion and the beam delivery sequence were monitored. Based
on these data, 4D treatment reconstructions were performed with TRiP4D for two of these
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patients. The calculations used the 4D treatment simulation functionality developed within the
scope of this thesis.
4D treatment reconstructions
The 4D reconstructions were carried out for patient A2 with abdominal compression and
patient G2, the first patient treated with respiratory gating at HIT. This also is the world’s first
patient treated with gating and scanned beam delivery. The reconstructed dose distributions
for the two patients were considerably affected by residual motion interplay effects, especially
in the case of patient A2. V95 values of 76–97% for patient A2 and of 88–99% for patient G2
were obtained for the single fractions. The total dose distribution of patient A2, obtained as
the sum of all fractions, exhibited an improvement in V95 (V95 = 92.8%) compared to the
single fractions. This improvement can be attributed to the averaging rescan effect introduced
by dose fractionation (Knopf et al., 2011). Compared to the static reference, a 25 % increase
in the mean lung dose was observed for patient A2 for the full treatment. This increase was
predominantly caused by range overshoots, due to organ motion, and the close proximity of
the tumor to the lung. The dose to the lung for patient G2 was largely unaffected. An 18 %
increase of the mean dose to the liver was observed w.r.t. the static dose delivery. For technical
reasons, the dose delivered in the first fraction and the resulting cumulative dose for patient G2
could not be calculated. However, a similar averaging effect of the dose is expected. The clinical
interpretation of the presented results and the possible implications are left to the physician.
Although 4D treatment reconstructions in TRiP4D have been demonstrated in chapter 4 to be
accurate to a few percent for a complex experimental setup, it is important to realize that the
sources of uncertainty for patient treatment reconstructions are much more diverse and difficult
to assess. The validity of the 4DCT at the time of treatment is a central issue. It has, for instance,
been reported by Siebenthal et al. that liver drift and deformations of more than 5mm can
occur on a time-scale of tens of minutes after patient positioning, potentially invalidating prior
imaging (von M. Siebenthal et al., 2007). Above that, intra-fractional changes of the breathing
pattern can occur (Shirato et al., 2004) which likewise are not covered by the 4DCT. In the
presented study, additional uncertainty of the 4DCT arises from deviations from the assumed
relation of HU numbers and water-equivalent path length. The analysis of this uncertainty was
beyond the scope of this thesis. However, visual inspection of the static dose distributions for
the clinical treatment plans of patients A2 and G2 indicate that range differences may be on the
order of few millimeters. For a routine clinical application of 4D treatment reconstructions a
more accurate estimation of the introduced errors and adequate modification of the HU look-up
table or the 4DCT protocol are essential. At the time of writing, research with respect to this
issue is under way at HIT.
Apart from the 4DCT, also the correlation of the external surrogate signal to the internal
tumor motion carries significant uncertainties. Systematic intra-fractional differences, such as
phase shifts, may occur (Hoisak et al., 2004; Ionascu et al., 2007) and will have a significant
impact on the dose reconstructions if the phase shift is not corrected for. Furthermore, the
technical limitations of the surrogate motion monitoring system and the respective module of
TRiP4D are relevant. While patient A2 showed a very regular breathing pattern, patient G2
had notably irregular respiration. Hence, even assuming acceptable correlation to the internal
tumor motion, it is to be expected that accurate determination of the respiratory phase from the
surrogate motion trace under these conditions is challenging.
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Finally, the acquisition of the BDS data during treatment is in principle well controlled and
sufficiently accurate. However, due to separate data acquisition systems, temporal correlation
of the BDS data and the motion trace is required. At HIT motion monitoring is performed us-
ing the ANZAI system (AZ-773V, ANZAI MEDICAL CO., LTD). For technical reasons, the beam
status is also acquired with the ANZAI device. The data can in principle be used to guide tem-
poral correlation. However, the fact that the ANZAI system is not a real-time system induces
significant timing inaccuracies. In the course of this study, discrepancies of up to 500 ms were
found between beam-off signals and the irradiation time of the last point in the respective beam
gate. The data indicate that these discrepancies are proportional to the acquisition time. For
this reason, manual temporal correlation was performed. To generate the required beam status
data from the treatment records, two simplifications had to be made. Firstly, a constant irra-
diation time of the first raster point in each beam gate and secondly, an instant interruption
of the beam were assumed. Since only few raster points are affected, the impact of these ap-
proximations is expected to be small compared to the residual effects introduced by the motion
trace uncertainties. The timing inaccuracies of the ANZAI system compromise the identification
of the motion state for each raster point which is equivalent to a time-dependent phase shift.
Data correction is only feasible if the phase shift is linearly increasing with the acquisition time.
Further investigation on this issue is required. To investigate the uncertainties due to manual
temporal correlation and the ANZAI system timing, phase shifts between the BDS and the mo-
tion trace of ±250ms were studied. As shown in section 5.2.3, the introduced variation in V95
is considerable and on the order of ±10 %. The discussed issue can be avoided, if an integrated
data acquisition is used for the synchronous monitoring of the BDS and the patient motion at an
acquisition rate smaller than 1ms. For an efficient application of 4D treatment reconstructions
in clinical routine such a system is strongly recommended.
4D treatment simulations
The treatment simulations reported in this chapter comprised over 1500 4D dose calculations
for gating and abdominal compression in eight patients with HCC. The dose homogeneity, dose
coverage and dose conformity were studied as a function of the employed beam parameters, i.e.
the beam FWHM, the IES spacing and the lateral raster spacing. Additionally, the correlation of
the dose parameters with the CTV motion amplitude was investigated. A statistical analysis was
carried out using multivariate linear regression models to investigate the impact of the beam
and CTV parameters on the dose homogeneity.
Similar to the results reported in chapter 4, the beam spot FWHM and the motion amplitude
exhibited the largest impact on all studied dose parameters. An increase in the beam FWHM
from 6mm to 15 mm resulted in a reduction of the lacking dose coverage (V95) by about 50–60%
for abdominal compression and 36–100 % for gating, depending on the CTV volume. Compa-
rable improvements were obtained for the dose homogeneity index and the V107. Assuming an
acceptance threshold for the V95 of 95 %, five out of six CTVs could have been treated with a
30% GW and a 15mm beam spot. In contrast, only two CTVs with abdominal compression
would have passed this threshold. These results suggest that an increase in the beam FWHM
yields considerable mitigation of residual motion interplay effects, especially for gating. How-
ever, the variability among different patients is large as can, for instance, be seen by comparison
of figures 5.5d,e. While the gain in V95 for patient G2 in this case is considerable, patient G3
shows little response to the increased beam FWHM. However, the overall motion of the two
CTVs is comparable. These observations suggest that a general prediction of the desired effect
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on the basis of the CTV motion only is not feasible. The individual anatomy of the patient,
tumor location and the tumor motion pattern may be starting points for a better understanding
of the observed variability. However, the multivariate analysis has confirmed that there was
generally a larger response to the beam FWHM for gated beam delivery, as can be seen from the
fraction of the explained variances in table 5.4. In the case of gating, the respective R2 values
were about twice as large as for abdominal compression. Moreover, the statistical analysis also
showed a different behavior for gating and abdominal compression w.r.t. the correlation of the
HI with the CTV motion amplitude. Only in the case of abdominal compression a large impact
(R2 > 0.4) of the SI motion amplitude and the length of the motion vector was found. Instead,
a stronger correlation of the HI with the AP motion amplitude was present (see also figure 5.9)
(r < 0.7 on average). A possible explanation for this behaviour is the relative motion between
the beam and the CTV. For the employed treatment plans horizontal line-by-line scanning was
used, i.e. parallel to the SI direction for the used beam port configuration (left lateral to me-
dial). Bert et al. (2008) have shown that a perpendicular configuration of scanning and target
motion in general leads to more severe interplay patterns. Hence, the AP motion component in
this case may predominantly drive the interplay patterns, although absolute motion amplitudes
are below 4mm. In addition, the CT resolution is only 3 mm in the SI direction, thus, absolute
uncertainties on this motion component may be larger. On the other hand, the registration ac-
curacy is on the order of 1 mm (Brock, 2010), causing the relative uncertainty of the AP motion
to be considerable, as well. Zhang et al. (2012) recently have reported even larger registration
errors for the liver of several millimeters, due to low image contrast. It should be noted, how-
ever, that the uncertainties of the mean and median motion amplitudes for statistical reasons
are subject to less uncertainty than the displacements of individual voxels. Nevertheless, the
latter are of interest for 4D dose calculation. In their study Zhang et al. found a considerable
impact of the registration accuracy in the liver on the 4D dose distribution of on average 3%.
The observed differences with regard to the two gating windows in general were smaller than
expected. Only for CTV TG3 a consistent advantage of the 30% GW w.r.t. dose coverage and
dose homogeneity was observed. TG3 was the tumor ehibiting the largest motion amplitude
and the largest difference in the SI and AP motion components between gating windows. The
small improvements for the smaller gating window are most likely due to the fact that the
employed 4DCT could not adequately sample the motion in the gating window. As can be seen
from figure 5.1b, for the 4DCT with eight phases only few CT phases are located in the gating
window and the phase distribution is strongly asymmetrical. For two of the patients a more
adequate 4DCT set with 10% steps was available. It has been shown in figure 5.10 that the
4D dose calculations in the presented case strongly depended on the 4DCT sampling. Hence,
the results obtained for gating may in general be considerably affected by the inadequate phase
sampling. The same also holds for the estimation of the motion amplitudes from the 4DCT, using
deformable registration. Therefore, the disadvantageous phase sampling may also be the reason
for the very small influence of the AP and SI motion components on the dose homogeneity in
the case of the 50% GW, as found in the statistical analysis. Although the number of patients
in this study is small, the results provide evidence that the 4DCT sampling has a considerable
impact on 4D dose calculation. A revision of the 4DCT protocol is recommended. The optimal
phase sampling should be determined in further studies.
Variation of the IES spacing only showed notable differences in few cases. CTVs TA1 and TA5
exhibited about 30–50% larger HI values for the 3 mm IES spacing. The statistical analysis, how-
ever, revealed that the impact on the total variance is on average about one order of magnitude
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smaller than for the beam FWHM and the motion amplitude (see table 5.4). An explanation
for the few cases with larger variation between different IES spacings can be resonance effects
between beam and CTV motion, leading to extreme interplay patterns. Comparable effects were
observed in chapter 4 for the impact of certain beam delivery sequences on the dose homogene-
ity (cf. figure 4.14). Since correlations are broken up more frequently by beam pauses for the
smaller IES spacing, formation of extreme interplay patterns should be less likely. This argument
also holds for gating where even more beam pauses are introduced, depending on the gating
window size.
For the lateral raster spacing no significant effect has been found. Hence, also a 3mm raster
spacing seems dosimetrically acceptable. This can potentially be exploited to reduce the treat-
ment time when used in combination with a large enough beam spot.
The results w.r.t. dose conformity demonstrate that a larger beam spot leads to less conformal
static dose distributions for all analyzed patients. However, large differences were observed
from patient to patient. The magnitude of the conformity decay varied between 5 and 30 %
over the full range of studied beam spot sizes. In a first approximation the characteristic loss
of conformity can be related to the tumor size. The relative increase of the irradiated volume
is larger for smaller tumors, resulting in a steeper decay of the conformity. Large variations in
conformity due to interplay are found, especially at small beam FWHM. Scattering of the CN
amounts to 15–30% around the mean in many cases (see figure 5.11). This is comparable to the
results obtained for the water phantom simulation study in section 4.3.2.2. Standard deviations
gradually decrease for increasing beam FWHM and approach the static reference. In general,
a larger beam FWHM decreases the static conformity, while on average increasing the dynamic
conformity. Application of an increased beam spot size may be feasible for those patients for
which the static conformity is not already unacceptable, e.g. due to normal tissue constraints. It
should be noted that, based on the results presented here, a smaller beam FWHM in most cases
does not yield an advantage in conformity for target motion, due to the variability introduced by
interplay effects. An exception to this, however, has been found for CTV 10 (see figure 5.11d).
Conclusion
The results of the 4D treatment reconstructions for two patients demonstrate considerable
dose degradation due to interplay effects, in particular in the case of abdominal compression.
The discussed 4D treatment planning study reveals that an increased beam FWHM can signifi-
cantly mitigate residual motion interplay effects. Based on the available data, a beam FWHM of
at least 15 mm is recommended for treatments under abdominal compression. The findings of
this study also suggest that a revised 4DCT protocol with adequate phase sampling is essential
for future treatment planning studies and dose reconstructions.
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6 Discussion
In 2011, the Heidelberg Ion-Beam Therapy Center (HIT) has commenced the treatment of liver
cancer patients with mobile tumors with a scanned carbon ion beam. To compensate for motion-
induced dose inhomogeneities, the treatments are delivered under abdominal compression or
using respiratory gating. However, both techniques can only establish partial compensation of
interplay effects. Therefore, further mitigation has been attempted using optimized treatment
plan parameters.
In the course of this thesis, a 4D treatment planning system (4DTPS) was developed, allowing
detailed 4D treatment simulations in a clinical environment and for various motion mitigation
techniques, including gating. The 4D dose calculation capabilities of the program were tested in
dedicated experiments, showing good agreement with the measurements. The 4DTPS enabled
extensive experiments, simulations and treatment planning studies for liver cancer patients,
addressing the mitigation of residual motion interplay effects using enhanced beam overlap.
The results demonstrate that an enlarged beam spot size (FWHM) can considerably reduce dose
heterogeneities caused by residual motion interplay effects. TRiP4D further allowed 4D dose
reconstructions of the first liver cancer patients treated with a scanned carbon ion beam at HIT.
Experiments and simulation studies
Bert et al. (2009) have proposed a concept of an enlarged overlap of individual pencil beams
to increase the robustness with regard to motion-induced dose heterogeneities. Their initial
studies indicated that a mitigation effect can likewise be reached by a decreased lateral raster
spacing or by an increased beam spot size. The findings in this work, however, suggest that
the ratio of the beam FWHM and the lateral raster spacing is not the crucial variable. In fact,
the presented studies revealed an impact of the beam spot size only. A systematic impact of the
lateral raster spacing on the dose homogeneity was not observed.
Comparing the two studies, the different preconditions have to be taken into account. Bert
et al. have performed experiments and simulations with gated irradiation of radiographic films
in two separate setups to independently study the effect of lateral and longitudinal pencil beam
overlap. In contrast, in this work absolute dose measurements and simulations were performed
for ungated beam delivery in a more complex water phantom setup with three dimensional
target motion. In general, radiographic film response is not directly comparable to the absorbed
physical dose (Spielberger et al., 2003). Hence, a quantitative comparison of the results of
the two studies is difficult. Bert et al. have aimed at the separation of lateral and longitudinal
overlap effects. In the presented study, both effects were studied in parallel. The observed
differences between the two studies may partially result from interaction of the lateral and
longitudinal beam overlap. Indeed, the results in chapter 4 suggest that lateral and longitudinal
overlap may not be fully independent, since a combined lateral and longitudinal overlap did not
always yield a better result than an increased lateral overlap only. Additional differences are to
be expected from the fact that for gated beam delivery only the dip-like motion characteristic
around the exhale minimum is of relevance. The impact of different motion characteristics has
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not been studied in the presented work. However, it seems unlikely that qualitative differences
are introduced by this fact.
Steidl (2011) has performed simulation studies for gated beam delivery which are very similar
to those discussed in chapter 4. He used the same water phantom setup and simulation envi-
ronment and reports comparable results with regard to the effect of an increased beam FWHM.
In agreement with the findings in this work, he also did not observe a significant impact of the
lateral raster spacing on the target dose homogeneity. He further reports a mitigation effect of a
decreased IES spacing. Although a smaller IES spacing in the presented study did not show the
same results in all cases, the general tendency was the same.
The observed differences between the two simulation studies may at least partially originate
from the different beam delivery sequences (BDSs) used. While Steidl employed simulated
BDSs, the study described in this thesis is based on measured sequences. Since the former were
generated using simplifications, they may not describe the beam delivery at HIT with sufficient
accuracy. The impact of the BDS on the 4D dose distribution was investigated in chapter 4,
revealing that a variation in the BDS translates into considerable variability of the 4D dose
distribution. The reason for this seems to be a modulation of the temporal structure of the beam
delivery and the extracted intensity pattern. In some cases, very large dose differences were
observed which may be caused by disadvantageous synchronization between beam delivery
and target motion and provoke resonance-like interplay patterns. There is reason to believe
that irregular target volume shapes and frequent beam interruptions, e.g., due to beam gating,
lower the probability for these synchronization effects. For the patient treatment studies carried
out in this work, similar effects were observed at a much smaller magnitude for patients with
abdominal compression. However, in the presented case only simulated BDSs could be studied.
So far, interplay patterns have been studied in the literature mostly with a focus on the target
motion component rather than the beam motion. This is due to the fact that the target motion
is usually better defined and simpler to control in experiments. Nevertheless, considering the
results of the discussed study, future research on the variability of BDSs and its dosimetric
impact is recommended. The large number of measured beam delivery sequences obtained
in the course of this study may serve as a starting point for these investigations. A better
understanding of the crucial variables affecting the dosimetric influence of the beam delivery
structure may open up possibilities for a directed modification of the beam delivery. In a first
approach, robustness considerations could be included into the choice of the particle intensity
level. In a more elaborate concept, real-time beam intensity control could be used to modulate
the extracted beam intensity as needed. Dynamic intensity control for synchrotron accelerators
has been developed at NIRS (Sato et al., 2007) and is currently under investigation at HIT and
GSI (Schömers et al., 2011).
Treatment planning studies
The potential of the mitigation of interplay effects using an enlarged beam spot size has been
confirmed in treatment planning studies for eight patients with liver cancer. For the analyzed
patients with abdominal compression an enlarged beam FWHM of up to 15 mm could not def-
initely establish V95 values larger than 95 %, except for very small tumor motion amplitudes
below 2 mm. In general, a larger mitigation effect of the beam FWHM has been observed for
gating. For three of the analyzed target volumes, V95 values larger than 95% were obtained
if the FWHM of the beam was increased to 15mm. While a decreased IES spacing only had a
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small impact on the dose distributions, considerable differences were found between different
patients.
In particular for gating, the CTV motion amplitude did not show a clear correlation with the
resulting level of dose heterogeneity due to residual motion interplay. Furthermore, apart from
one patient, no significant dosimetric differences were observed between the two selected gating
windows. A comparison of 4D dose calculations on two 4DCT sets with a different number of
CT phases inside the gating window was carried out for a sub-set of the patients. The results
suggest that the 4DCT protocol currently used at HIT is not well suited to study residual motion
interplay effects inside the gating window. Hence, quantitative interpretation of the obtained
results for gated beam delivery may be limited. Since also the tumor motion amplitudes were
estimated from the 4DCT, these may be subject to considerable uncertainties. Considering the
findings in this work, future studies to determine the optimal 4DCT sampling, especially in the
gating window, are recommended.
Apart from an increased pencil beam overlap, other approaches for the mitigation of tumor
motion have been published. Furukawa et al. (2010a) from NIRS have proposed to mitigate
residual tumor motion in the gating window by combining gating with rescanning. PSI plans to
use a similar approach (Knopf et al., 2011). Rescanning also can be used independently from
gating. It aims at an statistical averaging of the dose heterogeneities by performing multiple
scans of the target volume (Phillips et al., 1992). Rescanning is inherently robust, however,
large margins encompassing the full tumor motion have to be used. A similar effect to rescan-
ning can be achieved by the use of multiple fields. Knopf et al. (2011) have reported on the
effectiveness of rescanning for liver cancer using single and multiple fields. However, they have
only considered rigid liver motion and did not take into account range changes. An alterna-
tive approach to rescanning is to compensate the tumor motion by adapting the beam position
to the changing tumor position, so-called beam tracking. GSI has implemented beam tracking
into the therapy control system and has demonstrated the technical feasibility (Bert and Rietzel,
2007; Saito et al., 2009). While lateral beam adaptation is controlled via the scanner magnets,
range adaptation is facilitated using a fast double wedge absorber system. From a clinical point
of view, the application of beam tracking is currently limited by the precision of 4D treatment
planning routines and motion monitoring. Apart from modification of the beam delivery, direct
reduction of the tumor motion is also possible. RPTC routinely performs treatments of lung and
liver tumors in apnea under general anesthesia (RPTC, 2011). However, this produces a heavy
clinical workload. All of the above treatment modalities are subject to uncertainties which may
compromise the precision of the respective technique. The concept of enlarged beam overlap
might not only be of advantage to increase the robustness of treatments using gating or abdom-
inal compression. Also, a combination of this approach with beam tracking or rescanning inside
the gating window, as proposed by Furukawa et al., can be thought of.
4D treatment planning system
The parameter study of chapter 4 and the treatment planning study discussed above both were
enabled by the availability of the 4D treatment planning system, TRiP4D, which was developed
in the course of this work (chapter 3). The 4D treatment planning functionality incorporates
the current state of research in the field. That is, the treatment planning workflow is based on
4DCT and deformable image registration data. Basic concepts and algorithms developed earlier
by other authors (Bert and Rietzel, 2007; Gemmel et al., 2011) have been integrated into the GSI
in-house treatment planning system TRiP98 (Krämer et al., 2000). Dedicated tests have shown
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that the program is capable of performing 4D dose calculations for a complex experimental setup
with an accuracy of on average (−1± 4)% for the typical beam configuration (section 4.3.1). A
major enhancement of the 4D treatment planning functionality is the integration of deformable
image registration data and 4D volume segmentation which are indispensable for patient treat-
ment planning. Furthermore, compatibility to clinically used motion monitoring devices and
beam delivery sequence data has been established, thus, enabling 4D treatment simulations and
4D dose reconstructions for irregular patient respiration. Using motion monitoring and beam
delivery sequence data measured during treatment, TRiP4D is capable of retrospectively calcu-
lating the delivered dose. This functionality has been demonstrated for two patients with liver
cancer who were treated at HIT with abdominal compression and gating. The results indicate
that the dose delivery was considerably affected by interplay effects and is very sensitive to the
relative alignment between the motion trace and the BDS. To the author’s best knowledge, 4D
dose reconstructions for patients treated with a scanned ion beam are reported here for the first
time.
The possibility to perform 4D dose reconstructions based on data acquired during treatment
opens up new perspectives for quality assurance and treatment planning. One of the major prob-
lems related to interplay patterns is that they are very sensitive to all beam delivery and motion
parameters and, therefore, are very difficult to predict. Retrospective 4D treatment simulations
enable to assess the magnitude of dose heterogeneities for the individual patient, breathing
pattern and beam delivery. Such simulations may provide the possibility to change a treat-
ment course, if necessary. Thus, TRiP4D can be used to facilitate adaptive treatment planning
strategies. In a conventional approach, this can include changes to the treatment plan based on
repeated imaging. Further adaptive concepts may comprise changes of the motion mitigation
technique or modification of treatment parameters, such as the beam spot size. However, of
a greater clinical importance is the possibility to perform simulations prior to treatment. Al-
though the exact conditions are unknown, 4D simulations for the individual patient can serve to
determine necessary treatment parameters, such as the gating window size or the most suitable
motion mitigation technique. In order to determine robust treatment parameters, a large num-
ber of simulations can be performed to adequately sample the respective parameter space. The
results of such simulations can be exploited in two ways. Firstly, the motion-related uncertainties
of a treatment can be assessed for a specific treatment plan and, secondly, alternative treatment
options can be investigated on a patient-specific basis. Due to the large parameter space of these
simulations, clinical decision making is non-trivial. For this reason, research projects at HIT and
GSI currently aim at visualization concepts for the results of such simulations which shall enable
the physician to determine the best treatment option in an efficient way.
TRiP4D now also provides the opportunity to systematically investigate the sources of un-
certainty entering into the 4D treatment planning process in general and the 4D treatment
simulations in particular. Only some of the uncertainties shall be addressed here. All 4D treat-
ment planning attempts so far rely on the validity of 4DCT data. Research in the field has
shown that the expected variability is considerable, even over a short period of time (Shirato
et al., 2004; von M. Siebenthal et al., 2007). Therefore, a single 4DCT set does not necessarily
represent the moving anatomy of the patient accurately enough. Using the new 4DTPS, the
variability of the intra-fractional anatomy changes can be studied under controlled conditions,
for instance, using serial 4DCT data. The obtained understanding in turn may help to more
reliably perform 4D treatment simulations and to interpret their results accordingly.
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To take full advantage of 4DCT data, deformable registration is indispensable. Zhang et al.
(2012) recently have reported on registration uncertainties in the liver and their impact on
the 4D dose distribution. They found considerable variability in 4D dose calculations based on
registration results from different algorithms. They conclude that these variations originate from
registration uncertainties due to the typically low image contrast in the liver. Using deformable
registration data of different software packages for the same 4DCT set, similar studies can be
performed with TRiP4D in the future.
Finally, the use of external motion surrogates, for instance to control respiratory gating, usu-
ally assumes direct correlation between the external and the internal motion. However, for
instance, Hoisak et al. (2004) have reported on phase shifts between the internal motion and
the external motion surrogate. For gating these phase shifts can lead to partial irradiation out-
side the intended gating window. TRiP4D enables simulations which explicitly account for this
kind of miscorrelation and allow to study its dosimetric impact.
At the time of writing, TRiP4D is being further developed by colleagues to incorporate 4D
dose optimization techniques into the treatment planning process. To date, dose optimization
in 4D treatment planning is usually performed on a single reference 4DCT phase only, ignoring
most of the available 4DCT data. Recent publications have reported on optimization techniques
for intensity-modulated radiation therapy (IMRT) which include the full 4DCT information into
dose optimization (Nohadani et al., 2010) or incorporate robustness considerations (Unkelbach
et al., 2009). The development of similar approaches for scanned ion beam therapy in the future
seems particularly promising.
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7 Conclusion
In this work, a 4D treatment planning system (4DTPS) for scanned ion beam therapy was de-
veloped and implemented based on the GSI in-house planning system, TRiP98, and previous
efforts in the field. The 4D treatment planning functionality integrates state-of-the-art planning
tools, such as 4DCT imaging and deformable image registration, allowing therapy planning and
time-resolved treatment simulations in a clinical environment. The 4D dose calculation was
validated experimentally, reaching an average accuracy of (−1± 4)% for the typical beam con-
figuration. The new 4DTPS is currently used as the basis for further research on 4D treatment
planning solutions by several colleagues.
Within this work, the 4DTPS was used for extensive studies addressing the dosimetric influ-
ence of residual tumor motion for liver cancer patients. Aiming at optimized treatment plan
parameters, it could be shown for an artificial geometry in experiments and simulations that an
enlarged beam spot size considerably mitigates residual motion interplay effects. These findings
were supported by the results of 4D treatment planning studies based on clinical data. The
most appropriate beam parameter settings can be determined on a patient specific basis, using
individual treatment simulations or adaptive treatment planning concepts.
The 4DTPS contributed to the world’s first treatments of patients with mobile liver tumors with
a scanned carbon ion beam at HIT. 4D dose reconstructions of patients treated with gating and
abdominal compression demonstrated a considerable impact of tumor motion on the delivered
dose distribution and indicate a need for further motion mitigation efforts. To the author’s best
knowledge, these are the first retrospective treatment simulations of this kind.
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A Developed software and used materials
A.1 dcm2ctx — DICOM CT and contour converter software
The dcm2ctx program is capable of converting DICOM-CT and DICOM-RT data into the native
file format of the DKFZ-grown treatment planning system VOXELPLAN (Schlegel et al., 1992).
This file format also is used by TRiP98/TRiP4D. The software is command line-based, written
in C++ programming language and natively runs on LINUX operating systems. It depends on
the open source DCMTK (DICOM toolkit) libraries provided by OFFIS e.V. (Eichelberg et al.,
2004). dcm2ctx reads and manipulates DICOM-CT data sets and corresponding contour data
in DICOM-RT format. Various data manipulation options are provided. The input syntax and
available options are given in the following.
synopsis:
usage: dcm2ctx [-vdhsuyoim][-p <prefix>][-z < zmin, zmax >][-c <voi_file>]
[-t <threshold>][<ct_file1> <ct_file2> . . . ]
mandatory arguments:
<ct_file1>, <ct_file2>, . . . input DICOM files. These must be individual slices of the same
CT (in no particular order)
general options:
-h, --help print help text
-v, --verbose dcm2ctx is talkative (info messages)
-d, --debug turn on debug mode (loads of output)
output options:
-s, --write-separate-files write one .hed/.ctx set for each input file, per default all files
are combined into one .hed/.ctx file set
-p, --prefix <prefix> output files are named in the scheme: <prefix>[index][suffix]
-z, --z-range < zmin, zmax > manually select slice range in mm (zmin ≤ z ≤ zmax)
-u, --unsorted do not sort the slices according to their z-position and keep the
order in which they were given as input
-y, --flip-y flip CT/VOI data in y direction
-o, --use-original-hu use original Hounsfield units of CT and do not attempt to cor-
rect for a rescale intercept or rescale slope
-c, --contours <voi_file> convert corresponding contours along with CT. The input file
has to be a DICOM-RT file
-i, --interactive interactively handle multiple contours in a slice
-m, --multi-cont do not connect any multiple contours in a slice
-t, --th-multi-cont <num> set threshold to remove a multiple contour in a slice number of
points less than <num> will be removed (default num = 0)
example:
dcm2ctx --verbose -p my_prefix -y --contours voi_file ct_file1 ct_file2
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A.2 extract+ — dose extraction software
The extract+ program is a software to extract dose values at defined positions of a dose cube.
Extraction point geometries like dosimeter arrays can be defined using a dedicated text file.
Image format output is also available to overlay the extraction geometry with a CT or dose
distribution. The program is command line-based, written in C programming language and
natively runs on AIX and LINUX operating systems. extract+ depends on the TRiP98 libraries.
The input syntax and options are given in the following.
synopsis:
extract+ [OPTIONS...] -p x,y,z <dose cube> (<ct cube>)
arguments:
mandatory arguments:
-p, --extraction-point <x,y,z> dose extraction point, usually the center of the
dosimeter geometry in CT coordinates.
<dose cube> dose cube file (.dos) w/ or w/o file extension
optional arguments:
<CT cube> CT cube file (.ctx) w/ file extension
options (no long options on AIX):
general options:
-d, --debug switch on debug mode (a lot of output)
-q, --quiet switch on quiet mode (no output on screen)
-h, --help print help text
-H, --home-path extract+ home (installation) path
-e, --export-gd switch on gd image export. If <ct cube> is specified, also
triggers ct image export
output options:
-o, --output-directory <dir> output directory (default is current directory)
-f, --output-file <file> output file (.xtr) name
extraction options:
-g, --geometry <geo> detector geometry, default is ’waterB’
-c, --couch-angle <angle> couch angle in deg., default is 0 deg.
-a, --gantry-angle <angle> gantry angle in deg., default is 0 deg.
-v, --voi <voi> VOI file w/ file extension
-i, --interpolation-method <alg> dose interpolation algorithm, available are:
(i) ’ckarger’ or ’ck’, as used in old extract tool
(ii) ’trilinear’ or ’tl’, equivalent to ckarger, default
(iii) ’none’ or ’no’, nearest neighbour only
-k, --ckarger-mode switch on simulation of C. Karger’s classic extract tool,
equivalent to option chain: ’-g waterB -c 90 -a 0 -i ck’
-s, --single-point dose extraction at a single point as given by the -p option,
equivalent to option chain: ’-g point -i trilinear’
-r, --reference-dose reference (planned) dose, needed for correct gd color
wash
example:
extract+ -d -g waterB -c 90 -i trilinear -f output.xtr -p 10,20,15 -e dosefile.dos
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A.3 mbr2lmdout — beam delivery sequence generation software
The mbr2lmdout program is capable of generating TRiP4D beam delivery sequence input data
(.lmdout format) based on HIT treatment records (machine beam records) and beam status data
(ANZAI or EtherCAT format). Time alignment either is performed by using beam status data of
different formats or interpolation methods. mbr2lmdout is a command line tool and written
in C++. It natively runs on LINUX operating systems and depends on GSI and HIT in-house
libraries. The input syntax and options are given in the following.
synopsis:
usage: mbr2lmdout -[dvhmrbi] <machine beam record> <lmdout log file>
mandatory arguments:
<machine beam record> input HIT MBR file (.xml)
<lmdout log file> output lmdout log file (.lmdout)
options:
general options:
-h, --help print help text
-d, --debug switch on debug mode (a lot of output)
-v, --verbose switch on verbose mode (a lot of output)
-m, --monitor write ROOT file (.root) with monitoring information
-r, --try-repair try to repair scan log event sequence defects
output options:
One of these options needs to be defined:
-b, --beam-status <ID>:<file> use defined beam status log file, ANZAI (ID = az) format
(.daf) and Beckhoff EtherCAT (ID = ec) format (.dat) are
supported
-i, --interpolation-method
<method>:<arg>
use specific beam status interpolation method
1) ’fixed’: use fixed irradiation times for the first and last
raster point in a beam gate
2) ’linear’: linear fit of the irradiation time of the first
raster point in a beam gate, not yet implemented
example:
mbr2lmdout --debug -b az:beamstatus.daf mbr.xml record.lmdout
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B Water phantom measurements and
simulations
B.1 Gating simulations
Table B.1.: Agreement of 4D simulations with the respective measurements for all 52 gated and
the 18 static reference irradiations. The table is sorted by the plan parameters: RiFi
(effective Bragg peak width),∆s (lateral raster spacing),∆z (IES spacing) and FWHM
(average beam FWHM). ALR and A⊥ name the motion amplitudes in left-right BEV
and the remaining dimensions, respectively. The mean relative dose deviation ∆D
and standard deviation σD were calculated from the 22 measured and calculated
dose values per experiment.
No. plan parameters [mm] amplitude [mm] agreement [%]
RiFi ∆s ∆z FWHM ALR A⊥ ∆D σD
(S01) 3.0 2.0 2.0 6.1 static ref. −1.62 1.91
(S02) 3.0 2.0 2.0 8.3 static ref. −2.17 1.70
(S03) 3.0 2.0 2.0 10.1 static ref. −2.43 1.64
(S04) 3.0 2.0 3.0 6.1 static ref. −1.68 1.95
(S05) 3.0 2.0 3.0 8.3 static ref. −2.30 1.75
(S06) 3.0 2.0 3.0 10.1 static ref. −2.76 1.65
(S07) 3.0 3.0 1.0 10.1 static ref. −2.33 1.80
(S08) 3.0 3.0 2.0 10.1 static ref. −2.28 1.75
(S09) 3.0 3.0 3.0 10.1 static ref. −2.61 1.87
(S10) 4.0 2.0 2.0 6.1 static ref. −3.07 1.38
(S11) 4.0 2.0 2.0 8.2 static ref. −3.41 1.25
(S12) 4.0 2.0 2.0 10.1 static ref. −3.40 1.20
(S13) 4.0 2.0 3.0 6.1 static ref. −3.11 1.41
(S14) 4.0 2.0 3.0 8.2 static ref. −3.30 1.29
(S15) 4.0 2.0 3.0 10.1 static ref. −3.58 1.24
(S16) 4.0 2.0 4.0 10.1 static ref. −3.80 1.37
(S17) 4.0 3.0 2.0 10.1 static ref. −3.77 1.12
(S18) 4.0 3.0 3.0 10.1 static ref. −3.75 1.22
(01) 3.0 2.0 2.0 6.1 2.0 1.0 −0.39 4.17
(02) 3.0 2.0 2.0 6.1 4.0 2.0 −0.90 5.10
continued on next page
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No. plan parameters [mm] amplitude [mm] agreement [%]
RiFi ∆s ∆z FWHM ALR A⊥ ∆D σD
(03) 3.0 2.0 2.0 6.1 10.0 5.0 −1.51 5.49
(04) 3.0 2.0 2.0 8.3 2.0 1.0 −2.51 3.08
(05) 3.0 2.0 2.0 8.3 4.0 2.0 −1.13 4.88
(06) 3.0 2.0 2.0 8.3 6.0 3.0 −1.80 4.15
(07) 3.0 2.0 2.0 8.3 9.0 4.5 −1.12 5.09
(08) 3.0 2.0 2.0 8.3 10.0 5.0 −2.46 5.22
(09) 3.0 2.0 2.0 10.1 4.0 2.0 −1.94 2.32
(10) 3.0 2.0 2.0 10.1 5.0 2.5 −1.31 3.81
(11) 3.0 2.0 2.0 10.1 6.0 3.0 −1.88 3.30
(12) 3.0 2.0 2.0 10.1 10.0 5.0 −2.02 3.94
(13) 3.0 2.0 3.0 6.1 2.0 1.0 −1.90 4.11
(14) 3.0 2.0 3.0 6.1 4.0 2.0 −1.18 4.24
(15) 3.0 2.0 3.0 6.1 10.0 5.0 −0.27 7.81
(16) 3.0 2.0 3.0 8.3 4.0 2.0 −1.51 3.06
(17) 3.0 2.0 3.0 8.3 6.0 3.0 −1.72 3.98
(18) 3.0 2.0 3.0 8.3 10.0 5.0 −1.90 4.60
(19) 3.0 2.0 3.0 8.3 10.0 5.0 −1.90 4.60
(20) 3.0 2.0 3.0 10.1 4.0 2.0 −0.97 3.19
(21) 3.0 2.0 3.0 10.1 4.0 2.0 −2.13 2.66
(22) 3.0 2.0 3.0 10.1 6.0 3.0 0.16 5.76
(23) 3.0 2.0 3.0 10.1 6.0 3.0 −1.85 3.37
(24) 3.0 2.0 3.0 10.1 10.0 5.0 −0.36 5.28
(25) 3.0 2.0 3.0 10.1 10.0 5.0 −1.51 3.25
(26) 3.0 3.0 1.0 10.1 4.0 2.0 −1.59 2.72
(27) 3.0 3.0 1.0 10.1 10.0 5.0 −1.49 3.37
(28) 3.0 3.0 2.0 10.1 4.0 2.0 −1.37 2.76
(29) 3.0 3.0 2.0 10.1 10.0 5.0 −1.05 4.71
(30) 3.0 3.0 3.0 10.1 4.0 2.0 −1.58 3.08
(31) 3.0 3.0 3.0 10.1 6.0 3.0 −1.54 3.69
(32) 3.0 3.0 3.0 10.1 10.0 5.0 −2.45 4.34
(33) 4.0 2.0 2.0 6.1 2.0 1.0 −2.02 3.93
(34) 4.0 2.0 2.0 6.1 10.0 5.0 −1.57 5.35
(35) 4.0 2.0 2.0 8.2 4.0 2.0 −2.88 5.93
(36) 4.0 2.0 2.0 10.1 4.0 2.0 −3.12 2.89
(37) 4.0 2.0 2.0 10.1 6.0 3.0 −2.59 2.49
(38) 4.0 2.0 2.0 10.1 10.0 5.0 −2.32 3.01
(39) 4.0 2.0 3.0 6.1 2.0 1.0 −3.26 4.24
(40) 4.0 2.0 3.0 8.2 4.0 2.0 −2.69 3.49
(41) 4.0 2.0 3.0 8.2 6.0 3.0 −2.97 3.29
(42) 4.0 2.0 3.0 8.2 10.0 5.0 −2.80 5.04
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No. plan parameters [mm] amplitude [mm] agreement [%]
RiFi ∆s ∆z FWHM ALR A⊥ ∆D σD
(43) 4.0 2.0 3.0 10.1 10.0 5.0 −3.49 6.35
(44) 4.0 2.0 4.0 10.1 4.0 2.0 −3.21 3.06
(45) 4.0 2.0 4.0 10.1 6.0 3.0 −3.03 1.91
(46) 4.0 2.0 4.0 10.1 8.0 4.0 −3.99 3.18
(47) 4.0 2.0 4.0 10.1 10.0 5.0 −2.88 3.41
(48) 4.0 3.0 2.0 10.1 6.0 3.0 −3.46 3.39
(49) 4.0 3.0 2.0 10.1 10.0 5.0 −3.58 3.85
(50) 4.0 3.0 3.0 10.1 4.0 2.0 −3.03 2.43
(51) 4.0 3.0 3.0 10.1 6.0 3.0 −2.43 3.67
(52) 4.0 3.0 3.0 10.1 10.0 5.0 −3.26 4.22
B.2 Residual motion simulations
Table B.2.: Agreement of 4D simulations with the respective measurements for all 74 interplay
cases and the 19 static reference irradiations of the first and second measurement
series. The table is sorted by the plan parameters: RiFi (effective Bragg peak width),
∆s (lateral raster spacing), ∆z (IES spacing) and FWHM (average beam FWHM). ALR
and A⊥ name the motion amplitudes in left-right BEV and the remaining dimensions,
respectively. The mean relative dose deviation ∆D and standard deviation σD were
calculated from the 22 measured and calculated dose values per experiment.
No. plan parameters [mm] amplitude [mm] agreement [%]
RiFi ∆s ∆z FWHM ALR A⊥ ∆D σD
(S01) 3.0 2.0 2.0 6.1 static ref. −1.20 1.18
(S02) 3.0 2.0 2.0 8.3 static ref. −1.43 1.12
(S03) 3.0 2.0 2.0 10.1 static ref. −1.45 0.89
(S04) 3.0 2.0 3.0 6.1 static ref. −1.27 1.17
(S05) 3.0 2.0 3.0 8.3 static ref. −1.46 1.15
(S06) 3.0 2.0 3.0 10.1 static ref. −1.95 1.13
(S07) 3.0 2.0 3.0 10.1 static ref. −2.35 1.52
(S08) 3.0 3.0 1.0 10.1 static ref. −1.50 0.91
(S09) 3.0 3.0 2.0 10.1 static ref. −1.89 0.88
(S10) 3.0 3.0 3.0 10.1 static ref. −1.53 0.97
(S11) 4.0 2.0 2.0 6.1 static ref. −2.97 1.18
(S12) 4.0 2.0 2.0 8.2 static ref. −3.45 1.16
(S13) 4.0 2.0 2.0 10.1 static ref. −3.97 1.14
(S14) 4.0 2.0 3.0 6.1 static ref. −2.98 1.36
(S15) 4.0 2.0 3.0 8.2 static ref. −3.38 1.16
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No. plan parameters [mm] amplitude [mm] agreement [%]
RiFi ∆s ∆z FWHM ALR A⊥ ∆D σD
(S16) 4.0 2.0 3.0 10.1 static ref. −3.82 1.15
(S17) 4.0 2.0 4.0 10.1 static ref. −3.73 0.95
(S18) 4.0 3.0 2.0 10.1 static ref. −3.67 1.07
(S19) 4.0 3.0 3.0 10.1 static ref. −3.79 1.04
(01) 3.0 2.0 2.0 6.1 2.0 1.0 −1.06 1.68
(02) 3.0 2.0 2.0 6.1 4.0 2.0 −1.53 3.79
(03) 3.0 2.0 2.0 6.1 8.0 4.0 0.49 6.93
(04) 3.0 2.0 2.0 6.1 10.0 5.0 1.65 10.10
(05) 3.0 2.0 2.0 8.3 3.0 1.5 −1.60 2.31
(06) 3.0 2.0 2.0 8.3 5.0 2.5 −2.02 4.04
(07) 3.0 2.0 2.0 8.3 7.0 3.5 −1.68 5.77
(08) 3.0 2.0 2.0 8.3 10.0 5.0 −1.35 8.15
(09) 3.0 2.0 2.0 10.1 3.0 1.5 −1.33 1.77
(10) 3.0 2.0 2.0 10.1 5.0 2.5 −1.70 3.68
(11) 3.0 2.0 2.0 10.1 7.0 3.5 −0.72 5.61
(12) 3.0 2.0 2.0 10.1 10.0 5.0 −1.50 6.24
(13) 3.0 2.0 3.0 6.1 2.0 1.0 −1.58 2.25
(14) 3.0 2.0 3.0 6.1 4.0 2.0 −0.66 3.61
(15) 3.0 2.0 3.0 6.1 6.0 3.0 −1.71 5.69
(16) 3.0 2.0 3.0 6.1 8.0 4.0 −2.56 6.74
(17) 3.0 2.0 3.0 8.3 3.0 1.5 −1.42 3.22
(18) 3.0 2.0 3.0 8.3 5.0 2.5 −0.38 3.68
(19) 3.0 2.0 3.0 8.3 7.0 3.5 −2.06 4.89
(20) 3.0 2.0 3.0 8.3 10.0 5.0 −1.80 7.03
(21) 3.0 2.0 3.0 10.1 3.0 1.5 −2.32 2.19
(22) 3.0 2.0 3.0 10.1 3.0 1.5 −1.99 2.31
(23) 3.0 2.0 3.0 10.1 4.0 2.0 −3.44 2.85
(24) 3.0 2.0 3.0 10.1 5.0 2.5 −1.58 3.96
(25) 3.0 2.0 3.0 10.1 7.0 3.5 −1.23 5.38
(26) 3.0 2.0 3.0 10.1 7.0 3.5 −1.37 2.75
(27) 3.0 2.0 3.0 10.1 10.0 5.0 −2.96 8.23
(28) 3.0 2.0 3.0 10.1 10.0 5.0 −1.08 5.40
(29) 3.0 3.0 1.0 10.1 3.0 1.5 −1.79 2.72
(30) 3.0 3.0 1.0 10.1 5.0 2.5 −1.90 4.67
(31) 3.0 3.0 1.0 10.1 7.0 3.5 0.48 6.18
(32) 3.0 3.0 1.0 10.1 10.0 5.0 −0.95 6.49
(33) 3.0 3.0 2.0 10.1 5.0 2.5 −0.70 3.72
(34) 3.0 3.0 2.0 10.1 7.0 3.5 −2.14 4.47
(35) 3.0 3.0 3.0 10.1 3.0 1.5 −2.22 2.22
(36) 3.0 3.0 3.0 10.1 5.0 2.5 −1.42 3.03
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No. plan parameters [mm] amplitude [mm] agreement [%]
RiFi ∆s ∆z FWHM ALR A⊥ ∆D σD
(37) 3.0 3.0 3.0 10.1 7.0 3.5 −0.76 4.47
(38) 3.0 3.0 3.0 10.1 10.0 5.0 −1.38 6.19
(39) 4.0 2.0 2.0 6.1 2.0 1.0 −3.17 1.53
(40) 4.0 2.0 2.0 6.1 4.0 2.0 −2.88 4.78
(41) 4.0 2.0 2.0 6.1 6.0 3.0 −3.25 5.87
(42) 4.0 2.0 2.0 6.1 10.0 5.0 −2.65 9.64
(43) 4.0 2.0 2.0 8.2 3.0 1.5 −3.59 1.95
(44) 4.0 2.0 2.0 8.2 5.0 2.5 −3.59 4.48
(45) 4.0 2.0 2.0 8.2 7.0 3.5 −4.37 6.27
(46) 4.0 2.0 2.0 8.2 10.0 5.0 −3.57 7.53
(47) 4.0 2.0 2.0 10.1 3.0 1.5 −3.87 2.16
(48) 4.0 2.0 2.0 10.1 5.0 2.5 −3.78 3.70
(49) 4.0 2.0 2.0 10.1 7.0 3.5 −3.51 5.20
(50) 4.0 2.0 2.0 10.1 10.0 5.0 −3.34 5.36
(51) 4.0 2.0 3.0 6.1 2.0 1.0 −3.06 1.88
(52) 4.0 2.0 3.0 6.1 4.0 2.0 −3.02 3.38
(53) 4.0 2.0 3.0 6.1 6.0 3.0 −2.88 6.16
(54) 4.0 2.0 3.0 6.1 10.0 5.0 −2.84 7.69
(55) 4.0 2.0 3.0 8.2 3.0 1.5 −3.63 2.51
(56) 4.0 2.0 3.0 8.2 5.0 2.5 −3.26 3.91
(57) 4.0 2.0 3.0 8.2 7.0 3.5 −3.33 5.74
(58) 4.0 2.0 3.0 8.2 10.0 5.0 −2.83 7.16
(59) 4.0 2.0 3.0 10.1 3.0 1.5 −3.51 2.14
(60) 4.0 2.0 3.0 10.1 5.0 2.5 −4.26 3.93
(61) 4.0 2.0 3.0 10.1 6.0 3.0 −3.86 4.18
(62) 4.0 2.0 3.0 10.1 10.0 5.0 −4.72 6.70
(63) 4.0 2.0 4.0 10.1 3.0 1.5 −3.20 2.32
(64) 4.0 2.0 4.0 10.1 5.0 2.5 −3.43 3.37
(65) 4.0 2.0 4.0 10.1 7.0 3.5 −2.40 5.25
(66) 4.0 2.0 4.0 10.1 10.0 5.0 −5.39 7.12
(67) 4.0 3.0 2.0 10.1 3.0 1.5 −3.45 1.79
(68) 4.0 3.0 2.0 10.1 5.0 2.5 −3.39 3.44
(69) 4.0 3.0 2.0 10.1 7.0 3.5 −3.18 4.13
(70) 4.0 3.0 2.0 10.1 10.0 5.0 −2.99 4.49
(71) 4.0 3.0 3.0 10.1 3.0 1.5 −3.66 1.89
(72) 4.0 3.0 3.0 10.1 5.0 2.5 −3.66 3.76
(73) 4.0 3.0 3.0 10.1 7.0 3.5 −3.60 4.41
(74) 4.0 3.0 3.0 10.1 10.0 5.0 −3.75 6.22
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Table B.3.: Agreement of 4D simulations with the respective measurements for all 19 interplay
cases and the 10 static reference irradiations of the third measurement series. See
table B.2 on the previous page for details on the listed parameters.
No. plan parameters [mm] amplitude [mm] agreement [%]
RiFi ∆s ∆z FWHM ALR A⊥ ∆D σD
(S01) 3.0 2.0 2.0 6.1 static ref. −1.31 0.74
(S02) 3.0 2.0 2.0 8.3 static ref. −1.53 0.77
(S03) 3.0 2.0 2.0 10.1 static ref. −2.08 0.85
(S04) 3.0 2.0 3.0 6.1 static ref. −1.23 0.77
(S05) 3.0 2.0 3.0 8.3 static ref. −1.56 0.79
(S06) 3.0 2.0 3.0 10.1 static ref. −2.00 0.86
(S07) 3.0 3.0 2.0 10.1 static ref. −1.79 0.74
(S08) 3.0 3.0 3.0 10.1 static ref. −1.89 0.75
(S09) 4.0 2.0 2.0 10.1 static ref. −3.30 0.66
(S10) 4.0 2.0 3.0 10.1 static ref. −3.33 0.65
(01) 3.0 2.0 2.0 6.1 5.0 2.5 −1.89 2.25
(02) 3.0 2.0 2.0 6.1 10.0 5.0 −2.49 4.96
(03) 3.0 2.0 2.0 8.3 5.0 2.5 −1.47 1.68
(04) 3.0 2.0 2.0 8.3 10.0 5.0 −1.66 1.88
(05) 3.0 2.0 2.0 10.1 5.0 2.5 −1.34 1.44
(06) 3.0 2.0 2.0 10.1 10.0 5.0 −0.33 1.65
(07) 3.0 2.0 3.0 6.1 5.0 2.5 −2.11 2.81
(08) 3.0 2.0 3.0 6.1 10.0 5.0 −2.57 3.84
(09) 3.0 2.0 3.0 8.3 5.0 2.5 −1.52 1.02
(10) 3.0 2.0 3.0 8.3 10.0 5.0 −1.41 2.61
(11) 3.0 2.0 3.0 10.1 5.0 2.5 −2.45 2.22
(12) 3.0 3.0 2.0 10.1 5.0 2.5 −0.87 1.39
(13) 3.0 3.0 2.0 10.1 10.0 5.0 −2.10 2.33
(14) 3.0 3.0 3.0 10.1 5.0 2.5 −2.87 2.42
(15) 3.0 3.0 3.0 10.1 10.0 5.0 −1.57 2.37
(16) 4.0 2.0 2.0 10.1 5.0 2.5 −2.93 1.63
(17) 4.0 2.0 2.0 10.1 10.0 5.0 −4.62 2.11
(18) 4.0 2.0 3.0 10.1 5.0 2.5 −3.43 1.56
(19) 4.0 2.0 3.0 10.1 10.0 5.0 −4.64 2.65
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C Detailed results of 4D treatment
planning studies
C.1 Patient motion analysis
The 4DCT sets of the patients were used to estimate the amount of motion expected in the
target volume and the surrounding organs. A statistical analysis of the tumor motion in the
CTVs was performed for the full respiratory cycle and the two gating windows (patients G1–
G4). To assess the impact of the 4DCT phase sampling, the analysis was repeated for the 14
phase 4DCT (patients G2–G3). Additionally, the deformation fields were analyzed by visual
inspection of cross sections through the CTV.
In figure C.1 the organ motion is visualized for the individual patients in axial CT slices
through the CTV centers. It can be seen that for the analyzed patients the organ motion is
in general more pronounced for the posterior than for the anterior region of the liver and lung.
For patient A3 the overall motion is significantly smaller than for the other patients. For the
gated patients (figures C.1e–h) the motion near the skin and in the anterior part of the liver is
larger compared to most patients with abdominal compression (figures C.1a–d), with the ex-
ception of patient A4. The motion amplitudes for the gated patients as a function of the GW are
listed in table C.1. The motion vectors were determined using the registration of the CT phase
with the largest motion inside the gating window to the end-exhale phase. For a 50% GW, the
SI motion amplitudes are reduced below 8 mm for seven out of eight volumes. For the same
volumes and a 30% GW, SI amplitudes are smaller than 5 mm in seven out of eight cases and
smaller than 4mm for 50 % of the volumes. The starred values for patients G2 and G3 represent
the amplitudes obtained with the 4DCT with 14 phases. In the latter, CT phases matching the
GW limits more adequately were available. For both patients and gating windows the observed
changes, predominantly in the SI direction, are on the order of 1 mm or less, thus, they are of
the same magnitude as the expected registration accuracy.
C.2 Validation of static dose calculations with TRiP4D
To validate the treatment planning procedure and the 3D biological dose calculation with
TRiP4D, the static dose distributions of TRiP4D were compared to those obtained with the
commercial TPS used at HIT. The clinical treatment plans optimized at HIT for the patients
A1–A4 and G1 were converted for use with TRiP4D and the physical and biological dose dis-
tributions were re-calculated on the corresponding planning CTs. The differences of the dose
distributions were assessed by statistical analysis of the differential dose distributions. For a
direct comparison, the TRiP4D dose distributions were sampled to the same dose voxel spacing
as used in the HIT TPS (2× 2× 2mm).
Figure C.2 displays an axial cross section through the differential biologically effective dose
distribution obtained for the clinical treatment plan of patient A1. Dose differences between the
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Figure C.1.: Visualization of organ motion for the patients with abdominal compression (a–d)
and the gated patients (e–h). The contour map represents the length of the motion
vector for the transition from the end-inhale to the end-exhale CT phase (scale in
mm). Contours are overlayed on the axial CT slices through the CTV centers.
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mean motion amplitude and SD [mm]
GW patient CTV |A| SI AP LR
50%
G1
TG1 7.4±0.7 −7.4±0.7 −1.0±0.3 0.0±0.0
TG2 7.6±1.4 −7.1±1.3 −2.5±0.9 −0.9±0.5
TG3 11.7±1.2 −10.8±1.3 −3.7±0.7 −2.4±0.6
G2 TG4 6.1±1.5 −5.5±1.4 −2.5±0.6 −0.5±0.5
5.2±1.4∗ −4.7±1.3∗ −2.3±0.6∗ −0.3±0.3∗
G3 TG5 5.5±0.9 −5.4±0.9 −1.0±0.3 −0.1±0.3
5.5±1.0∗ −5.4±1.0∗ −1.1±0.2∗ −0.1±0.4∗
G4 TG6 7.2±0.9 −6.4±0.9 −3.2±0.3 0.0±0.1
30%
G1
TG1 4.7±0.8 −4.7±0.7 −0.2±0.3 0.0±0.0
TG2 3.8±0.9 −3.5±0.8 −1.1±0.9 −0.3±0.3
TG3 5.1±1.0 −5.1±1.0 −0.2±0.3 −0.1±0.2
G2 TG4 4.2±1.5 −3.6±1.4 −1.9±0.7 −0.2±0.3
3.2±0.9∗ −2.3±0.8∗ −1.9±0.6∗ −0.7±0.4∗
G3 TG5 4.7±0.8 −4.6±0.9 −0.9±0.2 0.2±0.2
4.1±1.0∗ −4.0±1.0∗ −0.6±0.2∗ −0.1±0.3∗
G4 TG6 3.2±0.4 −2.9±0.4 −1.2±0.2 0.0±0.1
Table C.1.: Statistical analysis of the CTV motion in the two gating windows of 50 % and 30 % of
the relative amplitude range. The mean motion amplitude and standard deviation
(SD) have been determined over all CT voxels inside the CTV for the SI, AP and LR
direction, as well as for the length of the motion vector, |A|. Starred values were
obtained from analysis of the 10 % step 4DCT and deformation maps.
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Figure C.2.: Analysis of the differential biologically effective dose distribution for TRiP4D and the
commercial treatment planning system used at HIT. (Left) Axial cross section of the
differential dose for the clinical treatment plan of patient A1 (dose in percent of the
target dose). (Right) Histogram of the relative dose differences inside the patient’s
skin contour. Note the logarithmic scale.
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dose differences in % of the prescribed dose
patient ∆Dphys± SD ∆Dphysmin ∆Dphysmax ∆Dbiol± SD ∆Dbiolmin ∆Dbiolmax
1 0.0±0.4 −16.5 47.4 0.0±0.8 −33.4 77.5
2 0.0±0.3 −9.5 48.6 0.0±0.6 −17.4 80.5
3 0.0±0.3 −15.2 44.4 0.0±0.5 −28.5 79.1
4 0.0±0.3 −17.8 45.4 0.0±0.5 −34.9 76.5
5 0.0±0.5 −7.9 40.8 0.1±1.0 −15.3 73.0
Table C.2.: Comparison of static dose distributions calculated with the HIT treatment planning
system and TRiP4D using the clinical treatment plans for patients A1–A4 & G1. Mean
deviations (∆D) and respective standard deviations, as well as minimum and maxi-
mum deviations are listed for the physical and biologically effective dose, respectively.
HIT TPS and TRiP4D are shown as a color map. A histogram of the relative dose differences is
given on the right. Negative values indicate that the dose was overestimated by TRiP4D w.r.t.
the clinical TPS. The dose differences exceed 10 % only in the fragment tail regions near the dis-
tal edges of the field. The mean, minimum and maximum deviations determined between dose
distributions for the clinical treatment plans of patients A1–A4 and G1 are given in table C.2.
While standard deviations of the mean differences are smaller than 1% in most cases, maximum
deviations can range up to 80% of the prescribed dose. However, most of these extreme devi-
ations occur in few voxels located near the patient skin contour, to which the dose calculation
was confined. These can be attributed to artifacts introduced by the re-sampling of the TRiP4D
dose distributions to the HIT TPS voxel spacing.
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C.3 Normal tissue exposure — treatment reconstructions
dose
distr.
liver dose [Gy (RBE)] lung dose [Gy (RBE)]
∆t [ms] mean max mean max
static — 0.9 8.7 1.6 8.6
fraction 1
−250 0.9 10.2 2.0 10.0
+0 0.9 10.5 2.0 10.3
+250 0.9 10.4 2.0 9.7
fraction 2
−250 0.9 10.4 2.0 9.3
+0 0.9 10.3 2.0 8.9
+250 0.9 10.3 2.0 8.9
fraction 3
−250 0.9 10.9 2.0 9.6
+0 0.9 10.0 2.0 9.6
+250 0.9 9.5 2.0 9.3
fraction 4
−250 0.9 10.4 2.0 9.5
+0 0.9 10.4 2.0 9.5
+250 0.9 10.5 2.0 9.6
total — 3.7 37.3 8.1 35.2
Table C.3.: Reconstructed mean and maximum dose to lung and liver for patient A2. For each
fraction three simulations were performed with varying temporal shifts (∆t) of the
beam delivery sequence w.r.t. the motion trace.
dose
distr.
liver dose [Gy (RBE)] lung dose [Gy (RBE)]
∆t [ms] mean max mean max
static +0 1.1 9.4 0.0 0.0
fraction 2
−250 1.3 10.6 0.0 0.4
+0 1.3 10.5 0.0 0.4
+250 1.3 10.5 0.0 0.3
fraction 3
−250 1.3 10.4 0.0 0.3
+0 1.3 10.6 0.0 0.3
+250 1.3 10.1 0.0 0.3
fraction 4
−250 1.4 10.5 0.0 0.8
+0 1.4 10.2 0.0 0.7
+250 1.4 11.1 0.0 0.7
Table C.4.: Reconstructed mean and maximum dose to lung and liver for patient G2. For each
fraction three simulations were performed with varying temporal shifts (∆t) of the
beam delivery sequence w.r.t. the motion trace. For technical reasons, the data of
the missing first fraction could not be analyzed.
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C.4 Target overdose
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Figure C.3.: V107 as a function of the beam spot FWHM for the five CTVs in patients A1–A4 with
abdominal compression. |A| denotes the motion amplitude for each CTV volume.
The dash-dotted lines are linear fits to the data.
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Figure C.4.: V107 as a function of the beam spot FWHM for the six CTVs in patients G1–G4 with
gating. |A|50(30) denote the motion amplitude in the 50 % and 30 % GW, respectively.
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amplitude-dependence of HI and V95 — correlation coefficient r
[mm] focus
level
HI V95
∆s ∆z SI AP SI AP
2 2 2 0.56 0.66 -0.59 -0.47
2 2 3 0.49 0.61 -0.48 -0.40
2 2 4 0.37 0.55 -0.35 -0.33
2 2 5 0.45 0.67 -0.36 -0.34
2 3 2 0.47 0.67 -0.55 -0.57
2 3 3 0.52 0.73 -0.52 -0.58
2 3 4 0.52 0.70 -0.40 -0.47
2 3 5 0.49 0.69 -0.38 -0.35
3 2 4 0.45 0.62 -0.46 -0.41
3 2 5 0.58 0.72 -0.55 -0.47
3 3 4 0.58 0.74 -0.53 -0.57
3 3 5 0.47 0.76 -0.35 -0.38
mean ± SD 0.50 ± 0.06 0.68 ± 0.06 −0.46 ± 0.08 −0.45 ± 0.09
Table C.5.: Pearson correlation coefficients, r, for the relationship of HI and V95 to the motion
amplitudes in the superior-inferior (SI) and anterior-posterior (AP) direction. The fo-
cus levels 2, 3, 4 and 5 approximately correspond to beam FWHM of 6, 8, 10 and
15 mm.
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C.5 Normal tissue exposure — treatment simulations
plan par. in mm liver dose [Gy (RBE)] lung dose [Gy (RBE)]
∆s ∆z FWHM mean max mean max
2 2 6.1 1.3 (1.3) 10.4 (9.2) 0.0 (0.0) 6.0 (5.7)
2 2 8.2 1.5 (1.5) 10.0 (8.9) 0.0 (0.0) 6.0 (5.7)
2 2 10.1 1.6 (1.6) 9.8 (8.7) 0.1 (0.0) 6.0 (5.7)
2 2 15.0 1.9 (1.9) 9.2 (8.8) 0.1 (0.1) 5.9 (5.8)
2 3 6.1 1.3 (1.3) 11.1 (9.8) 0.0 (0.0) 6.0 (5.8)
2 3 8.2 1.5 (1.5) 10.2 (9.3) 0.0 (0.0) 6.1 (5.8)
2 3 10.1 1.6 (1.6) 10.1 (9.0) 0.1 (0.0) 5.9 (5.8)
2 3 15.0 1.9 (1.9) 9.9 (8.9) 0.1 (0.1) 6.0 (5.8)
3 2 10.1 1.6 (1.6) 10.0 (9.0) 0.0 (0.0) 5.9 (5.8)
3 2 15.0 1.9 (1.9) 9.4 (8.8) 0.1 (0.1) 5.9 (5.8)
3 3 10.1 1.6 (1.6) 10.7 (9.2) 0.0 (0.0) 6.2 (5.7)
3 3 15.0 2.1 (2.1) 10.1 (8.7) 0.1 (0.1) 6.2 (5.8)
Table C.6.: Mean and maximum dose received by liver and lung in patient A1 for varying plan
parameters. Listed are the maximum and minimum values (in brackets) found over
all simulations with different motion parameters.
plan par. in mm liver dose [Gy (RBE)] lung dose [Gy (RBE)]
∆s ∆z FWHM mean max mean max
2 2 6.1 0.6 (0.6) 10.5 (9.8) 0.8 (0.7) 9.4 (8.2)
2 2 8.3 0.7 (0.7) 10.4 (9.5) 0.9 (0.9) 9.1 (8.3)
2 2 10.1 0.7 (0.7) 9.9 (9.2) 1.0 (0.9) 8.8 (8.2)
2 2 15.0 0.9 (0.8) 9.4 (8.9) 1.5 (1.4) 9.1 (8.3)
2 3 6.1 0.6 (0.6) 12.0 (10.1) 0.8 (0.7) 10.0 (8.2)
2 3 8.3 0.6 (0.6) 10.8 (9.7) 0.9 (0.8) 9.6 (8.8)
2 3 10.1 0.7 (0.7) 10.5 (9.4) 1.0 (0.9) 9.4 (8.6)
2 3 15.0 0.8 (0.8) 9.4 (9.0) 1.5 (1.4) 9.4 (8.3)
3 2 10.1 0.7 (0.7) 9.8 (9.3) 1.1 (1.0) 9.1 (8.4)
3 2 15.0 0.8 (0.8) 9.5 (8.8) 1.6 (1.6) 9.4 (8.5)
3 3 10.2 0.7 (0.7) 10.4 (9.7) 1.0 (1.0) 10.0 (8.4)
3 3 15.0 0.8 (0.8) 9.6 (8.9) 1.6 (1.5) 9.3 (8.6)
Table C.7.: Mean and maximum dose received by liver and lung in patient A2 for varying plan
parameters. Listed are the maximum and minimum values (in brackets) found over
all simulations with different motion parameters.
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plan par. in mm liver dose [Gy (RBE)] lung dose [Gy (RBE)]
∆s ∆z FWHM mean max mean max
2 2 6.6 0.8 (0.8) 9.9 (9.0) 0.0 (0.0) 0.6 (0.1)
2 2 8.9 0.8 (0.8) 9.5 (8.9) 0.0 (0.0) 1.5 (0.7)
2 2 10.7 0.9 (0.9) 9.4 (8.8) 0.0 (0.0) 1.8 (1.3)
2 2 15.0 1.0 (1.0) 9.4 (8.8) 0.0 (0.0) 2.8 (2.6)
2 3 6.6 0.8 (0.8) 9.9 (9.1) 0.0 (0.0) 0.5 (0.3)
2 3 8.9 0.8 (0.8) 9.7 (9.1) 0.0 (0.0) 1.4 (1.2)
2 3 10.7 0.9 (0.8) 9.5 (8.9) 0.0 (0.0) 1.7 (1.5)
2 3 15.0 1.0 (1.0) 9.1 (8.7) 0.0 (0.0) 3.0 (2.8)
3 2 10.7 0.9 (0.9) 9.4 (8.9) 0.0 (0.0) 1.7 (1.5)
3 2 15.0 1.0 (1.0) 9.0 (8.7) 0.0 (0.0) 2.8 (2.5)
3 3 10.7 0.9 (0.8) 9.7 (9.0) 0.0 (0.0) 1.7 (1.5)
3 3 15.0 1.0 (0.9) 9.5 (8.8) 0.0 (0.0) 2.7 (2.6)
Table C.8.: Mean and maximum dose received by liver and lung in patient A3 for varying plan
parameters. Listed are the maximum and minimum values (in brackets) found over
all simulations with different motion parameters.
plan par. in mm liver dose [Gy (RBE)] lung dose [Gy (RBE)]
∆s ∆z FWHM mean max mean max
2 2 6.7 1.5 (1.5) 11.3 (10.1) 0.2 (0.2) 9.9 (8.6)
2 2 8.8 1.6 (1.5) 10.8 (9.6) 0.3 (0.2) 9.0 (8.4)
2 2 10.7 1.6 (1.6) 10.5 (9.5) 0.3 (0.3) 9.1 (8.3)
2 2 15.0 1.8 (1.8) 9.5 (9.1) 0.6 (0.5) 8.7 (8.3)
2 3 6.7 1.4 (1.4) 12.5 (10.4) 0.2 (0.2) 10.0 (8.9)
2 3 8.8 1.5 (1.5) 11.9 (10.3) 0.3 (0.2) 10.0 (8.7)
2 3 10.7 1.6 (1.6) 11.1 (9.7) 0.3 (0.2) 9.3 (8.5)
2 3 15.0 1.8 (1.8) 10.6 (9.2) 0.6 (0.5) 9.0 (8.4)
3 2 10.7 1.6 (1.6) 10.2 (9.4) 0.4 (0.3) 9.1 (8.4)
3 2 15.0 1.8 (1.8) 9.5 (9.0) 0.6 (0.5) 8.8 (8.4)
3 3 10.7 1.6 (1.6) 11.6 (9.9) 0.4 (0.3) 9.6 (8.8)
3 3 15.0 1.7 (1.7) 10.3 (9.4) 0.6 (0.5) 9.0 (8.4)
Table C.9.: Mean and maximum dose received by liver and lung in patient A4 for varying plan
parameters. Listed are the maximum and minimum values (in brackets) found over
all simulations with different motion parameters.
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plan par. in mm liver dose [Gy (RBE)] lung dose [Gy (RBE)]
∆s ∆z FWHM mean max mean max
2 2 6.3 1.4 (1.4) 11.5 (11.0) 0.2 (0.2) 7.7 (6.9)
2 2 8.5 1.6 (1.6) 10.9 (10.7) 0.3 (0.3) 8.5 (6.9)
2 2 10.3 1.7 (1.7) 10.5 (9.6) 0.4 (0.3) 7.9 (7.1)
2 2 15.0 1.9 (1.9) 9.7 (8.9) 0.8 (0.7) 7.8 (7.5)
2 3 6.3 1.4 (1.4) 11.5 (10.8) 0.2 (0.2) 7.6 (6.7)
2 3 8.5 1.6 (1.6) 10.8 (10.1) 0.3 (0.3) 8.1 (7.3)
2 3 10.3 1.7 (1.7) 10.3 (9.2) 0.4 (0.3) 7.8 (7.5)
2 3 15.0 2.0 (2.0) 9.2 (8.7) 0.8 (0.7) 7.9 (7.8)
3 2 10.3 1.6 (1.6) 10.5 (10.4) 0.4 (0.3) 8.6 (6.8)
3 2 15.0 2.0 (2.0) 9.5 (8.8) 0.8 (0.7) 7.9 (7.7)
3 3 10.3 1.6 (1.6) 10.3 (10.0) 0.4 (0.3) 7.8 (7.0)
3 3 15.0 1.9 (1.9) 9.1 (8.8) 0.8 (0.7) 8.0 (7.8)
Table C.10.: Mean and maximum dose received by liver and lung in patient G1 for varying plan
parameters. Listed are the maximum and minimum values (in brackets) found over
all simulations with different motion parameters.
plan par. in mm liver dose [Gy (RBE)] lung dose [Gy (RBE)]
∆s ∆z FWHM mean max mean max
2 2 6.4 0.8 (0.7) 10.7 (10.5) 0.0 (0.0) 0.0 (0.0)
2 2 8.8 0.8 (0.8) 10.3 (9.9) 0.0 (0.0) 0.0 (0.0)
2 2 10.6 0.9 (0.9) 10.2 (9.9) 0.0 (0.0) 0.0 (0.0)
2 2 15.0 1.0 (1.0) 9.8 (9.1) 0.0 (0.0) 0.1 (0.1)
2 3 6.5 0.7 (0.7) 12.7 (12.3) 0.0 (0.0) 0.0 (0.0)
2 3 8.8 0.8 (0.8) 11.3 (10.5) 0.0 (0.0) 0.0 (0.0)
2 3 10.6 0.9 (0.8) 10.6 (9.6) 0.0 (0.0) 0.0 (0.0)
2 3 15.0 1.0 (1.0) 9.9 (9.3) 0.0 (0.0) 0.1 (0.0)
3 2 10.6 0.9 (0.9) 10.4 (10.0) 0.0 (0.0) 0.0 (0.0)
3 2 15.0 1.0 (0.9) 9.8 (9.2) 0.0 (0.0) 0.1 (0.1)
3 3 10.6 0.9 (0.8) 10.6 (9.7) 0.0 (0.0) 0.0 (0.0)
3 3 15.0 0.9 (0.9) 9.6 (9.1) 0.0 (0.0) 0.1 (0.0)
Table C.11.: Mean and maximum dose received by liver and lung in patient G2 for varying plan
parameters. Listed are the maximum and minimum values (in brackets) found over
all simulations with different motion parameters.
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plan par. in mm liver dose [Gy (RBE)] lung dose [Gy (RBE)]
∆s ∆z FWHM mean max mean max
2 2 6.3 1.7 (1.7) 9.8 (8.8) 0.0 (0.0) 6.6 (6.5)
2 2 8.5 2.0 (1.9) 9.3 (8.8) 0.0 (0.0) 6.6 (6.6)
2 2 10.3 2.2 (2.2) 9.1 (8.8) 0.0 (0.0) 6.7 (6.5)
2 2 15.0 2.9 (2.9) 9.0 (8.7) 0.0 (0.0) 6.8 (6.6)
2 3 6.3 1.7 (1.6) 9.7 (9.4) 0.0 (0.0) 6.7 (6.4)
2 3 8.5 1.9 (1.9) 9.3 (9.1) 0.0 (0.0) 6.7 (6.4)
2 3 10.3 2.2 (2.2) 9.2 (9.1) 0.0 (0.0) 6.8 (6.4)
2 3 15.0 2.8 (2.8) 8.9 (8.6) 0.0 (0.0) 6.7 (6.5)
3 2 10.3 2.2 (2.2) 9.0 (8.6) 0.0 (0.0) 6.8 (6.6)
3 2 15.0 2.9 (2.9) 8.8 (8.6) 0.0 (0.0) 6.8 (6.7)
3 3 10.3 2.2 (2.2) 9.1 (8.8) 0.0 (0.0) 6.8 (6.7)
3 3 15.0 2.9 (2.8) 8.8 (8.7) 0.0 (0.0) 6.8 (6.6)
Table C.12.: Mean and maximum dose received by liver and lung in patient G3 for varying plan
parameters. Listed are the maximum and minimum values (in brackets) found over
all simulations with different motion parameters.
plan par. in mm liver dose [Gy (RBE)] lung dose [Gy (RBE)]
∆s ∆z FWHM mean max mean max
2 2 6.1 0.7 (0.7) 9.9 (9.2) n/ a n/ a
2 2 8.3 0.9 (0.8) 9.3 (9.0) n/ a n/ a
2 2 10.1 1.0 (1.0) 9.2 (9.0) n/ a n/ a
2 2 15.0 1.3 (1.3) 9.2 (8.9) n/ a n/ a
2 3 6.1 0.7 (0.7) 10.2 (9.7) n/ a n/ a
2 3 8.3 0.9 (0.8) 9.7 (9.3) n/ a n/ a
2 3 10.2 1.0 (1.0) 9.8 (8.9) n/ a n/ a
2 3 15.0 1.3 (1.2) 9.1 (8.9) n/ a n/ a
3 2 10.1 1.0 (1.0) 9.2 (9.1) n/ a n/ a
3 2 15.0 1.3 (1.3) 8.9 (8.8) n/ a n/ a
3 3 10.2 1.0 (1.0) 9.6 (9.2) n/ a n/ a
3 3 15.0 1.3 (1.2) 9.1 (8.9) n/ a n/ a
Table C.13.: Mean and maximum dose received by liver and lung in patient G4 for varying plan
parameters. Listed are the maximum and minimum values (in brackets) found over
all simulations with different motion parameters.
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